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Alzheimer disease (AD) and cerebral vascular disease (CVD) are common 
causes of impaired cognition and behavior in humans. Epidemiological studies 
have shown that AD and CVD development and progression associated with 
metabolic risk factors including type 2 diabetes (T2D). However, the underlying 
molecular mechanisms remain elusive, which hampers the development of 
treatment and prevention strategies. Research results from our laboratory and 
others have shown that amylin, a hormone secreted by the pancreas and involved 
in glucose homeostasis, induces small-vessel-type pathologies and modulates 
amyloid composition in both familial (genetically predisposed) and sporadic forms 
of AD. The results indicate amylin as a potential molecular modifier of the course 
of Alzheimer’s and brain microvascular pathologies. 
The present work provides a basis for understanding the role of pancreatic 
amylin in brain injury and neurologic deficits associated with aging and metabolic 
dysfunction. First, we used brain tissues from humans with T2D and AD, and a rat 
model expressing human amylin in the pancreas (the HIP rat), to test the impact 
of amylin dysregulation on the brain. We found that high blood levels of amylin 
promoted vascular accumulation of amylin leading to endothelial cell dysfunction 
and microvascular injury. Amylin-mediated injury of the cerebrovasculature leads 
to brain white matter disease and neurological dysfunction in HIP rats. Next, we 
sought to understand the role of amylin in the development of AD pathology and 
progression of the disease. Using brain tissues from humans with sporadic and 
familial forms of AD, AD model rats expressing human amylin (ADHIP rats) and 
AD model rats expressing non-amyloidogenic rat amylin, we found that high blood 
levels of amylin modulates AD pathology via amylin-Aβ cross-seeding in the grey 
matter and also contributes to non-AD molecular pathways such as injuries to 
small blood vessels supplying the white matter. By staining and imaging of brain 
amylin and Aβ, we showed that amylin accumulated in the brain parenchyma and 
small blood vessels, and formed mixed plaques with Aβ. Elevated plasma amylin 
ROLE OF PANCREATIC AMYLIN IN ALZHEIMER’S AND BRAIN 
MICROVASCULAR PATHOLOGIES 
ABSTRACT OF DISSERTATION 
with aging in ADHIP rats was associated with brain microvascular damage and 
neurological dysfunction. Based on these studies, we inferred that amyloid-forming 
amylin secreted by the pancreas modulates brain amyloid composition in both 
sporadic and familial forms of AD, and that pancreatic expression of human amylin 
in AD model rats accelerates behavioral deficits. Further, we tested effects of 
lowering peripheral amylin and the suppression of amylin secretion in AD model 
rats. We found that the amylin-related pathological processes are reduced by 
pharmacological lowering amylin deposition in brain capillaries and amylin-Aβ 
cross-seeding. Genetic suppression of amylin in AD model rats reduces amylin-
Aβ cross-seeding and neurologic deficits.  
Our data show evidence for a role of pancreatic amylin in AD and cerebral 
microvascular pathology and suggest that drugs reducing amylin accumulation in 
brain capillaries or preventing amylin from interacting with Aβ-associated 
pathology could provide benefit in patients with AD. Therefore, targeting amylin 
dyshomeostasis may be an effective strategy to prevent or slow the advancement 
of Alzheimer and cerebrovascular disease.  
KEYWORDS: Amylin, Alzheimer disease, cerebrovascular disease, type 2 
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CHAPTER 1. AMYLIN: FROM THE PANCREAS TO DEMENTIA 
1.1. Introduction 
Dementia is an important public health challenge that affects multiple 
aspects of life. Alzheimer disease (AD) and cerebral vascular disease (CVD) 
are common causes of impaired cognition and behavior in humans (1). The 
development and progression of AD and CVD are complex and are affected by 
metabolic risk factors, including type 2 diabetes (T2D). Although extensive 
research studies have been conducted, the underlying molecular mechanisms 
remain unclear. Research results from our laboratory and others have shown 
that amylin, a satiation hormone that forms pancreatic amyloid in patients with 
T2D, promotes small-vessel-type pathologies (2-4) and modulates amyloid 
composition (2, 5-7) in both familial (genetically predisposed) and sporadic 
forms of AD. Overexpression of human amylin in rodents (rodent amylin does 
not form amyloid) leads to late-life onset T2D and neurological deficits (2, 8). 
The results suggest amylin as a potential molecular modifier of the course of 
AD and brain microvascular pathologies. 
This chapter covers the overview of AD and CVD in relation to metabolic 
risk factors, research studies on amylin, as well as the physiological and 
pathological roles of amylin with emphasis on how amylin is recognized as a 
link between pancreatic dysfunction and diabetic complications. This chapter 
will also discuss the clinical evidence of amylin pathology in AD and CVD, 
together with proposed disease mechanisms; to identify critical characteristics 
of animal models that could help to better understand molecular mechanisms 
underlying the increased risk of AD and CVD in patients with prediabetes or 
T2D. Lastly, the scope of this dissertation is also included.   
1.2. Alzheimer disease and cerebral vascular disease: discovery, 
pathology and metabolic risk factors 
1.2.a. Alzheimer disease  
On November 4th, 1906, Dr. Alois Alzheimer gave an important lecture at 
the Tübingen meeting that changed the medical view on dementia. He reported 
a medical case of Auguste Deter, a 51-year-old woman patient, who had died 
of an unusual mental illness. She was diagnosed with a progressive cognitive 
disorder, focal symptoms, hallucinations, delusions, and psychological 
incompetence. Dr. Alzheimer examined her brain autopsy and found 
abnormally thin cerebral cortex with regions responsible for memory, language, 
judgment, and thinking severely impaired. He noticed senile plaques (now 
known as amyloid plaques) and tangles in nerve fibers (now known as 
neurofibrillary/tau tangles) in the cerebral cortex (9). However, the scientific 
community showed rejection toward his works, because there is a consensus 
among medical doctors that dementia did not occur in patients younger than 
70-year-old (senile dementia). In the published abstracts from the conference, 
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only the title of Alzheimer’s lecture was presented with a statement in 
parentheses that the lecture “was not appropriate for a short publication”. It was 
not until 1907, Alzheimer published his lecture under the title “Über eine 
eigenartige Erkrankung der Hirnrinde” (On an Unusual Illness of the Cerebral 
Cortex) (10). Dr. Emil Kraepelin, the father of modern psychiatry, supported 
and honored the works by Dr. Alzheimer by naming this peculiar disease after 
Alzheimer in his famous Handbook of Psychiatry published in 1910. In 1911, 
Dr. Alzheimer reported the second case of presenile dementia from patient 
Johann F., who died at 57 years of age, and his brain showed “plagues-only” 
without neurofibrils (11). Currently, both cases would be diagnosed as early-
onset Alzheimer dementia (presenile dementia). A recent study postulated that 
Johann case was a form of genetically predisposed or familial AD (12).  
AD patients suffer from progressive decline in memory, cognitive functions, 
and psychosocial ability. Most of the AD cases occur on a sporadic basis. 
Patients develop AD symptoms before age 65 are categorized under early-
onset AD (EOAD), which makes up about 5% of AD cases. Sporadic EOAD 
shares a similar pathology profile with the “late-onset Alzheimer disease” 
(LOAD), the most common form of the disease occurs after age 65. Although 
the etiology of sporadic AD is unknown, 10-15% of EOAD cases are caused by 
autosomal dominant mutations in three genes—amyloid precursor protein 
(APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2), causing familial AD 
(fAD). fAD symptoms develop earlier than sporadic AD, typically between 30 
and 50 years of age, and progress quickly (13).  
The cardinal features of Alzheimer pathology are the accumulation of 
amyloid β (Aβ) and neurofibrillary tangles in the cerebral cortex (14). According 
to the amyloid cascade hypothesis and the Tau hypothesis, the accumulation 
of plaques and tangles triggers pathways to abnormal cellular metabolism and 
neurodegeneration (14). Longitudinal community-based clinical-pathologic 
study shows that probable AD, mild cognitive impairment (MCI), and amnestic 
MCI, are pathologically heterogeneous disorders with mixed pathologies, 
including vascular abnormalities, Lewy bodies (15, 16), and TAR DNA-binding 
protein 43 (TDP-43) (17). Although nearly 90% of persons with clinically 
probable AD met pathologic criteria for AD, mixed pathologies were as common 
as “pure” AD pathology and are associated with the decline in cognitive function 
(16).     
1.2.b. Cerebral vascular disease  
The term cerebral vascular disease (CVD) is used to refer to a group of 
medical conditions that affect brain blood vessels and cerebral circulation. 
Structural and functional changes in blood vessels cause vascular narrowing, 
blockage, or rupture that affect oxygen and nutrient delivery to the brain (18). 
As a result, stroke, transient ischemic attack, aneurysm, and vascular 
malformation occur, leading to serious neurological complications and life-
threatening events.  
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Cerebrovascular pathologies contribute to vascular dementia (VD), which 
made up at least 20% of cases of dementia, being second only to AD (19). 
Various factors, including older age, hypertension, hypercholesterolemia, 
diabetes, obesity, atherosclerosis, and cardiac diseases, have been shown to 
enhance vascular risk and facilitate onset and progression of CVD-related 
cognitive impairment (20, 21). Clinical-pathological studies shown that 
concurrent CVD is an adjuvant to the expression of dementia caused by AD or 
other neurodegenerative pathologies (19, 22, 23). Importantly, the severity of 
small-vessel disease (visualized as white matter hyperintensities on magnetic 
resonance imaging) contributes to the presentation of AD and predicts AD 
conversion from mild cognitive impairment beyond Aβ status (24). Although it 
is still not clear whether CVD is a concomitant pathology that is independent of 
AD basic neuropathology (amyloid deposition and tauopathy) or one of the 
triggers for AD expression, protecting cerebrovascular health can slow the 
progression of cognitive impairment in aging individuals (20, 21). 
1.2.c. Alzheimer disease, cerebral vascular disease, and diabetes 
Clinical studies have found that dementia caused by CVD and AD are 
associated with metabolic risk factors including T2D (25-31). Despite recent 
advances in the care of patients with T2D, the risk of dementia remains higher 
(up to 2-fold) in the population with T2D or prediabetes compared to 
metabolically normal individuals (26, 27). The causative mechanisms 
underlying diabetes-associated cognitive dysfunction and dementia remain 
elusive. Clinical evidence indicates that overt hyperglycemia is linked to 
diabetes-associated cognitive decline (32) and dementia risk in non-diabetic 
individuals (33). However, multi-centered, randomized controlled studies have 
shown that stringent control of glycemic parameters, i.e., glycated hemoglobin 
(hemoglobin A1c) and fasting plasma glucose levels, does not improve 
cognitive function (34, 35); rather, it increased mortality in patients with 
dementia (35). Repeated hypoglycemic episodes are clearly linked to cognitive 
decline and increased dementia risk (32, 36). From these studies, we foresee 
a need to identify novel contributing factors to the risk of cognitive impairment 
in humans with T2D or prediabetes. 
Amylin, also known as islet amyloid polypeptide (IAPP), is a hormone 
peptide co-synthesized with insulin by pancreatic β-cells and participates in 
glucose homeostasis and the central regulation of satiation (37). Individuals 
with prediabetic insulin resistance have hypersecretion of both insulin and 
amylin (37). Thus, hyperamylinemia (high levels of amylin in the blood) always 
coincides with hyperinsulinemia and prediabetic insulin resistance. Clinical 
investigations found that human amylin, an amyloidogenic peptide, forms islet 
amyloid in more than 90% of T2D patients (37-39). Studies from our lab first 
show that amylin accumulates in the cerebral small vessels of patients with 
dementia and T2D (2, 5). In brains of T2D patients with pathological AD, we 
found amylin deposition and mixed amylin-β amyloid (Aβ) plaques (5, 6). These 
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results are important because they suggest a novel pathological role of amylin 
dyshomeostasis in the development and progression of AD and CVD.  
1.3. The discovery of islet amyloid and amylin 
The term “islet hyalinization” was initially used to describe islet amyloid in 
the islets of Langerhans from diabetic patients when it was first independently 
discovered by two researchers, Eugene L. Opie and Anton Weichselbaum (40, 
41). When Opie found the hyaline materials in the pancreas, he could not 
conclude on the amyloidosis of those hyaline materials because of inadequate 
staining methods (40). For decades, abundant discussions and histological 
studies took place on the nature of those hyaline deposits, which were often 
thought to be connective tissue hyaline. It was assumed so until Nils Gellerstedt 
and Jacques H. Ahronheim challenged the premise that the hyaline materials 
frequently found in the pancreatic islets were connective tissue hyaline; rather, 
based on its staining reaction and affinity for Congo-red, should be considered 
amyloid (42, 43). In the 1960s, Ehrlich and Ratner confirmed that the Congo 
Red-positive hyaline substance in the Langerhans islets was amyloidosis (44), 
along with results from electron microscopy by Per Westermark suggested that 
islet amyloid in human islets of Langerhans had fibrillary structure (45).  
Summary of scientific discoveries is displayed in (Fig 1.1). 
Islet amyloid deposits have greater insolubility compared with most other 
amyloid forms (46), except for the amyloid core in Alzheimer disease’s plaques 
(47). Hence, attempts to purify the major fibril protein in the islet amyloid was 
hindered by its insolubility until formic acid was used to disintegrate amyloid 
(48). Per Westermark and his colleagues extracted fibril protein from an 
amyloid-rich insulinoma and characterized the protein by NH2-terminal amino 
acid sequence analysis (48). They thought that this fibril protein might resemble 
proinsulin, but this purification process revealed a novel peptide that has 
significant sequence similarities to human calcitonin gene-related peptide (48) 
(Fig. 1.2). The peptide was initially named “insulinoma amyloid peptide” by the 
group (48). In 1987, Garth JS. Cooper successfully isolated this novel peptide 
from the islet amyloid of T2D patients and showed it to be a 37-amino-acid 
residue peptide (49) (Fig. 1.2). He named it “diabetes-associated peptide” (49). 
It was finally named “islet amyloid polypeptide” (IAPP) (50) or “amylin” (51), 
because it was found to be a normal secretory product, along with insulin, from 
the pancreatic β-cells, not specific for diabetes (52, 53). This evidence suggests 
that amylin might have physiological functions under normal conditions. 
1.4. Amylin protein structure, protein expression and physiological 
functions 
1.4.a. Protein structure, processing and expression 
Amylin is a 37-amino acid residue hormone peptide, synthesized, and co-
secreted with insulin by pancreatic β-cells (53). The release of insulin and thus, 
amylin from pancreatic β-cells is regulated by proopiomelanocortin neurons in 
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the hypothalamus (54). In humans and rodents, plasma amylin levels rapidly 
increase several-fold after meals (55). Amylin is expressed by one single-copy 
gene on the short arm of chromosome 12, and it belongs to the calcitonin 
peptide family, which includes calcitonin gene-related peptide, adrenomedullin, 
and calcitonin. Amylin is derived from pre-pro-amylin, an 89-amino acid peptide 
that contains 22-amino acid N-terminal signal peptide, and two short flanking 
peptides (Fig. 1.3a). The signal peptide is removed in the endoplasmic 
reticulum to produce a 67-amino acid pro-amylin. Pro-amylin contains cleavage 
sites for prohormone convertase (PC) 2 and PC1/3, and the C-terminus is 
cleaved by carboxypeptidase (CPE) during late Golgi process, exposing the 
glycine residue for C-terminus amidation. The C-terminus is then amidated by 
the peptidyl glycine α-amidating monooxygenase. An intramolecular disulfide 
bond between amino acid residues 2-7, subsequently forms ring structure at 
the N-terminus, producing mature amylin peptide (Fig. 1.3a). Pro-amylin is fully 
converted to mature amylin in the β-cells secretory vesicles where insulin is 
stored. The amylin concentration in the secretory granule ranges from ~500 μM 
to 4mM. Amylin is co-secreted with insulin into the extracellular space within 
the pancreatic islets; the peptide then diffuses into blood vessels and enters 
the circulation (pM concentrations). (review in (37)).  
Structurally, mature human amylin is relatively hydrophobic with several 
positively charged residues: Lys-1, Arg-11, and His-18 (Figs. 1.3b-d). At or 
below physiological pH, the peptide net charge ranges from +2 to +4, which is 
important for interactions with negatively charged cell lipid membrane and 
sulfated proteoglycans of the extracellular matrix (review in (56)). Normally, 
human amylin is soluble and unfolded in its monomeric stage. Human amylin 
forms insoluble amyloid when overexpressed (37). The amyloid formation by 
human amylin is similar to that of other amyloidogenic proteins, where there 
are three distinct phases: a lag phase, a growth phase, and a saturation phase. 
Starting from the monomeric building blocks, amylin forms amyloid fibrils. 
Based on time-resolved studies, it is now known that the soluble, low order 
oligomeric intermediates are formed during the lag phase (57). The protein 
conformation is an important feature in producing amylin toxicity effects 
(discussed in section 1.5.a). 
Reports show that amylin is found in other sites in the peripheral system, in 
addition to the site of secretion. Amylin is found in pancreatic δ-cells of rat and 
mouse (37), in the gastrointestinal tract of rat, mouse, cat, and human (58), and 
the developing kidney (59). Amylin expression is also found in the primary 
sensory neurons in dorsal root ganglia and the jugular-nodose and trigeminal 
ganglion in rats (60). Mice with a null mutation in their rodent amylin gene had 
reduced pain response without altered peripheral inflammation (61), 
suggesting that amylin has a function in pro-nociceptive function in primary 
sensory neurons (61). Additionally, amylin expression in the degenerative 
human intervertebral disc (62) and varicella-zoster virus-infected human spinal 
astrocytes (63) appear to play important roles in mediating the molecular 
interaction and the pathology severity. In the central nervous system, amylin 
 6 
mRNA expression is below cutoff/not detected (in the brain tissues of rats and 
humans) (8); rather, the source of amylin deposition in the brain is from the 
periphery (64, 65).  
1.4.b. Physiological functions 
The physiological function of amylin and its mechanisms are not well 
understood. Because it is co-secreted with insulin, amylin was hypothesized to 
participate in glucose metabolism. Researchers have investigated amylin 
functions in insulin secretion and insulin resistance, glucagon secretion, 
glycogen synthesis in skeletal muscles, satiation, and gastric emptying (Fig. 
1.4). Investigations on this matter in the animal and human systems have 
generated interesting, yet, mixed results due to two main factors: lacking 
appropriate experimental concentrations and unknown aggregation stage of 
amylin, especially in the earlier studies done on amyloidogenic species of 
amylin.  
Insulin secretion and insulin resistance 
Soon after amylin was discovered, ex vivo study showed the antagonistic 
effects of amylin to insulin-stimulated glucose uptake and glycogenesis in rat 
skeletal muscle (51); in vivo infusion of amylin in cats impaired glucose 
tolerance (66). These studies generated hope that amylin was an underlying 
mechanism for insulin resistance in T2D. However, experimental 
concentrations for amylin in the above studies were higher than the 
physiological concentration, placing difficulty to separate the 
pathophysiological functions from the physiological ones. In contrast, the 
administration of lower amylin concentration in rats did not affect glucose-
stimulated insulin secretion from the pancreatic islet, in vivo and in vitro (67). 
Moreover, lower circulating amylin levels (~15 pM) in lean and non-diabetic 
chronic kidney failure patients did not affect insulin secretion and did not cause 
insulin resistance (68). Only at a very high plasma amylin level (about 90 times 
normal postprandial peaks), amylin was found to decrease insulin secretion in 
response to glucose (69). Notably, these studies did not consider the 
aggregation stage of amylin, which is affected by high circulating amylin levels 
and preparation/measuring methods in the experimental setting. It appears that 
the high plasma amylin level accelerates amylin aggregation (amylin is an 
amyloidogenic protein) and that amylin aggregation plays a role in decreasing 
insulin secretion (through inducing β-cell apoptosis, will be discussed in section 
1.5.a). From these studies, whether amylin plays a significant role in insulin 
secretion and insulin sensitivity remains unclear and needs further 
investigations.  
Glycogen synthesis 
Because it is plausible that circulating amylin affects insulin sensitivity, 
amylin may affect insulin-stimulated glycogenesis in the skeletal muscles. 
Results from several studies showed that synthetic human amylin inhibits 
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insulin-stimulated rates of glucose incorporation into glycogen in both isolated 
skeletal muscles and the diaphragm from fasted rats (55, 70). 
Glucagon secretion 
As part of the glycemic controlling factor, amylin is hypothesized as a potent 
inhibitor of postprandial glucagon secretion. Limited data is available to support 
this notion. During meals, glucagon secretion from the pancreatic α-cells is 
stimulated by amino acids to mobilize amino acids to their storages in 
peripheral tissues. Glucagon primarily acts on the liver to initiate glycogenolysis 
and gluconeogenesis, leading to an increase in the endogenous production of 
glucose. Thus, the inhibitory effect of amylin on glucagon secretion indirectly 
controls blood glucose by suppressing endogenous glucose production (71). 
This inhibition is extrinsic to the pancreatic islet, occurring only in intact animals 
and humans, not in isolated islets or isolated perfused pancreas preparations 
(71). The mechanism for these antagonistic effects remains elusive.  
Regulation of satiation and gastric emptying 
Although available evidence is scant, studies suggest that amylin regulates 
satiation and inhibits gastric emptying via the central nervous system in animal 
models and humans (72). Peripheral amylin normally crosses the blood-brain 
barrier (64, 65) to bind to various regions in the central nervous system. Using 
in vitro autoradiographic, investigators found high amylin binding areas, 
including subfornical organ (circumventricular area), vascular organ of the 
lamina terminalis, area postrema in the hindbrain, and the hypothalamus (55, 
73, 74). Other high-moderate levels of binding areas include the thalamus (stria 
terminalis) and mid-caudal nucleus accumbens (55, 73, 74). Evidence supports 
the anorexic effect of peripheral amylin is mediated by direct humoral action on 
the area postrema. Intraperitoneal injection and subcutaneous infusion of 
amylin reduced food intake in rats (75, 76), whilst thermal ablation of the area 
postrema significantly attenuated the anorexic effects of amylin delivered by 
intraperitoneal injection in rats (77). On the other hand, blocking amylin 
receptors with amylin antagonists increased food intake in rats (78).  Although 
it has been less-well investigated, amylin was also shown to lower body weight 
in rats that were infused with rat amylin (79, 80). However, a recent study on 
transgenic mice that overexpress [25, 28, 29triprolyl] human amylin, a laboratory-
generated non-amyloidogenic form of human amylin, showed a significant 
increase in body weights of transgenic mice (81). Both centrally and 
peripherally injected amylin appear to decrease the rate of gastric emptying 
and intestinal transit (82, 83), therefore, controlling the nutrients/glucose from 
entering the small intestine and subsequently into circulation. Specifically, 
amylin seems to act through the central nervous system to inhibit gastric 
emptying, as vagotomy in rats did not affect the ability of amylin to suppress 
gastric emptying (84). Further studies on humans are necessary to elucidate 
the mechanisms of amylin-induced satiation and gastric emptying.  
1.5. The pathogenic role of human amylin on the islet β-cells 
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Whether islet amyloid has pathogenic importance was an enigma. Islet 
hyalinosis was initially found in association with diabetes, particularly in elderly 
individuals, but not in all individuals with diabetes (44, 85, 86). Interestingly, 
islet hyalinosis was also observed in nondiabetic individuals, especially in the 
elderly, although not as extensive compared to diabetic individuals (43, 86, 87). 
These observations seemed to dim the hypothesis that islet amyloid might be 
a potential cause of T2D; rather, scientists proposed that islet amyloid is a 
pathological response from the pancreas. 
Despite the previous notion that islet amyloid formation was a pathological 
response, later studies showed that amylin amyloid formation is important for 
the pathogenesis of T2D. Pancreatic islet amyloid, in which amylin is the major 
peptide component (37), is a common pathology in patients with T2D (40, 42-
44), and was reported in more than 90% of subjects with T2D (38, 39). A high 
level of amylin in the blood, contributing to amylin aggregation, appears to 
occur in patients with insulin resistance (88). Humans with a rare substitution 
mutation in amylin (S20G, which increases amylin propensity to form amyloid 
(89)) are associated with increased incidence or severity of T2D in the 
Japanese population (90). Multiple mechanisms of human amylin-induced β-
cell toxicity have been proposed and tested. Those involve cellular membrane 
disruption, oxidative stress, activation of the inflammasome, endoplasmic 
reticulum stress, autophagy dysfunction, and the activation of cell death 
signaling pathways, leading to the gradual loss of β-cell mass in T2D (38, 91-
94). Mechanisms relevant to this dissertation will be discussed in section 1.5.b. 
1.5.a. The amyloidogenicity of human amylin is crucial for 
cytotoxicity 
Amylin from humans and several mammalian species including cats, dogs, 
and monkeys (but not rodents) are amyloidogenic (37). The amyloidogenicity 
of human amylin is central in amylin-mediated pathology in the pancreatic β-
cells (37, 91, 93, 95) and other organs (2-7, 96-99). The amyloidogenicity of 
amylin in several species correlates with the fact that islet amyloid deposition 
is species-specific, and is associated with the onset of diabetic syndrome in 
humans and cats, but not in most rodents (100). Not all forms of aggregated 
human amylin are cytotoxic to β-cells. Researchers previously assumed that 
amylin mature fibrils were toxic to β-cells because it was commonly detected 
near the islet cells (91, 101, 102). However, the recent data show that the 
soluble oligomeric form, representing intermediate assemblies in the 
aggregation process, exerts greater toxicity compared to the non-toxic mature 
fibrillary form (57, 103, 104).  
A specific region of human amylin is responsible for amyloid formation and 
amyloid-mediated pathological functions. The 8-37 amino acid amylin variant, 
which contains the amyloidogenic 20-29 amino acid sequence, is responsible 
for the formation of the transient, parallel β-sheet structure during amyloid 
formation in solution (105) (Fig. 1.3b, c). In rat amylin, the substitution for 
proline residues in positions 25, 28, 29 of the amyloidogenic region disrupts the 
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β-sheet secondary structure in this region. As the result, rat amylin oligomers 
form α-helical secondary conformation (Fig. 1.3c), but the human amylin 
oligomers form two stable conformations: an α-helical conformation with a short 
β-sheet near the C-terminus (Fig. 1.3d), and a more stable full β-hairpin 
conformation (106). When comparing similar-sized oligomers formed by human 
amylin and rat amylin, studies found that the rat amylin oligomers are not toxic 
to β-cells (57). The incubation of amyloidogenic 20-29 amino acid sequence 
induces insulinoma cells apoptosis (100), whilst the substitution of three 
prolines in the amyloidogenic region (rat amylin) abrogates the caspase 
cascade activation and cellular apoptosis (92). Therefore, the differences in 
oligomer conformational properties and/or their stability may well be an 
important feature for enhancing toxicity by human amylin.  
1.5.b. Mechanism of human amylin-induced toxicity in the 
pancreas 
Membrane disruption 
The first mechanism of toxicity, and the most widely accepted one, is 
membrane disruption and subsequent consequences of cellular homeostasis. 
Initial observations by Westermark et al. (100) and Lorenzo et al. (91) provide 
insight on the membrane disruption by human amylin causing cell death, and 
the interaction of amylin with the cellular membrane is crucial for its toxicity, 
respectively. Subsequent studies found that oligomeric human amylin can 
directly incorporate into the plasma lipid bilayer and form membrane ion pores, 
allowing the passage of molecules with the size of a calcium ion (107-110). 
This results in membrane destabilization and leakage (107-111), as well as 
disruption in islet architecture, which is critical for cell survival (112). The 
process of fibril growth from the incorporated monomers or oligomers also 
causes membrane damage (104, 107). In contrast, the monomeric and fibrillary 
forms were not found to damage the cellular membrane (104, 107), although a 
study showed that monomeric human amylin can destabilize the plasma 
membrane by increasing its fluidity (113). Human amylin induces membrane 
leakage in a much lower concentration than rat amylin, which is not 
amyloidogenic (111). In addition to plasma membrane disruption, more 
evidence suggests that aggregate human amylin can penetrate and may target 
the mitochondrial and endoplasmic reticulum membranes, resulting in β-cell 
mitochondrial dysfunction (114), endoplasmic reticulum stress and apoptosis 
(115). However, there are issues with these proposed membrane disruption 
mechanisms that they are not fully defined for the physiologically relevant 
model, as the commonly used model membranes are very different from that 
of the β-cell (111).   
Oxidative stress, activation of inflammasome, and apoptosis pathways 
The second mechanism of toxicity involves amylin-induced oxidative stress, 
inflammation and apoptosis, which can be interrelated with cellular membrane 
disturbance. Incubation of human amylin on rat insulinoma cells activated the 
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apoptotic pathway involved caspase cascade activation (caspase-1 and -3 and 
partially, caspase-8) (92). Islets from human amylin transgenic mice had 
increased reactive oxygen species (ROS) levels and apoptosis in association 
with amyloid deposition (116). A study on T2D human islets showed pro-
inflammatory cytokine interleukin 1β (IL-1β) deposition in both macrophages 
and extracellular space surrounding amylin-filled pancreatic islets (117). Co-
localization of macrophage’s IL-1β and human amylin in pancreatic islet cells 
was accompanied by a drop in insulin-producing cells (117). Mechanistically, 
amyloidogenic human amylin, but not the non-amyloidogenic rat amylin, can 
trigger NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) 
inflammasome activation and IL-1β production in bone-derived macrophages 
and dendritic cells. Caspase-1 and NLRP3 are the mediators in human amylin-
induced IL-1β production, which eventually triggers apoptosis (117). Thus, 
inhibition of amyloid formation by human amylin (92, 116), specifically, 
inhibition of oligomer formation during the lag phase, rather than the fibril 
formation in the growth phase (57), can prevent oxidative stress, inflammation, 
and apoptosis in β-cells.  
Endoplasmic reticulum (ER) and mitochondrial stress 
Studies have reported ER stress and defects in ER-associated protein 
degradation and unfolded protein response caused by human amylin (115, 118, 
119). Defective protein folding machinery causes the accumulation of 
misfolded and/or partially cleaved pro-amylin in the intracellular secretory 
granules, which is postulated to be deleterious to β-cells (37).  
Mitochondria from the β-cells of T2D patients show lower ATP levels, 
impaired hyperpolarization of the mitochondrial membrane, and increased 
density volume (120). Morphological and functional alteration of the 
mitochondria indicates modification in oxygen sensing and oxygen metabolism. 
Accumulation of human amylin oligomers in the ER causes a rise in cytosolic 
calcium that leads to fragmentation of the mitochondrial network, slows down 
mitochondria TCA cycle, and activates hypoxia signaling (121). This adaption 
preserves β-cells survival in exchange for cell dysfunction (121).  
1.6. Amylin accumulation and its effects on the extra-pancreatic tissues 
(the heart and the kidney) 
T2D increases risk for cardiovascular complications including heart and 
kidney diseases, but the molecular link remains elusive. An early study on the 
nature of the islet amyloid found a large number of hypertensive patient cases 
was amyloid-positive, both diabetic and non-diabetic (43). Giving that amyloid 
was found near the pancreas endothelial structure first, Ahronheim postulated 
that amyloid interferes small blood vessels, resulting in increased blood 
pressure, in a manner comparable to that leading to renal hypertension (43). A 
later study by Ehrlich and Ratner (44) specifically showed Congo Red-positive 
deposits between the capillary wall and islet cells. In contrast to findings by 
Ahronheim, this study did not find a significant statistical correlation between 
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the occurrence of amyloid and the degree of sclerosis of pancreatic arteries 
and arterioles.  
Interestingly, recent investigations from our lab and others report that 
patients with T2D have an abnormal accumulation of aggregated amylin in 
extra-pancreatic tissues, including the hearts (98, 122) and the kidneys (96, 
97). In failing hearts of diabetic patients and human amylin expressing rats (HIP 
rats), amylin accumulates in the heart blood vessel wall, perivascular space, 
cardiac parenchyma, and cardiomyocyte sarcolemma (98, 122). Accumulation 
of human amylin the kidneys of the HIP rats contributes to vascular injuries and 
renal failure (97). 
1.6.a. Mechanisms of human amylin-induced toxicity in the heart 
and kidney tissues 
Membrane disruption, oxidative stress, calcium dysregulation 
Myocardial amylin incorporation destabilizes the sarcolemma membrane, 
thus exposing the unsaturated fatty acids in the cellular membrane to cytosolic 
ROS (123). This process triggers the formation of reactive aldehydes including 
4-hydroxy-2-nonenal and malondialdehyde, which perturb intracellular 
homeostasis and further leading to increased ROS and IL-1β production (98, 
122, 123). Moreover, the ability of amylin oligomers to incorporate in the 
sarcolemma causes Ca2+ leakage and Ca2+ dysfunction including elevated 
cytosolic Ca2+ transients and activation of hypertrophic remodeling pathways 
(98, 122, 124, 125). Using a transgenic rat model expressing human amylin 
(HIP rat), studies found that high levels of blood amylin facilitate cardiomyocyte 
remodeling (124), cardiac hypertrophy, and diastolic dysfunction (98, 122). 
These alterations occur before the onset of overt hyperglycemia (prediabetes). 
In contrast, prediabetic rats expressing nonamyloidogenic rat amylin display 
normal heart structure and function (98, 122, 124).  
Hypoxic-ischemic injury 
Renal amylin deposition (in the glomeruli, interstitium, and blood vessels) 
was found in ~48% of patients with diabetic nephropathy (96). Amylin 
deposition was associated with a high level of plasma amylin and the severity 
of renal tissue lesions and kidney dysfunction (96). Investigations from our lab 
suggest that microcirculatory disturbances seen in the diabetic kidney tissue 
are mediated by the accumulation of amylin in red blood cells and capillary 
endothelium (97). Amylin accumulation consequently damages red blood cells 
and endothelial cells, leading to tissue hypoxic-ischemic injury, and these 
events take place before the onset of overt hyperglycemia (97). Therefore, 
hyperamylinemia during the progression of T2D contributes to comorbidities, 
including cardiovascular disease and chronic kidney disease, which are 
commonly observed in diabetic patients (126).  
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1.7. Amylin dyshomeostasis is a contributing factor for cerebrovascular 
disease and Alzheimer disease 
The postulated mechanisms linking T2D and dementia involve 
cerebrovascular and noncerebral vascular ones (127, 128), in which amylin 
infiltration from the circulation (as observed in hearts (98, 123, 124) and kidneys 
(96, 97)) may be an important contributor to cerebrovascular injury and 
neurodegeneration observed in demented humans.  
1.7.a. Cerebrovascular mechanisms 
Amylin infiltration from the periphery to the brain  
Peripheral amylin can cross the blood-brain barrier to enter the brain 
parenchyma, as demonstrated by early studies by Banks et al. (64, 65). The 
studies found a significant amount of peripherally secreted amylin in the 
interstitial fluid surrounding the cerebral cortex, and a small percentage of 
amylin was associated with the capillaries (64, 65). This could represent one of 
the transit routes for amylin from the periphery to the brain, although 
alternatively, amylin could enter the brain through the leaky capillaries of the 
choroid plexus. Banks and his colleagues postulated that amylin potentially had 
a role in manifesting the effects of diabetes mellitus on the central nervous 
system through the cerebrovasculature (64, 65). This hypothesis has been 
proven to be true given the later supporting evidence. 
Neurovascular unit injury 
Mounting evidence indicates the presence of amylin deposition in the brains 
of patients with T2D and dementia (2-7, 99, 129). Amylin accumulation is 
abundant in the cerebral small vessels and is occasionally co-localized with Aβ 
in cerebral amyloid of AD patients (2, 5) (Fig. 1.5). The severity of amylin 
angiopathy increases in AD patients with T2D (2, 5). Areas with amylin 
accumulation display altered vascular structure including enlargement of 
perivascular space and disrupted vessel wall (2, 5). Our investigation first 
showed that microvascular amylin accumulation is associated with infarction 
and perivascular astrocyte recruitment, indicative of microvascular injury (2). 
Specifically, amylin deposits were found in the neurovascular components (2-
4, 129). We detected amylin accumulation in the endothelial cells (2), and these 
deposits were associated with endothelial cell apoptosis (2). Schultz et al. 
found that amylin formed intracellular inclusions in the brain microvascular 
pericytes of AD patients with T2D (4). These amylin-containing pericytes 
showed fragmented nuclei and loss of neuron-glial antigen 2 expression, which 
is necessary for pericyte viability and function (4). Additionally, amylin appeared 
to modulate pericyte autophagy and induced higher toxicity compared to Aβ 
amyloid in vitro (4). Results from the same research team showed the presence 
of aggregated amylin in the retinal microvessels of AD patients (3). Analysis of 
capillary amylin accumulation in the retina appeared to correlate with 
hippocampal amylin angiopathy and amylin burden (3). Other sites of amylin 
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accumulation in the neurovascular unit such as astrocytes and microglia were 
also detected in the brain of AD patients (129). These data suggest that the 
brain blood vessels, as well as other components of the neurovascular unit, are 
one of the sites of injuries caused by amylin accumulation. 
Taken together, these results (2-6, 99, 129) infer the possibility of using 
peripherally-mediated amylin dyshomeostasis as a biomarker of 
cerebrovascular risk in patients with T2D. 
1.7.b. Non-cerebrovascular mechanisms 
Amylin-Aβ protein-protein interaction 
One potential mechanism underlying diabetic contributions to dementia 
involves the interaction of diabetes-related amylin dyshomeostasis with AD 
pathology (Fig. 1.6). Our lab first identified elevated human amylin levels in the 
brains of AD patients with or without T2D, and human amylin interacts with Aβ, 
forming depositions in the brain parenchyma and brain blood vessels of those 
patients (5) (Fig. 1.5). Similar results confirming our findings are later shown 
by Fawver et al. and Oskarsson et al. (6, 7). Fawver et al. identified amylin in 
the cerebrospinal fluid, brains of diabetic patients with vascular dementia or 
AD, and non-diabetic patients with AD. Oskarsson et al. showed that the level 
of amylin is increased in the diffuse and dense cerebral plaques and within 
vascular amyloid deposits in the brains of patients with pathological AD, without 
the clinical diagnosis of T2D (6). Interestingly, early in vitro evidence by 
Kapurniotu’s group proposed that human amylin cross-assembly with Aβ 
species (Aβ1-40 and Aβ1-42) inhibits the self-fibril formation by both amylin and 
Aβ, thus stabilizing the oligomeric conformation (130, 131), which is later known 
to be cytotoxic (57, 132). Additionally, the study by Fawver and colleagues 
found human amylin augmenting Aβ oligomerization in the dose-dependent 
manner (7). The results are consistent with later data showing that ex vivo 
cross-seeding by amylin aggregates exponentially promote mixed amylin-Aβ 
amyloid formation (6). In line with these findings, a recent investigation 
demonstrated that mice expressing a mutated form of the amyloid precursor 
protein (APP) (Tg2576) in neurons and human amylin in the pancreatic islets 
developed mixed amylin-Aβ plaques in the brain (133), similar to the pathology 
observed in individuals with T2D and AD (5-7). When compared to transgenic 
mice expressing only the human amylin or the mutated form of APP protein 
alone, mice with mixed amylin-Aβ pathology show accelerated neurological 
dysfunction (133). The mechanism for exacerbated neurological function in this 
mice model is postulated due to the increased Aβ burden in association with 
elevated amylin accumulation in the brain (133). However, clinical data suggest 
that patients with T2D and sporadic AD do not display augmented Aβ burden 
(128, 134). Such contradictions can be explained. First, the transgenic mouse 
model for AD over-expresses human Aβ, and along with aging, accumulating 
senile plaques (fibrillary form) that are easy to detect by histological or 
neuroimaging techniques. Second, amylin-Aβ cross-seeding does not 
necessarily increase plagues formation in the context of “non-overexpressing 
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Aβ” humans (sporadic AD), but the levels of toxic oligomers, which are not 
readily detected in neuroimaging, may elevate. Third, T2D can worsen AD 
outcomes by affecting the cerebrovasculature (29, 128, 135). Further 
investigations are required to clarify the specific mechanisms in which amylin 
dyshomeostasis interacts with AD pathology and exacerbates the progression 
of AD. 
The increased propensity of amylin and Aβ to interact may be due to the 
fact that the amino acid sequence of human amylin is 52% similar to that of 
Aβ1-40 and Aβ1-42. The studies mentioned above suggest the Aβ-seeding ability 
of human amylin in the brain. Nonetheless, one cannot exclude that the Aβ-
seeding for amylin deposition is also a possible process that may occur parallel 
or independent from amylin-seeding Aβ. 
In the brain of AD patients, amylin deposits co-localized with Tau and 
abnormal forms of Tau in the hippocampal neurons (129). The co-localization 
suggests that the area with amylin deposition is associated with neuronal 
structural damage since normal forms of Tau maintain the dynamic of the 
microtubule network (136).  
Genetic interaction between amylin gene and AD pathophysiology 
In addition to protein-protein interaction, intriguingly, amylin-Aβ interaction 
is also found at the genetic level. Genome-wide association analysis further 
supports the interaction between the amylin gene and AD pathophysiology 
(137). Specifically, near genome-wide significant interaction effect was 
observed for an imputed variant rs73069071, located on chromosome 12p 
12.1, within the amylin gene (137). The rs73069071-by-Aβ deposition was 
found for interaction effect on global cognitive function in AD patients (137). 
Although remaining elusive, the postulated mechanism involves the effect of 
this single nucleotide polymorphism on amylin production, whose product is 
known to interact with Aβ or possibly altering Aβ metabolism, hence modulating 
the impact of Aβ deposition on cognitive performance. 
Amylin receptor-mediated cytotoxicity 
Within the effort to understand the interaction of amylin and Aβ pathology, 
several investigations suggest that the interaction is mediated through amylin 
receptors (138, 139). Experimental data indicate that Aβ directly activates 
amylin receptors and that the oligomerized Aβ-induced neurotoxicity can be 
blocked with specific amylin receptor antagonists or downregulation of amylin 
receptor expression (138, 139). Interestingly, amylin receptor expression in the 
brain was up-regulated within the area of increased amyloid burden in AD 
transgenic mice which overexpress the mutated form of APP (TgCRND8) 
(139). Furthermore, amylin receptors inhibitor (AC253) can re-establish long-
term potentiation in the hippocampus of AD mice (140). While amylin 
accumulation appears to have deleterious effects, overexpression of amylin 
receptor (by the unknown mechanisms) possibly provides a platform for Aβ-
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induced neurotoxicity. Another study on primary rat hippocampal neurons 
proposed that at low concentrations, the amylin receptor mediates neuronal 
excitatory response (141). On the other hand, at high concentrations, human 
amylin aggregates activate TRPV4 channels, triggering neuronal membrane 
voltage-gated calcium channel opening, and membrane depolarization (141).  
Amylin and amyloid precursor protein processing 
Amylin and its analog, pramlintide, are shown to elevate Aβ production and 
Aβ-related pathology in AD mice brains (142). The mechanism is through the 
increased expression of γ-secretase, which participates in amyloid cleavage of 
full-length amyloid protein precursor, in lipid rafts. However, the AD mice model 
treated with amylin and pramlintide did not show a decline in long-term memory 
tested by Morris water maze (142). Further studies employ other AD models 
and sensitive tests for cognitive function are necessary to understand the 
effects of amylin- or pramlintide-induced Aβ pathophysiology. In contrast, the 
opposite results from several studies suggest that using human amylin and its 
analog pramlintide could be beneficial for AD mice (143, 144). Nonetheless, it 
is still not clear whether the lower concentration is required to prevent the 
amyloid formation in those studies, and the problem with dosage control needs 
more supporting data. 
Mitochondrial dysfunction, calcium dysregulation, oxidative stress, and 
inflammation 
Besides the pathological interaction with Aβ and Tau, aggregated amylin 
itself is neurotoxic because of its ability to 1) destabilize/damage the cellular 
membrane, as discussed in section 1.5.a, and 2) possibly triggers deleterious 
signaling pathways mediated by receptors, as discussed above. Several 
mechanisms of amylin-induced neuronal toxicity, including mitochondrial 
dysfunction, calcium dysregulation, and oxidative stress have been proposed 
(99, 138, 145-149). A study by Estus and colleagues investigating the gene 
expression pattern in human amylin-treated cortical neurons showed a total 
decrease in mRNA synthesis from genes that are necessary for cell viability, 
and the rate of neuronal death positively correlates with incubated amylin 
concentration (150).  
Human amylin shares a similar neurotoxicity profile with Aβ and other 
amyloidogenic peptides. Both human amylin and Aβ trigger mitochondrial 
dysfunction. Treatment of human amylin and Aβ on neuroblastoma cells were 
shown to deregulate mitochondrial proteins, metabolism proteins, cell cycle, 
and cytoskeleton-related proteins; thus, reducing mitochondrial functions and 
eliciting abnormally high ROS generation (148, 149). Amylin-induced neuronal 
death is mediated by increasing ROS production, following by elevated 
intracellular Ca2+ with glutamate exposure (145). Removal of extracellular Ca2+ 
reduces Ca2+ influx, protecting cultured hippocampus neurons from human 
amylin toxic effects (145). Pretreating neurons with antioxidants attenuates the 
rise in intracellular Ca2+ and significantly preserves neuron survival (145), 
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indicating that amylin first provokes the production of ROS, leading to a spike 
in intracellular Ca2+. Interestingly, only the oligomeric form of amylin causes a 
rapid increase in the cytosolic Ca2+ level, which triggers the Ca2+-dependent 
apoptosis pathway (146). The mechanism of action for amylin mediated Ca2+ 
dysregulation is still not clear. Previous studies proposed that the mechanism 
of elevated intracellular Ca2+ was resulting from extracellular Ca2+ influx 
through calcium membrane channels and cation-channels formed by amyloid 
peptides (146, 147). Some evidence suggests that amyloid oligomers may first 
increase the cell membrane permeability, then penetrating into the cytoplasm 
and causing leakage of stored intracellular Ca2+ (146). Despite the specific 
pathway for Ca2+ entry or release, oligomeric amylin is capable of inducing 
calcium dysregulation, confirming its toxic profile compared to the fibrillary form.  
Our experiment on isolated rat neurons showed that human amylin forms 
adduct with 4-hydroxynonenal, a marker of peroxidative membrane injury, and 
leading to increased synthesis of IL-1β (99). The amylin-mediated neuronal 
injuries (elevated levels of peroxidative product and IL-1β production) were 
blocked ex vivo by membrane stabilizers and lipid peroxidation inhibitors (99). 
Interestingly, soluble endogenous Aβ and human amylin are recognized by 
CD36 (pattern recognition glycoprotein on macrophage surface), engulfed by 
macrophage, and turned into oligomers/fibril amylin through intralysosomal 
conversion, eventually leading to NLRP3 inflammasome activation and IL-1β 
production (151). Thus, aggregated amylin deranges the lipid membrane and 
predisposes it to calcium dysregulation and related apoptosis pathway, 
peroxidative injury, and inflammatory responses. 
Given the pathological function of aggregated amylin (2, 5, 8), the 
interaction of amylin with Aβ may accentuate neurotoxicity. Therefore, 
prevention strategies to effectively block amylin-mediated neurodegeneration 
should involve the inhibition of amylin-induced neuronal membrane injury and 
amylin-Aβ interaction.  
1.8. Animal models to study contributions of T2D to cognitive impairment 
and dementia 
Rodents are the most commonly used laboratory models for diabetes and 
dementia owing to their 99% similarity to the human genome (152). However, 
neither diabetes nor dementia-like pathology spontaneously occurs in rodents. 
Conditions associated with diabetes, dementia, or both can be induced in 
rodents (2, 8, 153-155). For the most part, insights from these interventions 
have been restricted to cerebral effects of inducing diabetes in normal rodents 
and in rodents genetically modified to develop neurodegeneration linked to the 
accumulation of Aβ in the brain. In humans with T2D, the variation in the clinical 
phenotype of cognitive dysfunction or dementia may result from multiple 
pathologies (25, 128). An existent challenge of using rodent models to uncover 
mechanisms underlying the impact of T2D on brain structure and function lies 
in the fact that some genetic modifications that lead to T2D phenotype directly 
impact brain structure and function. For example, leptin or leptin-receptor 
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deficiency, which is the commonly used genetic modification to induce obesity-
related metabolic disturbances in rodents (156), has negative effects on 
learning and memory (157). Thus, interpretations made on specific molecular 
mechanisms of diabetes-induced brain dysfunction need careful consideration. 
Overexpression (3-fold) of human amylin in rats leads to the mid-life onset 
of hyperglycemia linked to pancreatic amylin amyloid and β-cell apoptosis (95). 
Diabetes in human amylin expressing rats (HIP rats) is associated with 
neurological deficits including declined learning and memory, vestibulomotor 
dysfunction, and gait abnormalities (2, 8). In brains of the HIP rats with motor 
abnormalities, amylin accumulation is found in the brain parenchyma and blood 
vessels (2, 8). Amylin deposition in small blood vessels correlates with 
microhemorrhages, decreased tight-junction proteins levels, and perivascular 
astrocyte activation (2), indicating that systemic amylin dyshomeostasis 
damages the blood-brain barrier. Magnetic resonance imaging of HIP rat brains 
showed increased ventricular volumes with white matter hyperintensities and 
brain atrophy (2). Further assessment of cerebral blood flow in HIP rats 
revealed that amylin dyshomeostasis was associated with capillary loss and 
decreased cerebral perfusion (2). Amylin dyshomeostasis occludes or/and 
damages the brain small vessels, leading to brain parenchymal loss. 
The metabolic consequences of amylin dyshomeostasis have been 
observed in the HIP rat heart, brain, liver, and plasma using non-targeted 
metabolomics analysis (158). In HIP rat brains, there is a 50% reduction in 
tyrosine and phenylalanine (precursor for tyrosine), which is significant 
because tyrosine and phenylalanine are precursors of catecholamine 
neurotransmitters (dopamine, norepinephrine, and epinephrine) (158). Also, 
HIP rat brains have significantly altered pentose phosphate pathway that is 
preferentially used by neurons to metabolize glucose and maintain their anti-
oxidant status) (158). Altered pentose phosphate pathway is commonly seen 
in neurodegenerative diseases (159). Importantly, these metabolic 
consequences are not characteristic of diabetes (158), but uniquely related to 
the amylin-driven pathology in the amylin dyshomeostasis rat model. Both the 
reduction in the levels of neurotransmitter precursors and alteration in pentose 
phosphate pathway correlate with the neurological dysfunction in HIP rats (2, 
8). Therefore, the animal model with amylin dyshomeostasis has the advantage 
of recapitulating vascular injury, brain atrophy, and metabolic changes seen in 
the brains of individuals with T2D and neurodegenerative diseases (for reviews 
(128, 159)). 
1.9. The future of brain amylin research 
Till today, there remains much of what we wish to know about this peptide. 
However, current encouraging investigations have allowed us to gain a better 
understanding of the basic mechanisms of amylin-mediated physiological 
processes and pathologies. Along with robust technology development during 
these past decades (genetically engineered non-human vertebrates and non-
vertebrate models, advance imaging techniques, next-generation sequencing, 
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bioinformatics, etc.), useful tools will be used to decipher the role of amylin 
dyshomeostasis in the early pathological progression of AD and CVD, and 
hopefully, the results can be translated to the characterization of the biomarkers 
for early diagnosis of dementia and therapeutic interventions. 
1.10. Scope of dissertation 
1.10.a. The role of amylin dyshomeostasis in CVD: cerebral 
microvascular injury and brain white matter disease 
The general hypothesis tested is that aggregated amylin circulates through 
the blood, deposits in brain blood vessels and provokes brain microvascular 
injury by degrading endothelial cell coverage and tight junctions.  
Specific aim 1: To test this hypothesis, we performed in vivo phenotyping 
of rats expressing amyloidogenic human amylin in the pancreas (HIP rats) and 
generated amylin knockout rats that were intravenously infused with 
aggregated human amylin.  
Specific aim 2: To test this hypothesis, we also carried out biochemical 
analyses of brain tissues from humans and studied the effects of the 
aggregated amylin on endothelial cells, ex vivo.  
1.10.b. The role of amylin dyshomeostasis in the development of 
AD and progression of the disease 
The general hypothesis tested here is that amylin dyshomeostasis 
exacerbates AD pathology and disease progression by modulating the amyloid 
composition and vascular injuries in both familial and sporadic forms of AD.  
Specific aim 1: To test the potential relationship between pancreatic 
amylin, the brain and familial AD, we analyzed brain tissues from fAD patients 
for amylin deposition and interaction with areas of AD-related histopathology. 
Brains from sporadic AD was also used to assess the amylin pathology and 
interaction with Aβ. 
Specific aim 2: To assess the consequences of amylin pathology seen in 
human brains, we generated transgenic AD and non-AD rat models in which 
the consequences of elevated blood levels of human amylin can be directly 
addressed in terms of AD pathology and neurological deficits. To further test 
the mechanism, we intravenously injected human amylin in AD rats that 
express non-amyloidogenic rat amylin; and assessed amylin-mediated 
pathology without confounders due to the development of amylin 
dyshomeostasis. 
Specific aim 3: To test whether lowering blood amylin ameliorates the 
disease pathology and progression, we generated AD rats with the amylin gene 
deleted to test effects of suppression of amylin secretion on AD pathology and 
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neurological function. We also pharmacologically lowered amylin 





Figure 1.1. Timeline for amylin-related research publications with highlights 
in major discoveries. PubMed searches were performed using the “IAPP” (islet 
amyloid polypeptide) or “Amylin” keywords for the number of publications per year. 
The discovery of insulin is also included in the highlights due to its important role 
to the study of glycemic-regulating hormones secreted from the pancreatic β-cells. 
This consequentially leads to the study of islet dysfunction, islet amyloid and 





Figure 1.2. Amino acid sequences of human amylin and human calcitonin 
gene related peptide (CGRP). Human amylin has significant sequence 




Figure 1.3. Schematic of amylin protein processing and structural 
differences between human and rat amylin peptides. (a) The amino acid 
sequence of human pre-pro-amylin (89-amino acid residues) with the cleavage 
sites for prohormone convertase (PC) 2, PC1/3, and carboxypeptidase (CPE). 
After being cleaved by PCs, CPE then removes the KR residues, exposing the 
glycine residue (blue) used for C-terminus amidation by the peptidyl glycine α-
amidating monooxygenase. Mature human amylin contains 37-amino acid 
residues with amidated C-terminus and intramolecular S-S bond between residues 
2–7 at the N-terminus (ring structure). (b) Structural differences between 
amyloidogenic human amylin vs. non-amyloidogenic rat amylin. In rat, the 
substitution for proline residues in positions 25, 28, 29 of the amyloidogenic region 
(20-29) inhibits the amyloid formation. (c) Cartoon diagram of rat amylin in helical 
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form, colored in rainbow spectrum with N-terminal ring structure in blue. Helix 
spanning residues are A5-S23. Substituted residues from human amylin colored 
in orange and pale blue sticks: R18, L23, P25, V26, P28, and P29. Three prolines 
(prevent amyloid formation) in rat amylin are highlighted in pale blue sticks. (d) 
Cartoon diagram of human amylin in helical form, colored in rainbow spectrum with 
N-terminal ring structure in blue. Helix spanning residues are A5-S28. Residues 
on human amylin that are different from rat amylin are colored in purple sticks: 






Figure 1.4. Schematic summary of amylin physiological functions. Amylin 
possibly inhibits insulin secretion and participates insulin resistance. Amylin may 
inhibit glucagon secretion and insulin-stimulated glycogen synthesis in the skeletal 
muscles. Amylin regulates satiety and possibly slows gastric emptying via the 




Fig. 1.5. First reports from our laboratory on amylin accumulation in the 
brains of AD patients. (a-d) Representative immunohistological images of 
vascular amylin deposits (a) and vascular amylin-Aβ interaction (b-d) in the brains 
of T2D patients with sporadic AD (T2D-D) (b, d) and cognitively unimpaired non-
diabetic individuals (Controls; Ctl) (c). (e) Analysis of amylin angiopathy in Ctl, 
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T2D-D, and AD, assessed from immunohistological staining. (f, g) Representative 
immunohistological images of amylin plaques (f) and amylin-Aβ mixed plaques (g) 
in the brains of T2D-D. (h) Analysis of amylin-Aβ mixed plaques in the brains of 
T2D-D vs. AD, assessed from immunohistological staining. (i, j) Representative 
immunohistological images of intraneuronal amylin accumulation (i) and 
intraneuronal amylin and Aβ plaques (j) in the brains of T2D-D. Data are mean ± 
SEM; P ≤ 0.05 *, P ≤ 0.01 **; two-tailed, unpaired t test. Figures are adapted from 






Fig. 1.6. Diabetes-related amylin dyshomeostasis leads to the formation of 
pancreatic amyloid and promotes amylin accumulation in the brain 
microvasculature. Circulating oligomerized amylin deposits in the brain 
microvasculature and induces small vessels injury by deranging the microvascular 
endothelium. Oligomerized amylin also forms mixed amylin-Aβ plaques in the brain 
parenchyma, accentuating neurotoxicity. Diabetes related amylin dyshomeostasis 
promotes a feed-forward pathological process by which circulating oligomerized 
amylin injures brain microvasculature and synergizes with Aβ pathology to induce 
dementia. 
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CHAPTER 2. BRAIN MICROVASCULAR INJURY AND WHITE MATTER 
DISEASE PROVOKED BY DIABETES-ASSOCIATED HYPERAMYLINEMIA 
2.1. Introduction 
Microvascular-related brain injury is associated with focal neurologic deficits 
and dementia (18, 160-163). The distal territories of small penetrating vessels 
(arterioles and capillaries) supplying brain white matter are particularly 
vulnerable to vascular pathologies (also known as cerebral small vessel 
disease). High blood pressure, atherosclerosis and inflammation are among 
the major causes of brain white matter disease of vascular origin (18, 160-163). 
Recent investigations (4-6) have revealed that the brain microvasculature of 
patients with dementia contains large deposits of amylin, a ~4 kDa peptide co-
synthesized with insulin by pancreatic β-cells (37). Vascular deposition of 
amylin is particularly abundant in the brains of patients with dementia and type 
2 diabetes (5, 6). The peptide amylin (or islet amyloid polypeptide) normally 
crosses the blood brain barrier (64) and binds to neurons in the feeding centers 
(164, 165), where it is believed to induce an anorexic effect (55, 166). In 
patients with type 2 diabetes, amylin forms amyloid in the pancreatic islets that 
triggers β-cell apoptosis (37, 93, 119). Deposits of aggregated amylin are also 
identified in failing hearts (98, 123) and kidneys (96) of individuals with type 2 
diabetes or obesity. Of note, apolipoprotein E4 (APOE4), which is strongly 
associated with β amyloid (Aβ) pathology (167, 168), modulates amylin 
aggregation (169) and amylin amyloid formation (170, 171).  
Amylin from species that do not develop type 2 diabetes (i.e. mice and rats) 
is non-amyloidogenic due to proline substitutions at the 25, 28, and 29 sites 
(100). Pharmacological induction of insulin resistance in transgenic mice 
expressing the amyloidogenic amylin variant (i.e., human amylin) caused intra- 
and extracellular amylin amyloid deposition, β-cell apoptosis and overt 
hyperglycemia (172). Similar pathologic changes occur in rodents 
overexpressing human (95), but not murine amylin (119). We previously 
reported that rats overexpressing human amylin in the pancreas accumulate 
aggregated amylin in the brain (8), which correlates with the development of 
neuroinflammation (8, 99), reduced synthesis (by >50%) of catecholamine 
precursors (phenylalanine and tyrosine) (158) and neurologic deficits (8). 
Furthermore, a recent study demonstrated that transgenic mice overexpressing 
human amylin in pancreatic islets and a mutant form of the amyloid precursor 
protein (APP) in neurons have exacerbated Aβ pathology compared to 
transgenic mice expressing only one or the other protein (133).  
Distinct from other diabetic complications, glucose dysregulation does not 
appear to be the primary determinant of progressive brain injury in patients with 
diabetes (25, 26, 29, 173-175). The pathophysiology underlying slowly 
progressive functional and structural brain changes in the setting of type 2 
diabetes is largely unknown (25, 26, 29, 173-175). Given the toxicity of 
aggregated amylin (37, 93, 96, 98, 119, 123), we hypothesized that the 
complex pathophysiology (25, 26, 29, 173-175) underlying slowly progressive 
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functional and structural brain changes in patients with type 2 diabetes involves 
accumulation of aggregated amylin in the brain blood vessels. Here, we tested 
the hypothesis that aggregated amylin circulates through the blood, deposits in 
brain blood vessels (possibly via the interaction with plasma apolipoproteins) 
and provokes brain microvascular injury by degrading endothelial cell coverage 
and tight junctions. To test this hypothesis, we performed in vivo phenotyping 
of rats expressing amyloidogenic (human) amylin in the pancreas (HIP rats 
(95)) and generated amylin knockout (AKO) rats that were intravenously 
infused with aggregated human amylin. We also carried out biochemical 
analyses of brain tissues from humans and studied the effects of the 
aggregated amylin on endothelial cells, ex vivo. Our findings may contribute to 
the understanding of the complex molecular mechanisms underlying the 
diabetes-associated stroke and dementia (25, 26, 29, 173-175). 
2.2. Materials and methods 
This investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 
85-23, revised 1996) and was approved by the Institutional Animal Care and
Use Committees at University of Kentucky.
Paraffin embedded brain tissues were provided by the Alzheimer Disease 
Center biobank at the University of Kentucky. The protocol was approved by 
the Institutional Review Board. 
For immunohistochemistry, formalin fixed dorsolateral frontal cortex 
(Brodmann area 9) tissue was used from three autopsied individuals >80 years 
of age at death, with type 2 diabetes and dementia and three age-matched 
cognitively normal individuals without type 2 diabetes (Table 2.1). The 
absence/presence of diabetes was determined during life (at longitudinal 
clinical visits) by patient or caregiver self-report and the use of diabetic 
medications (176). The assessment of clinical dementia and the 
neuropathologic features - neuritic amyloid plaques (Consortium to Establish a 
Registry for Alzheimer’s disease; CERAD), Braak NFT stage and cerebral 
amyloid angiopathy (CAA) severity - were scored as previously described (177-
181). Neuropathological information, APOE genotype, age and sex of each 
individual included in the present study are summarized with specific findings 
related to the vascular amylin pathology. 
2.2.a. Experimental animals 
HIP rats (n = 79; breeding pairs provided by Charles River Laboratory, 
Wilmington, MA) were used in behavior testing and physiological analyses. HIP 
rats are Sprague-Dawley rats that overexpress (3-fold) human amylin in the 
pancreatic β-cells (95). Wild-type (WT) littermate rats (n = 49) were used as 
non-diabetic controls.  
AKO rats were used to identify a possible interaction of amylin with plasma 
apolipoproteins (APOE) and to test whether intravenous infusion of aggregated 
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human amylin injures the brain microvessels independently of glucotoxicity. 
AKO rats (rather than WT rats) were used in amylin-injection experiments to 
eliminate the confound that rodent amylin and human amylin form mixed 
oligomers (182). AKO rats were generated in collaboration with Transposagen 
Biopharmaceuticals (Lexington, KY). The rat amylin gene was targeted at two 
sites by producing double strand breaks in the genome using the 
CRISPR/CAS9 system (183). The CRISPR gRNAs and Cas9 mRNA were 
microinjected into the pronucleus of fertilized Sprague-Dawley rat embryos by 
standard techniques, and the embryos were re-implanted to produce the 
genetically modified offspring. Amylin gene knock-out was confirmed by 
genotyping using the following primers for DNA amplification: Forward: 3’-
AGAGCTAAGCAAGTTGAGGGAT-5’; reverse: 
ACCACTAGTTCACATTCACAGAGG. AKO rat pancreas was tested for amylin 
immunoreactivity signal by Western blot.  
 Behavior testing 2.2.b. 
Inclined Plane 
Rats were placed on the flat plane in the horizontal position with head facing 
either up or down to the side to be raised. Starting at 30o, the angle was 
increased at 2o/second. The angle at which the animal starts to free-fall was 
recorded. Each rat received 3 trials per head facing direction. Rats were 
allowed to rest 1 minute between trials. Results were averaged for 6 trials.  
Cylinder Test/Forelimb Use Test 
To evaluate forelimb deficits, the animal was placed in a transparent 
cylinder for 5 minutes, and the activity was video recorded. The time that 
forepaws contacted with the cylinder wall during vertical rearing up was 
calculated using slow-motion playback software (Kinovea).   
Morris water maze 
Visuospatial learning and memory retention was tested in a 1.5 m diameter 
Morris water maze (184). HIP and WT littermate rats with no motor impairments 
were given 10 learning trials per day for two consecutive days using random 
starting locations (N, E, S, W). Animals were allowed to stand on the platform 
for 30 seconds after the first trial and 15 seconds after each additional trial. If 
the animals failed to locate the platform, they were picked up and put on the 
platform for 15 seconds. To assess reference memory, a probe trial was given 
24 hours after the second acquisition day. The probe trial was scored on 
latency to cross the platform. Trials were recorded by EthoVision XT software 
(Noldus, VA).  
2.2.c. Magnetic resonance imaging 
MRI data were acquired using a horizontal 7T nuclear magnetic resonance 
scanner (ClinScan, Bruker BioSpin MRI, Ettlingen, Germany) and a 38-mm rat 
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brain coil. Rats were first anesthetized with isoflurane (4.0% for induction, 1.2% 
for maintenance) and air mixture. Heart rate (90 to 130 b.p.m.), respiration rate, 
and rectal temperature (37 ± 0.5oC) were continuously monitored. Heart rate 
and blood oxygen saturation level were maintained within normal physiological 
ranges. Coronal T2-weighted MR images were obtained using the following 
variables: repetition time, 3000 milliseconds; echo time, 24 milliseconds; field 
of view, 40 mm; thickness, 1mm, 7 slices. Ventricular volume was measured 
from the frontal horn of lateral ventricle to the foramen of Luschka by combining 
hyperintensity ventricular area using ImageJ over all slices and multiplying by 
section thickness (185). Similarly, total brain volume was measured by 
multiplying combined brain area over all slices to section thickness. 
Parenchymal volume was calculated by subtracting ventricular volume from 
total brain volume.  
2.2.d. Isolation of rat brain capillaries 
Freshly isolated brain was homogenized in capillary PBS (cPBS) (137 mM 
NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.47 mM KH2PO4, 1.05 mM MgCl2, 0.9 
mM CaCl2, 5 mM glucose, 0.9 mM sodium pyruvate). To separate blood 
vessels from brain parenchyma, the brain homogenate was centrifuged in 30% 
Ficoll PM 400 solution (F-4375, Sigma, MO) at 5000 xg for 20 minutes, 4oC. 
The capillaries were then isolated by the glass bead column filtration method. 
In the first step, the pellet resulting from the centrifugation was re-suspended 
with 1% BSA in cPBS and passed through a 300 µm strainer. Then, the filtered 
pellet suspension was added into the glass bead column. Two hundred 
milliliters of 1% BSA was passed through the column. Capillaries were retrieved 
from the beads by agitation in 1% BSA and filtering through a strainer, followed 
by centrifugation at 500 xg for 5 minutes, 4oC. Capillaries were washed twice 
with cPBS before the experiment. For quality control, capillaries were stained 
with Texas red dye and were examined under confocal microscope.  
2.2.e. Cerebral blood flow measurement 
Fluorescent microspheres (15 μm diameter; F8839, Thermo Fisher, MA) 
were vortexed for 30 seconds in heparinized saline (106/mL fluorescent 
microspheres). Anesthetized HIP and WT rats were injected with a 200 µl 
volume containing microspheres and heparinized saline through the jugular 
line, twice (15 mins apart). Animals were sacrificed, and the brains collected 
for tissue digestion, capillary isolation (as described above) and microsphere 
recovery by filtration followed by fluorescence measurements. 
Equal weights of brain capillaries and remaining parenchymal tissue from 
WT and HIP rats were individually digested in 4M KOH and 2% tween 80 
(Sigma Aldrich, MO). The tissue was completely digested within 24 hours. The 
digested tissue was then filtered through 10μm pore polycarbonate filters 
(Millipore, CA). The vial and filtering syringe were washed twice with 2% tween, 
and wash was filtered to recover residual microspheres. The filter and filtered 
material from each tissue were placed in 1.25 ml of Cellosolve acetate (Sigma 
32 
Aldrich, MO) in tubes. After ≥4 and up to 24 hours, 100µl samples from each 
tube were placed in a 96 well microplate and the fluorescence of each was 
determined by fluorescent spectrophotometer. 
2.2.f. Histology 
HIP, WT and AKO rat brains were analyzed by staining with Prussian blue 
and Luxol fast blue (LFB). For Prussian blue staining, sections were 
microwaved in solution containing 5% HCl and 5% potassium ferrocyanide 
(14459-95-1, Acros, Geel, Belgium). Nuclei were stained with neutral red 
(N7005, Sigma, MO). For LFB staining, sections were treated with LFB 
(AC212170250, Acros, Geel, Belgium) solution overnight (O/N) at 56oC, 
followed by 95% ethanol and dH2O rinse. Slides were differentiated in lithium 
carbonate solution then 70% ethanol, followed by hematoxylin and eosin (H&E) 
staining (BP2424-25, E511-100, Fisher, PA). Images were obtained on the 
Nikon Eclipse 55i upright microscope (Nikon, Tokyo, Japan).  
2.2.g. Immunohistochemistry 
We used brain tissues from humans, HIP, WT and AKO rats. Tissues were 
processed as previously described (5, 99). Antibodies against amylin (1:200, 
T-4157, Bachem-Peninsula Laboratories, San Carlos, CA), glial fibrillary acidic 
protein (GFAP; 1:600, MAB360, Millipore, MA) or myelin basic protein (MBP; 
1:5,000, AMAB91064, clone CL2829, Sigma, MO) were the primary antibodies. 
Anti-mouse or anti-rabbit IgG (1:50, A3562, A3687, Sigma, MO) were 
secondary antibodies. The specificity of the amylin antibody in both human and 
rat brain tissues was established in previous studies (5, 6, 99).
2.2.h. Demyelination scoring 
Demyelination of the white matter (MBP and LFB staining) was scored by a 
blinded observer. Ordinal pathologic scoring was used, ranging from normal to 
severe demyelination (0-3) (186).    
2.2.i. Immunofluorescence 
We used brain tissues from humans, HIP, WT and AKO rats, and isolated 
brain capillaries from HIP, WT and AKO rats. Brain tissue was processed as 
previously (99) described. Brain capillaries were isolated (as described above) 
and then plated on laminin (23017-015; Gibco, Waltham, MA)-coated 
chambered cover glass for 1-hour, to allow time to attach.  
Antibodies against human amylin (1:200, SC-377530; Santa Cruz, TX), 
collagen IV (1:500, SAB4200500; Sigma, MO), caveolin1 (1:1,000, sc-894; 
Santa Cruz, TX) and APOE (1:200, ab183597; Abcam, MA) were the primary 
antibodies. Alexa Fluor 488-conjugated anti-mouse IgG (A11029, Invitrogen, 
MA) and Alexa Fluor 568-conjugated antirabbit IgG (A11036, Invitrogen, MA) 
were the secondary antibodies.  
2.2.j. Immunoprecipitation 
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HIP rat plasma was investigated in these experiments. Protein 
concentration was determined by bicinchoninic acid protein assay prior to 
immunoprecipitation. APOE was precipitated from 700 µg plasma protein. 
Samples were incubated at 4oC O/N with 5 µg anti-APOE antibody (ab183597, 
Abcam, MA) or anti-APOA-1 antibody (H00000335-D01P; Abnova, Taipei, 
Taiwan). Antibody-antigen complex was precipitated out by protein A/G 
agarose (20421, Thermo Scientific), rotated for 3 hours at 4oC. 
Immunoprecipitates were collected by centrifugation followed by washing three 
times with buffer (5 mM ethyleneglycoltertraacetic acid [EGTA], 50 mM Tris, 
1% Triton X-100, phosphatase and protease inhibitors 1:100 ratio, pH 7.5). 
Proteins were eluted two times with elution buffer (0.2 M glycine, 80 mM HCl, 
pH 2) and incubated on ice for 5 minutes with the supernatant collected by 
centrifugation. Centrifugation speed was 1000 xg for 1 min at 4oC. Samples 
were resuspended in loading buffer and subjected to Western blotting. 
2.2.k. Western blot analysis 
Western blot analysis was performed on isolated brain capillaries from rats 
and plasma and whole blood lysates from rats and humans. Plasma and whole 
blood were processed as described previously (5, 123). Capillaries were 
isolated as described above and then lysed in buffer containing 1% NP-40, 
150mM NaCl, 10mM Tris-HCl, 2mM EGTA, 50mM NaF, 1% phosphatase and 
1% protease inhibitors. The lysate was centrifuged at 17,000 xg for 30 minutes. 
The supernatant was used for Western blotting. Primary antibodies against 
amylin (1:2,000, T-4157, Bachem-Peninsula Laboratories), occludin (1:300, 
71-1500, Invitrogen), claudin-5 (1:1,000, 35-2500, Invitrogen), ZO-1 (1:300, 61-
7300, Invitrogen), collagen IV (1:1,000, ab6586, Abcam), caveolin1 (1:1,000,
sc-894, Santa Cruz Biotechnology) or β-actin (1:10,000, PIMA515739, Fisher
Scientific) were used in these analyses. Equal loading in Western blot
experiments was verified by reprobing with a monoclonal anti-β-actin antibody
(raised in mouse, clone BA3R, Thermo Scientific; 1:2000). Protein levels were
compared by densitometric analysis using ImageJ software.
2.2.l. Real-time quantitative reverse transcription polymerase 
chain reaction 
Expression levels of caveolin-1 and collagen IV in rat brain capillaries were 
measured using a protocol described previously (99). Caveolin-1 primers 
(forward, 5’-CTTAAATCACAGCCCAGGGAAAC-3’; reverse, 5’-
GCGTCGTACACTTGCTTCTC-3’) and collagen IV primers (forward, 5’-
AAATGGCGCTCCTGATCCAA-3’, reverse: 5’-
TTCTTGTGGAGTTCTCGCCC-3’) were used in these experiments. Actin 
primers (forward, 5’-CTGGCTCCTAGCACCATGAA-3’ and reverse, 5’- 
AAAACGCAGCTCAGTAACAGTC-3’) were used as internal controls.  
2.2.m. Cell culture and flow cytometry analysis 
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Prior to plating, culture flasks were coated with cell attachment factor 
solution (123-100, Sigma). Brain microvascular endothelial cells from WT adult 
Sprague Dawley rats (RA-6023, Cell Biologics, Chicago, IL) were plated for 24 
hours and used for experiment when they reached 70% to 90% confluency. 
Cells were incubated with 50 μM human amylin (AS-60804, AnaSpec, Fremont, 
CA) for 2 hours at 370C. Cells were dissociated with trypsin and washed with 
cold PBS before being stained with propium iodide (PI) and Annexin V (AnV), 
according to manufacture protocol (V13241, Life Technologies, Waltham, MA). 
Apoptotic cells and necrotic cells were detected with analytical flow cytometer 
(LSRII; Becton Dickinson, Franklin Lakes, NJ).  
2.2.n. Statistical analysis 
Parametric comparison of 2 groups was done using 2-tailed unpaired t test. 
Non-parametric comparison of 2 groups was done using Mann–Whitney 
unpaired t test. Two-ways analysis of variance (ANOVA) with repeated 
measures followed by Bonferroni post hoc tests were used to analyze the 
Morris water maze data. Data are presented as means + standard error of the 
mean. Difference between groups was considered significant when p < 0.05. 
All analyses were performed using GraphPad (LA Jolla, CA) Prism 5.0 
software. 
2.3. Results 
2.3.a. Impaired neurological functioning upon inducing amylin 
dyshomeostasis in rats 
Both male and female HIP rats had increased plasma levels of amylin and 
developed overt hyperglycemia (>200 mg/dl; nonfasted; Fig. 2.1). Western blot 
analysis of amylin in plasma samples showed multiple molecular weight bands 
(higher amylin immune-reactive signal was seen in HIP rats compared to WT 
rats). The higher molecular weight bands could correspond to circulating amylin 
aggregates, as suggested by previously published data(8, 122, 123), or amylin 
binding to plasma components (including plasma APOE; see below).  
In contrast to WT littermate rats that had normal behavior, HIP rats had gait 
abnormalities and impaired balance (Supplementary Videos 1 and 2), 
spontaneous forelimb use, hind limb clasping, and altered balance on a 
stationary inclined plane (Fig. 2.1c-e). HIP rats and WT controls had similar 
swim speeds; however, latency to platform over the 20 learning trials was 
longer for HIP rats compared to WT littermates (p = 0.03), indicating that HIP 
rats had impaired learning. Reference memory, defined as the latency to cross 
the platform at 24 hours after the second acquisition day (probe trial), was 
similar for HIP and WT rats, indicating no significant memory deficits associated 
with amylin dyshomeostasis once the task had been learned. Compared to 
males, female HIP rats developed hyperglycemia and neurologic deficits 
(Supplementary Videos 1 and 2) later in life (ie, ~12 months vs ~18 months 
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of age). Balance and gait abnormalities were milder in females compared to 
male HIP rats.  
2.3.b. Brain white matter injury in HIP rats 
Based on in vivo MRI (T2-weighted sequences), the brains of HIP rats had 
structural abnormalities, which were not present in control WT littermates (Fig. 
2.2a). Compared to controls, brains of diabetic male HIP rats showed areas of 
high T2 signal in the lateral hippocampus and around the temporal horns of the 
lateral ventricles and expansion of the ventricles (Fig. 2.2b). Expansion of the 
ventricles and the high T2 signal in the surrounding tissue may reflect defects 
in the resorption of cerebrospinal fluid or/and subcortical atrophy. Because the 
current MRI protocol only included coronal T2 images, we cannot formally 
distinguish between these possibilities.  
The volume of brain parenchyma was smaller in diabetic animals compared 
to controls (Fig. 2.2c). Injured ependyma and amylin deposition in choroid 
plexus were found in HIP rats with considerably enlarged ventricles (Fig. 2.2d, 
e). The brains of rats with falls and impaired balance often revealed 
intracerebral hemorrhages (Fig. 2.2f, arrow), which were not found in control 
WT littermates.  
We used the fluorescent microsphere technique to assess the brain 
perfusion status in diabetic HIP rats relative to controls. The retrieval of 
fluorescent microspheres was lower in brain capillaries (but not parenchymal 
tissue) of HIP rats compared to controls (Fig. 2.2g), suggesting brain 
hypoperfusion in HIP rats.  
Immunohistochemical analysis of brain paraffin sections (corpus callosum, 
lateral ventricle area, thalamus, and hypothalamus) from diabetic rats showed 
parenchymal rarefaction. HIP rat brains had a loss of MBP immunoreactivity 
compared to brains from control animals (Fig. 2.3a). LFB stain of the white 
matter (Fig. 2.3b) showed the same degree of myelin loss in the brains of 
diabetic rats compared to controls. Vacuoles were found through the entire 
white matter in HIP rats in contrast to controls.  
2.3.c. Cerebral microhemorrhages and perivascular astrocyte 
recruitment in HIP rats 
Histologic analysis of brain tissues from HIP rats showed 
microhemorrhages (Fig. 2.4a). Serial staining of the periventricular region with 
the amylin antibody showed amylin deposits in microvessels and perivascular 
areas (Fig. 2.4b). Vascular amylin deposition coincided with white matter 
vacuolation. At higher magnification, the same brain area stained with H&E 
showed loss of cellular details and erythrocytes around a blood vessel (Fig. 
2.4c). Amylin was present within the vessel wall and was associated with 
enlarged Virchow–Robin spaces (Fig. 2.4b, d). In contrast, tissue sections from 
similar levels of the brain from a WT animal had no vascular or tissue 
abnormalities (Fig. 2.4a-d). Staining for GFAP revealed robust recruitment of 
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astrocytes in areas of vascular tissue damage, whereas sections taken at a 
similar level of the hypothalamus from a control animal lacked obvious 
abnormalities, including no astrocytosis near intact microvessels (Fig. 2.4e). 
Amylin deposition was also found in association with infarction cores (Fig. 2.4f, 
g) and disrupted vessel walls (Fig. 2.4h). Amylin deposition was also present 
in hippocampal capillaries of HIP rats (Fig. 2.4i). 
2.3.d. Cerebral microhemorrhages and perivascular astrocyte 
recruitment following intravenous infusion of aggregated 
amylin in AKO rats 
HIP rats had elevated circulating levels of aggregated amylin (Fig. 2.1a). 
To test whether circulating aggregated amylin injures the endothelium 
independently of glucotoxicity, we generated rats with deleted amylin gene 
(AKO rats; Fig. 2.5a, b). AKO rats were intravenously infused with aggregated 
human amylin (2 µg/g body weight, every day (q.d.) for 7 days; approximately 
3 orders of magnitude higher than the physiological level of amylin in HIP rats). 
Western blot analysis of blood lysates from amylin-infused AKO rats, HIP rats, 
and humans with type 2 diabetes showed similar distributions of amylin- 
positive molecular complexes (Fig. 2.5e). Infusion of aggregated amylin 
provoked accumulation of amylin in the brain microvessels (Fig. 2.5f), astrocyte 
recruitment in areas of vascular injury (Fig. 2.5g), and brain microhemorrhages 
(Fig. 2.5h); however, the white matter in amylin-injected animals was intact as 
assessed by in vivo MRI (Fig. 2.5i).  
2.3.e. Vascular amylin deposition is modulated by the Amylin–
APOE interaction 
To test for a possible interaction of amylin with APOE in vivo, AKO rats 
(which express rat APOE, but lack amylin) were intravenously infused with 
combined aggregated human amylin (2 µg/g body weight) and APOE4 (1.2 
µg/g body weight), or only aggregated human amylin for 7 days (q.d.). Western 
blot analysis of plasma samples from rats in the 2 groups showed greater 
amylin binding to APOE4 compared to the endogenous rat APOE (Fig. 2.6a), 
consistent with previous ex vivo data demonstrating that APOE4 modulates 
amylin aggregation (169). To further test the interaction of amylin with plasma 
APOE, plasma samples from HIP rats were enriched in APOE by 
immunoprecipitation and were analyzed by Western blot with an anti-amylin 
antibody. Fig. 2.6b depicts amylin that formed molecular complexes with 
plasma APOE in HIP rats. Not surprisingly, amylin bound to other plasma 
apolipoproteins, as indicated by the immunoreactivity signal of amylin in APOA-
I enriched by immunoprecipitation. 
Because amylin appears to bind to APOE4 in vivo, we hypothesized that 
infusion of APOE4 would exacerbate systemic amylin dyshomeostasis and 
cerebral vascular injury in HIP rats. To test this hypothesis, HIP rats were 
intravenously infused with APOE4 (1.2 µg/ g body weight, q.d., for 7 days). The 
infusion of APOE4 enhanced amylin accumulation in the brains of HIP rats (Fig. 
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2.6c). Fig. 2.6c depicts leakage of amylin from a brain microvessel of a HIP rat 
that was infused with APOE4. No obvious extravasation of APOE4 was present 
in the APOE4-infused HIP rats.  
2.3.f. Shared feature of amylin vasculopathy in brains of HIP rats, 
human amylin–infused AKO rats, and humans with dementia 
and type 2 diabetes 
Immunohistochemical analysis with an amylin antibody of brain tissues from 
patients with type 2 diabetes and dementia showed vascular changes 
associated with amylin deposition. Fig. 2.7a, b display sections from the brain 
of a 93-year-old man (APOE 4/4 carrier with type 2 diabetes and CERAD 
definite Alzheimer disease (AD), Braak stage V, and CAA severity 2). The 
vascular histopathology includes amylin deposits in the smooth muscle layer of 
arterioles and distortion of the amylin-positive vascular wall contours in 
capillaries. Fig. 2.7c shows a brain section from a 92-year-old woman with type 
2 diabetes and unknown APOE genotype (CERAD definite AD, Braak stage V, 
and CAA severity 3). Amylin deposition was found in association with disruption 
of the vessel wall. Fig. 2.7d is from the brain of another man (91 years old, 
APOE 3,4 carrier, CERAD definite AD, Braak stage V, but no CAA). Amylin 
immunoreactivity signal was detected in an area corresponding to a chronic 
infarct. In the brain that is displayed in Fig. 2.7a, amylin is co-localized with 
perivascular reactive astrocyte recruitment in disrupted blood vessel walls (Fig. 
2.7e). Reactive astrocytosis was lower around blood vessels of aged control 
individuals, with the caveat of the limited sample size (Fig. 2.7f). These 
pathologic changes were not present in the brain blood vessels of healthy aged 
individuals.  
Fig. 2.7g provides a representative section from the 3 brains investigated 
in this study. Immunoconfocal microscopy analysis of amylin and collagen IV, 
a component of the basement membrane structure of the blood vessels, in the 
brain tissue from the 91-year-old patient described above showed amylin 
deposition in an arteriole and a presumed capillary profile (Fig. 2.7g). Brain 
microvessels of HIP rats and AKO rats that were intravenously infused with 
aggregated human amylin had similar amylin deposits as in dementia patients 
who also had type 2 diabetes (Fig. 2.7h). In contrast, brain sections from a WT 
rat showed no amylin staining in brain blood vessels (Fig. 2.7j).  
2.3.g. Vascular amylin deposition injures endothelial cells and 
degrades tight junction components 
To assess the impact of aggregated amylin on the endothelium, cerebral 
capillaries were isolated from HIP and WT rat brains and stained for amylin and 
caveolin-1, a protein that is abundant in endothelial cells. Areas of amylin 
deposition (green) showed weak immunoreactive caveolin signal, suggesting 
the loss of endothelial cells (Fig. 2.8a). Consistent with immunoconfocal data, 
Western blot analysis demonstrated depletion of caveolin and collagen in brain 
capillary lysates from HIP rats compared to WT littermates (Fig. 2.8b). There 
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was similar depletion of collagen and caveolin-1 in human amylin-infused AKO 
rats (Fig. 2.8b). The transcript levels for caveolin-1 and collagen IV were 
unchanged (Fig. 2.8c), suggesting that the loss of capillary stability was 
associated with degradation of basement membrane structure and 
endothelium. 
A flow cytometry analysis of cultured brain microvascular endothelial cells 
from rats was performed to test the viability of endothelial cells after exposure 
to aggregated human amylin. The interaction of aggregated human amylin with 
endothelial cells resulted in a significant increase of both early apoptotic 
(AnV+/PI-) and end-stage apoptotic (AnV+/PI+) populations, and a reduction of 
the live cell population (AnV-/PI-; Fig. 2.8d).  
The tight junction components, claudin-5, occludin, and ZO-1 adapter 
proteins were degraded in cerebral capillaries from HIP rats (Fig. 2.8e). There 
was some reduction in tight junction components in amylin-infused AKO rats 
(Fig. 2.8e). Thus, microhemorrhages and amylin vasculopathy in HIP rat brains 
were associated with endothelial damage.  
2.4. Discussion 
Our data suggest that the amyloidogenicity of the human amylin peptide, 
amylin hypersecretion, and plasma APOE are important mediators of amylin 
deposition in the cerebral microvasculature. Vascular amylin deposition was 
associated with endothelial cell damage and degradation of tight junctions, 
which could explain the associated microhemorrhages and recruitment of 
perivascular astrocytes that occurred in HIP rats and in AKO rats infused with 
aggregated human amylin. Accumulated injury to cerebral small vessels can 
contribute to hypoperfusion, leading to injury of brain parenchyma, loss of brain 
volume, and neurologic deficits (as seen in HIP rats; see proposed mechanism 
in Fig. 2.8f). Our findings are consistent with previous reports that implicated 
amylin dyshomeostasis as a contributor to the development of type 2 diabetes 
(37, 93, 95, 100, 119, 172) and cardiovascular disease (96, 98, 123).The most 
important finding of this study is the demonstration of amylin-provoked 
microhemorrhages in HIP rats and AKO rats infused with aggregated human 
amylin. This provides direct evidence that diabetes-associated amylin 
dyshomeostasis provokes a microangiopathy. This is a noteworthy finding 
because amylin deposits are present in the brain microvessels of patients with 
type 2 diabetes and dementia. Cerebral microhemorrhages occur frequently in 
patients with both ischemic and hemorrhagic stroke (187) and in individuals 
with CAA (162). In contrast to CAA, brain microvessels in AKO rats infused with 
aggregated human amylin showed concentric amylin deposition, indicating that 
circulating aggregated amylin results in luminal amylin deposition. Thus, 
amylin-mediated narrowing of brain microvessels is a likely contributor to brain 
hypoperfusion and parenchymal loss, leading to impaired neurological 
functioning in diabetic HIP rats. Cerebral microvascular injury that occurs in 
patients with type 2 diabetes is suggested to result from non-enzymatic 
glycation of proteins and sub- sequent production of toxic derivatives that 
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induce endothelial cell oxidative damage (25, 173). The induction of cerebral 
microhemorrhages and surrounding neuropil injury occurred in amylin-infused 
AKO rats in the absence of hyperglycemia, which suggests that circulating 
aggregated amylin is a pathologic substrate for endothelial dysfunction in the 
setting of diabetes. Further study is required to establish a causal link between 
the level of circulating amylin and the effect of the resulting micro- vascular 
injury on brain parenchyma and functional outcomes in humans.  
The cellular and molecular mechanisms that underlie the impact of cerebral 
microvascular injury on neural circuit function are complex and incompletely 
understood. This limitation stems in part from a paucity of experimental models 
(188, 189). In HIP rats, neurological deficits are associated with white matter 
injury caused by vascular amylin deposition. The present results indicate that 
expressing human amylin in species that do not develop type 2 diabetes (ie, 
mice and rats) can provide a means to better understand the complex vascular 
factors affecting white matter integrity in patients with diabetes and dementia.  
APOE is a plasma protein that serves as a ligand for low-density lipoprotein 
receptors, participates in the transport of cholesterol and other lipids among 
various cells of the body (190), and is present in amylin amyloid- containing 
pancreatic tissue from humans (170, 171). The infusion of APOE4 exacerbated 
amylin-mediated capillary injury and brain amylin accumulation in HIP rats. The 
result suggests an interaction between amylin and plasma APOE as a potential 
mechanism underlying brain amylin pathology. Because APOE4 may modulate 
amylin aggregation (169), we speculate that elevated levels of plasma APOE4 
could trigger the formation of toxic amylin aggregates in the blood. Additional 
studies are needed to elucidate the potential role of APOE alleles in promoting 
vascular amylin deposition.  
Amylin plays a complex role in modulating the peripheral energy balance 
(55, 164-166). We demonstrated that systemic amylin dyshomeostasis 
contributes to microvascular injury in the setting of diabetes. Thus, amylin 




TABLES AND FIGURES 
 
Table 2.1: Neuropathological information, APOE genotype, age and sex of 
each individual included in the study in Chapter 2. The absence/presence of 
diabetes was determined during life (at longitudinal clinical visits) by patient or 
caregiver self-report and the use of diabetic medications (176). The assessment 
of clinical dementia and the neuropathologic features-—neuritic amyloid plaques 
(Consortium to Establish a Registry for Alzheimer’s Disease; CERAD), Braak NFT 
stage and cerebral amyloid angiopathy (CAA) severity- were scored as previously 
described (177-181).  
 
  




severity AD CERAD 
1 M 4/4 93 Yes 5 2 Yes 3 
2 M 3/4 91 Yes 5 0 Yes 3 
3 F  92 Yes 5 3 Yes 3 
4 F 3/3 91 No 2 3 No 0 
5 F 3/3 83 No 2 0 No 0 




Figure 2.1. Amylin, blood glucose, and neurologic deficits in rats expressing 
human amylin in the pancreatic islets (HIP rats). (a) Western blot analysis of 
amylin in plasma from human amylin expressing (HIP) and wild-type (WT) male 
(M) and female (F) littermates, 15 months of age. (b) Blood glucose in HIP and WT 
male and female littermates. (c) Spontaneous forelimb use in male HIP rats vs. 
WT littermates assessed at 15 months of age by forepaws-to-wall contact time 
during vertical rearing up in the cylinder test (n = 5). (d) Pathologic hind limb 
clasping in a 15-month-old male HIP rat compared to a WT littermate rat. (e) 
Inclined plane test in 15-month-old male HIP rats vs. WT rat littermates (n = 5). (f) 
Swim speed for HIP and WT rats in the Morris water maze test (n = 10, 15–16 
months old). (g) Latency for HIP and WT rats to swim to target platform in Morris 
water maze test (n = 10, 15–16 months old). (h) Latency to platform in the probe 





Figure 2.2. Periventricular injury and hypoperfusion in rats expressing 
human amylin in the pancreatic islets (HIP rats). (a) Three slices (1, 3, and 5 
of 7 consecutive slices 1mm apart) of coronal T2-weighted magnetic resonance 
(MR) images comparing the brains of a 15-month-old male HIP rat vs. a WT 
littermate rat. Hyperintensity areas (arrows) in the lateral hippocampus and 
temporal horns of HIP rats reflect extracellular fluid accumulation. (b, c) Volumes 
of ventriclular hyperintensity and brain parenchyma in male HIP and WT littermate 
rats computed from coronal T2-weighted MR images; 1 image pixel area = 0.024 
mm2 (n = 7). (d) Hematoxylin and eosin (H&E) staining of the lateral ventricle area 
in brains of HIP rats with considerably enlarged ventricles. Arrowhead indicates 
injured ependyma. (e) Immunohistochemical analysis with an amylin antibody of 
the choroid plexus in the same rat as in (d). (f) Example of intracerebral 
hemorrhages (arrow) that occurred in male HIP rats, but not WT littermates (>12 
months of age). (g) Cerebral perfusion in male HIP and WT rats at 15 months of 
age (n = 3) assessed by the retrieval from brain capillaries and parenchyma of 
intravenously infused fluorescent microspheres. Data are mean ± SEM; P ≤ 0.05 





Figure 2.3. White matter rarefaction in rats expressing human amylin in the 
pancreatic islets (HIP rats). (a) Representative immunohistochemical analysis of 
myelin basic protein (MBP) in the hypothalamus (htha) of a 15-month-old male HIP 
rat vs. a wild-type (WT) littermate rat. Analysis of MBP level in HIP and WT brain 
white matter areas (CC = corpus callosum; HTha = hypothalamus; LV = lateral 
ventricle area; Tha = thalamus; n = 3). (b) Representative IHC analysis of myelin 
level assessed by Luxol fast blue (LFB) staining in the hypothalamus of a 15-
month-old male HIP rat vs. a WT littermate rat. Analysis was carried out in the 
same brain areas as above (n = 3). (c) Scoring criteria for demyelination in myelin-
binding protein and LFB staining. Exampled images of LFB staining of HIP rat brain 
tissues. Data are mean ± SEM; P ≤ 0.05 *, P ≤ 0.01 **; Mann–Whitney unpaired t 
test. WT rat: wild-type rat. 
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Figure 2.4. Brain microhemorrhages and perivascular astrocyte recruitment 
in rats expressing human amylin in the pancreatic islets (HIP rats). (a) 
Analysis of the number of brain microhemorrhages stained with Prussian blue dye 
in HIP vs. wild-type (WT) rats (n = 7). Representative staining with Prussian blue 
dye of a microhemorrhage in the lateral hypothalamus–ventricular area of a 15-
month-old HIP rat is shown. The same brain area from a WT rat is the control. (b) 
Representative image of serial staining with an amylin antibody in the same brain 
region as in (a) shows amylin deposits in microvessels (arrows) and perivascular 
area (inset; brown deposits) in HIP rats but not WT rats. White matter vacuolation 
(arrowheads) was found in HIP rat brains. (c) Images with a higher magnification 
(original magnification, 40x and 100x, respectively) of the same brain area stained 
with hematoxylin and eosin (H&E). (d) Representative immunohistochemical (IHC) 
analysis of amylin in a small arteriole (HIP vs WT rats). (e) Representative IHC 
analysis of activated astrocytes in areas of vascular injury in the brain of a HIP rat 
assessed by staining for glial fibrillary acidic protein (GFAP; brown). Images are 
from hypothalamus. The same area from a WT rat brain is the control. (f–h) IHC 
analysis of amylin in areas of microvascular injury in HIP rat brains. (i) 
Representative IHC analysis of vascular amylin deposition in the hippocampus of 





Figure 2.5. Infusion of aggregated amylin in amylin knockout (AKO) rats. (a) 
Amylin gene deletion with CRISPR/Cas9. The 2 cut guide sites are shown below 
in uppercase. Pre-proamylin nucleotide sequence is shown in green. (b) Gel 
electrophoresis showing a 1.2kb sequence from the wild-type (WT) rat amylin DNA 
and a 430bp sequence remaining after deletion of amylin gene. (c) Gel 
electrophoresis showing a 650bp sequence that includes part of the amylin gene 
that was deleted in transgenic animals. (d) Western blot analysis of pancreatic 
tissues demonstrating that the protein level of amylin is reduced in the AKO rats 
compared to WT littermates. (e) Cropped Western blot of amylin in blood lysates 
from amylin-infused AKO rats, HIP rats, and T2D patients. The amylin band at 
10kDa (the amylin dimer) required longer exposure time and is displayed 
separately. (f, g) Representative images of immunohistochemical staining with 
amylin (f) and co-staining for amylin (brown) and glial fibrillary acidic protein 
(GFAP; green; g) in the cerebral cortex of an amylin-infused AKO rat vs. an age-
matched AKO rat without amylin infusion (n = 3). (h) Prussian blue dye in the brain 
cortex area of an amylin-infused AKO rat vs. an age-matched AKO rat without 
amylin infusion. Analysis of the number of brain microhemorrhages in amylin-
infused (inf.) AKO and control AKO rats (n = 6). (i) Three slices of coronal T2-
weighted magnetic resonance images comparing the brain in an AKO rat before 
and after infusion with aggregated human amylin (2 µg/g body weight, every day, 
7 days; n = 3). Data are mean ± SEM; two-tailed, unpaired t test. HET: 




Figure 2.6. Amylin interaction with plasma apolipoproteins in vivo. (a) 
Cropped Western blot of amylin in plasma from amylin knockout rats infused with 
amylin (AMY) alone or in combination with apolipoprotein E4 (APOE4; n = 3). (b) 
Western blot analysis with an anti-amylin antibody of HIP rat plasma samples that 
were enriched in APOE or APOA-1 by immunoblot (Ib) and immunoprecipitation 
(Ip) (n = 3). (c) Representative immunofluorescence images of amylin–APOE4 
vascular deposition in brain microvessels of HIP rats injected with human APOE4. 
Analysis of amylin fluorescence intensity in the brain blood vessels of WT, HIP, 
and APOE4-infused HIP rats (graph; n = 3) is shown. (d) The same as in (c) for 
brain parenchyma. The bar graph shows analysis of amylin fluorescence intensity 
in brain parenchyma of WT, HIP, and APOE4-infused HIP rats (n = 3). Data are 
mean ± SEM; P ≤ 0.05 *; two-tailed, unpaired t test. HIP rat: human amylin 




Figure 2.7. Cerebral amylin vasculopathy in patients with dementia and type 
2 diabetes (T2D-De), rats expressing human amylin in the pancreatic islets 
(HIP rats), and amylin-infused amylin knockout (AKO) rats. (a–d) 
Representative immunohistochemical (IHC) analysis of amylin deposition (brown) 
in the brain blood vessels of T2D-De patients (n = 3 patients). (e) Representative 
IHC showing co-staining of glial fibrillary acidic protein (GFAP; green) and amylin 
(brown) in areas of cerebral vascular injury on brain sections from the same T2D-
De patients as in (a–d). (f) Representative IHC analysis with amylin and GFAP 
antibodies on brain sections from healthy aged individuals (control; n = 3). (g) 
Representative immunofluorescence images of amylin deposition (green) on the 
luminal side of the vessel basement membrane stained with collagen IV (red) in 
the brain microvessels of T2D-De patients (n = 3). Arrow indicates arteriole. 
Arrowhead indicates presumed capillary profile. (h–j) Representative 
immunofluorescence images of amylin deposition (green) on the luminal side of 
vessel basement membrane stained with collagen IV (red) in the brain 
microvessels of HIP rats (h; n = 3), amylin-infused (inf.) AKO rats (i; n = 3), and 
age-matched wild-type (WT) rats (j; n = 3). WT rat: wild-type rat.  
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Figure 2.8. Vascular amylin deposition injures endothelial cells and degrades 
tight junction components. (a) Representative immunofluorescence images of 
isolated brain capillaries from HIP and wild-type (WT) littermate rats (15 months 
old) showing endothelial cells (caveolin-1, red) and amylin deposition (green; n = 
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3 rats). (b) Cropped Western blot of caveolin-1 (Cav1) and collagen IV (Col IV) in 
capillary lysates from HIP and WT rats (n = 5-6; left panel), and amylin-infused 
(amy. inf.) amylin knockout (AKO) and control AKO (no amylin) rats (n = 3; right 
panel). Corresponding densitometry analyses of caveolin-1 and collagen IV levels 
are displayed in the lower panel. (c) Quantitative real-time polymerase chain 
reaction of caveolin-1 and collagen IV mRNA in isolated capillaries from HIP and 
WT rats (caveolin-1, n = 4; collagen IV, n = 3). (d) Flow cytometry analysis of rat 
brain microvascular endothelial cell apoptosis when incubated with 50 µM human 
(h) amylin (n = 3). Apoptotic cells are detected with annexin V (AnV) and dead 
cells are detected with propidium iodide (PI). Live cells are AnV--/PI--, early 
apoptotic cells are AnV+/PI--, end-stage apoptotic cells are AnV+/PI+, and necrotic 
cells are AnV--/PI+. (e) Cropped Western blot of endothelial cell tight junction 
proteins (ZO-1, occludin, and claudin-5) in capillary lysates from HIP and WT brain 
(n = 5; left panel), and amylin-infused AKO and control AKO rats (n = 3; right 
panel). Corresponding densitometry analyses of tight junction protein levels are 
displayed in the lower panel. (f) Proposed mechanism: aggregated amylin causes 
endothelial dysfunction and microvascular injury and is modulated by amylin 
transport in the brain via plasma apolipoprotein E4 (APOE4). Data are mean ± 
SEM; P ≤ 0.05 *; P ≤ 0.01 **, P ≤ 0.001 ***; two-tailed, unpaired t test. HIP rat: 
human amylin expressing rat; WT rat: wild-type rat; AKO rat: amylin knock-out rat. 
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CHAPTER 3. PANCREATIC AMYLIN CONTRIBUTES TO THE 
MODULATION OF BRAIN MICROVASCULAR AND ALZHEIMER 
PATHOLOGIES IN PSEN1 AND APP MUTATION CARRIERS 
3.1. Introduction 
Alzheimer disease (AD) affects cognition and behavior and is characterized 
by β-amyloid (Aβ) plaque and tau tangle pathology in the cerebral cortex (14). 
These prototypical AD pathologies commonly co-occur with vascular 
abnormalities (144, 191, 192). It is suggested that there is an interplay between 
these disease processes both in sporadic and familial (genetically predisposed) 
forms of AD (144, 191). Accumulating evidence from several research teams 
(2-7, 99, 129, 193), including our reports (2, 5, 99), indicates that the blood (5, 
193) and brains (2-7, 99, 129) of individuals with sporadic AD (sAD) have 
elevated levels of amylin, an amyloidogenic hormone secreted by the pancreas 
(53). In the brain, amylin forms homogenous plaques (5, 129), the protein core 
of some amylin-Aβ deposits (5, 129), space-filling lesions in neurons (99, 129) 
and pericytes (4), and amyloid deposits in the blood vessels (2, 5, 6). No amylin 
mRNA was detected in human brains (5), indicating the peripheral source of 
amylin that is deposited in the brain. By considering the innate difference 
between human amylin (amyloid-forming) and rodent amylin (non-
amyloidogenic) (100), we also showed that pancreatic overexpression (3-fold) 
of human amylin in non-AD rats provokes cerebral microhemorrhages 
associated with axonal degeneration and neurologic deficits (2). The 
relationship between elevated blood levels of amylin and AD pathology 
remains, however, unknown. 
Here, we investigated how amylin affects the brains of PSEN1 and APP 
mutation carriers (familial AD; fAD), as these mutations have known 
biochemical effects on AD pathology. To assess mechanistically the functional 
consequences of amylin pathology seen in human brains, we generated 
transgenic AD and non-AD rat models in which the consequences of elevated 
blood levels of human amylin can be directly addressed in terms of AD 
pathology and neurological deficits. To further test the mechanism, we 
intravenously injected human amylin in AD rats that express non-
amyloidogenic rat amylin. We also generated AD rats with the amylin gene 
deleted to test the effects of the suppression of amylin secretion on brain 
function. To further test the hypothesis that amylin dyshomeostasis accelerates 
the development of AD, we pharmacologically lowered amylin dyshomeostasis 
in aged ADHIP rats. 
3.2. Materials and methods 
3.2.a. Human samples 
The protocol concerning the use of biopsy from patients was approved in 
agreement with Institutional Review Board approval and informed consent was 
obtained prospectively. Human brain tissues were used in this study. 
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Postmortem frozen brain tissues from patients with fAD and age-matched 
cognitively unaffected (CU) individuals (temporal cortex) were provided by 
Queen Square Brain Bank for Neurological Disorders, UCL Queen Square 
Institute of Neurology, United Kingdom. Brain tissues from fAD patients were 
provided by King’s College London, United Kingdom. Brain tissues from 
patients with sporadic AD (sAD) and age-matched CU individuals (Brodmann 
areas 9 and 21/22) were provided by the Alzheimer’s Disease Center at the 
University of Kentucky. Brain samples from CU individuals were used as 
controls.  Frozen brain tissues from fAD patients and controls were used for 
biochemical analyses. For immunohistochemistry, formalin-fixed, paraffin-
embedded brain tissues from sAD patients, fAD patients, and age-matched 
controls were used. Details on patient information and sample size can be 
found in Table S3.1. 
3.2.b. Experimental animals 
This investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 
85-23, revised 2011) and was approved by the Institutional Animal Care and 
Use Committees at University of Kentucky. Alzheimer disease (AD) model rats 
(TgF344-19, provided by RRRC) are Fischer rats that express human Aβ (A4) 
precursor protein (hAPP) gene with the Swedish mutation (K595N/M596L), and 
presenilin 1 (PSEN1) gene with a deletion of exon 9, driven by mouse prion 
promoter (Prp) (194). HIP rats (provided by Charles River Laboratory) are 
Sprague-Dawley rats that overexpress (3-fold) human amylin in the pancreatic 
β-cells (95). The AD rats (n = 10) were crossbred with HIP rats (n = 10) to 
generate rats of four genotypes: wild-type, HIP, AD, and rats that are triple 
transgenic for human amylin, APP, and PSEN1 (ADHIP rats). A total of n = 135 
male and female rats were generated to obtain the predicted number of rats for 
differentiating between the effects of amylin pathology and Aβ pathology on the 
behavior deficits in ADHIP rats. Male ADHIP (n = 10), AD (n = 10), HIP (n = 
10), and WT rats (n = 10) were used in behavior testing and physiological 
analyses. Amylin knock-out in AD model rat (AD-AKO) was generated by first 
crossbreeding AD rats (n = 4) with AKO (n = 3) rats. The generation of AKO rat 
model was described previously (2). A total n = 162 male and female rats were 
generated to obtain the predicted number of rats to uncover the effects of 
amylin gene deletion on the behavior deficits in AD-AKO rats. Male AD and AD-
AKO littermates (n = 8-9/group) were used in behavior testing and physiological 
analyses. Blood glucose and weights were measured monthly in all rats. Animal 
physical health was followed and documented. Rats were housed in a 
temperature-controlled room under a 12-hour light/dark cycle with free access 
to food and water. All rats were fed a normal chow diet. In this study, we used 
male rats because amylin dyshomeostasis develops earlier in males (~12 
months) than in females (> 18 months) (2). 
3.2.c. Genetic analysis 
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The specific association of genetic variants in IAPP identified by the 
International Genomics of Alzheimer’s Project (IGAP) consortium was 
analyzed. These results correspond to the meta-analysis of genotyped and 
imputed data (7,055,881 SNPs, 1000G phase 1 alpha imputation, Build 37, 
Assembly Hg19) of 17,008 AD cases and 37,154 controls. To assess rare 
genetic variants in IAPP (ENST00000240652) in AD, the exome sequencing 
data from a UK cohort of 331 AD cases were analyzed. The variability of the 
IAPP gene in a cohort of healthy elderly samples from the Healthy Exomes 
(HEX) database was also analyzed. HEX includes data corresponding to the 
exome sequencing of 468 individuals categorized as cognitively healthy and 
neuropathologically normal (195). Given the finding of p.Asn64fs in a healthy 
sample aged >90 years, loss of function variants described in gnomAD, and 
the respective available information for age was examined (Table S3.2). 
3.2.d. Antibodies and reagents 
The following primary antibodies were used: Amylin (1:200, T-4157, 
Bachem-Peninsula Laboratories), human Aβ (1:300, clone 6E10, Biolegend), 
phosphorylated tau (1:400, clone AT8, MN1020, Pierce). The following 
secondary antibodies were used: Biotinylated anti-rabbit IgG (1:300, BA-1100, 
Vector), AP-conjugated anti-mouse IgG (1:100, A3562, Sigma), Alexa Fluor 
568 anti-rabbit IgG plus (A11036) and Alexa Fluor 647 anti-mouse IgG plus 
(A21236), Alexa Fluor 488 anti-mouse IgG (A11029), Alexa Fluor 488 anti-
rabbit IgG (A11034), and Alexa Fluor 568 anti-mouse IgG (A11031), and anti-
rabbit IgG (1:2,000, 32460) from Thermo Fisher. The following reagents were 
used: DAB chromogen substrate (ab64238, Abcam), AEC chromogen 
substrate (SK-4200, Vector), StayGreen/AP chromogen substrate (ab156428, 
Abcam), citrate buffer (S1699, Dako), Thioflavin S (1326-12-1, Sigma), Sudan 
black (4197-25-5, Sigma), luxol fast blue dye (AC212170250, Acros Organics), 
potassium ferrocyanide (AC211095000, Acros Organics), Congo Red (C580-
25, Fisher), and lyophilized amidated human amylin peptide (AS-60254, 
Anaspec). BCA (23225) and Micro-BCA (23235) protein assays are from 
Thermo Fisher Scientific. All other reagents are from Thermo Fisher Scientific 
unless specify.  
3.2.e. Bio-fluid collection from animals 
CSF was collected from isoflurane-anesthetized rats every two months by 
inserting needles through the cisterna magna without any skin incision (protocol 
was described in (196)). CSF was obtained by syringe aspiration. The volume 
extracted did not exceed 120 µL per each collection. Blood was collected 
through the tail vein by syringe aspiration. EDTA was added to blood samples 
to prevent coagulation. The collection volume did not exceed 500 µL per each 
collection. Red blood cells and plasma were separated by centrifugation at 
1,000 xg for 10 minutes at 4oC. Samples were stored at -80oC.   
3.2.f. Amylin aggregation and injection 
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Lyophilized amidated human amylin peptide was dissolved in PBS pH 7.4 
to the concentration of 50 µM. The mixture was incubated in 370C for 72 hours 
with occasional shaking to allow amylin to form aggregates. Every 3 days 
aggregated human amylin solution was injected into 7 months old AD rat via 
tail vein (60 µg/kg). The age-matched AD control group received the same 
volume of PBS per injection without aggregated human amylin. The animals 
received injections for 60 days. Bio-fluids from each animal were collected 
before- and post-injection.    
3.2.g. Pharmacological treatment on animals 
To increase epoxyeicosatrienoic acids (EETs) levels, the animals were 
treated with TPPU (1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) 
urea, N-[1-(1-Oxopropyl)-4-piperidinyl]-N′-[4-(trifluoromethoxy)phenyl]-urea), a 
soluble epoxide hydrolase inhibitor (sEHi) (HY-101294, MedChem Express). 
12 months (n = 5; early-stage) and 16 months (n = 6; late-stage) old ADHIP 
rats were subjected to treatment with sEHi. Age-matched ADHIP rats that 
received vehicle treatments (n = 5 for early-stage; n = 6 for late-stage) were 
used as controls. TPPU was dissolved in PEG-400 at 60oC, overnight, and was 
diluted in drinking water or PBS for injection (122). For treatment at early stage 
(ES), the drug was administered through drinking water (3mg/L, daily) and 
intravenous injection (20 µg/kg, once a week) to ensure equal intake for each 
animal. For treatment at late stage, the drug was administered through 
intravenous injection (20 µg/kg, daily, 1 month) and then through drinking water 
(3 mg/L, daily, 1 month). The amount of water intake was measured daily.    
3.2.h. Behavior testing 
Cognitive function 
Novel Object Recognition (NOR): The NOR test was used to test for short-
term recognition, as previously described (8).  
Morris Water Maze: Spatial learning and long-term memory retention were 
tested in a 1.5 m diameter Morris Water Maze, as previously described (2). 
Animals were given 4 learning trials per day for four consecutive days using 
random starting locations. Animals were allowed to stand on the platform for 
30 seconds after the first trial and 15 seconds after each additional trial. If the 
animals failed to locate the platform, they were picked up and put on the 
platform for 15 seconds. To assess reference memory, a probe trial was given 
24 hours after the fourth acquisition day. Trials were recorded by EthoVision 
XT software (Noldus, VA). In the 8-month old rat group, 2 AD rats and 3 ADHIP 
rats were not performing (floating/ non-learning). In the 12-month old rat group, 
1 HIP rat was not performing. In the 16-month old rat group, 4 HIP rats and 1 
AD rat were not performing. Non-performing rats were excluded from the 
analysis. After locating the platform, AD-AKO rats had difficulty to climb on the 
platform due to heavy body weights; thus, the difficulty discourages animals 
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from finding escape in later trials. The result from the water maze test excluded 
from the behavior analysis for AD-AKO rats. 
Motor function 
Forelimb use test/ Cylinder test, inclined plane, hind limb clasping test: 
Experimental protocols were described previously (2). The rat’s forelimb 
deficits were evaluated by forelimb-to-wall contact time in the cylinder test. The 
rat’s balancing ability was determined by recording the angle at which the 
animal started to slip on a rising inclined plane. Abnormalities in the rat’s hind 
limbs were assessed by scoring the severity of hind limb clasping (197). 
Because of the impact of the amylin gene deletion on the body weight (see 
data), the result from the inclined plane test was not taken into the behavior 
analysis for AD-AKO rats. 
Rotarod assessment: Motor coordination and balance were tested by the 
Rotarod (Rotamex 5, Columbus Instrument, OH) test (8). Animals were 
acclimatized to the static rod 2 days before testing. On the testing day, the 
speed of the rotarod was increased from 0 rpm to 40 rpm within 2 minutes. 
Each rat was tested on the Rotarod for a total of 4 trials per day over 5 
consecutive days. For each training day, the smallest value of latency-to-fall for 
each rat was discarded. The remaining read-outs were averaged, and a group 
average was calculated for each genotype. In the 8-month old AD rat group, 
two rats were not performing. In the 8-month old ADHIP rat group, one rat was 
not performing. In the 12-month old AD rat group, 3 rats were not performing 
on day 1, 5 rats were not performing on day 2, and 7 rats were not performing 
on days 3-5. In the 16-month old AD rat group, 4 rats were not performing in all 
days. In the 12-month old WT rat group, 4 rats were not performing. In the 16-
month old HIP rat group, 4 rats were not performing. Non-performing rats were 
excluded from the analysis. Because AD-AKO rats were too large to fit on the 
rotarod, AD-AKO rats could not perform on the rotarod; hence, this assessment 
was excluded from the behavior analysis for AD-AKO rats. 
Composite z-score analysis for behavior tests 
The composite z-score analysis method was previously described (198). 
For each behavior test, mean and standard deviation were calculated from 
individual variables collected from longitudinal assessments from animals 
across the experimental groups. Z-score (neurological score) for each animal 
in each behavior test was calculated using the following equation:  
𝑧 − 𝑠𝑐𝑜𝑟𝑒 = 	
𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙	𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒 − 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒	𝑚𝑒𝑎𝑛
𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒	𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑	𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛  
The composite score for each animal was calculated by averaging z-scores 
from each test. 
3.2.i. Magnetic resonance imaging (MRI) 
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MRI scans were performed on ADHIP and AD littermates using a horizontal 
7T nuclear MRI scanner (ClinScan, Brucker BioSpin MRI, Ettlingen, Germany) 
as described in ref. 7. Coronal T2-weighted images were obtained using 
generic parameters: field of view (FOV) 40 mm, repetition time (TR) 3000 ms, 
echo time (TE) 24 ms, slice thickness 1 mm, inter-slice gap 1 mm, 7 slices. 
Ventricular hyperintensities volume was calculated as described in ref. (2).     
3.2.j. Histology and demyelination scoring 
Microhemorrhages in rat brains were identified with Prussian blue dye and 
analyzed as described in ref. (2). Congo red staining was performed on the 
human brains as described in ref. 5. Myelination in rat brains was analyzed by 
staining with luxol fast blue (LFB) dye (2). Scoring was performed by observers 
that were blinded to the experimental groups as described in ref. (2). 
3.2.k. Immunohistochemistry 
We used formalin-fixed, paraffin-embedded brain, and pancreas tissues 
from humans, wild-type, HIP, ADHIP, AD, and AD-AKO rats. Tissues were 
processed as described in (2, 5, 99). After tissue rehydration, the endogenous 
peroxidase was quenched in 3% H2O2 in methanol for 30 minutes. For amylin 
and Aβ antigen retrieval, sections were treated with 100% formic acid for 5 
minutes at room temperature (R.T.), followed by 0.5% pepsin digestion in 5mM 
HCl for 20 minutes at 37oC. To retrieve other antigens, tissue sections were 
heated in citrate buffer for 30 minutes. Non-specific antibody binding was 
blocked by 15% horse serum for 1 hour at R.T. Primary antibodies against 
amylin or human Aβ was incubated on slides overnight at 4oC. Sections were 
then washed and incubated with secondary antibodies. Signal was developed 
with AEC peroxidase substrate. For co-staining with two antibodies, after the 
signal was developed for the first antibody, sections were then rinsed in water. 
Non-specific antibody binding was blocked with 10% normal goat serum, and 
the sections were incubated with the second primary antibody overnight at 4oC. 
Sections were then washed and incubated with an AP-conjugated secondary 
antibody and developed with StayGreen/AP chromogen substrate. Sections 
were mounted with aqueous mounting medium. Amylin antibody specificity was 
established in our previous studies (2, 5, 99). 
Image analysis: Images were obtained using Nikon Eclipse 55i upright 
microscope and NIS-Element Software. The immunoreactivity signal for each 
antibody was analyzed by ImageJ. Signal pixels were selected to establish the 
RGB profile of the color of interest. The threshold for each color signal was 
adjusted to reduce background noise. The established RGB profile and 
threshold were applied to a macro script command, using Color Deconvolution 
plugin in ImageJ. The percentage of area positive for the immunoreactivity 
signal was calculated using ImageJ. Clearly defined plaques that are larger 
than 20 µm in AD and ADHIP rat brains were counted. The number of plaque 
counts were normalized to the total imaging area.   
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3.2.l. Immunofluorescence staining 
Immunofluorescence staining for brain tissue sections was modified from 
the previously described protocol (2, 99). The antigen retrieval method for 
amylin and Aβ is modified. The antigen retrieval for amylin and Aβ was 
described in the immunohistochemistry session above. For Thioflavin S 
staining, after secondary antibody incubation, brain slides were incubated in 
0.5% Thioflavin S for 15 minutes at R.T. Slides were then incubated for 3 
minutes in 70% ethanol, 3 minutes in 0.2% Sudan black and 3 minutes in 70% 
ethanol, before washing and mounting.  
3.2.m. Isolation of rat brain capillaries 
Rat brain capillaries were isolated following the protocol described 
previously (199). Freshly isolated brain capillary was snap frozen, crushed and 
homogenized in homogenate buffer (150 mM NaCl, 50 mM Tris-HCl, 50 mM 
NaF, 2% Triton X-100, 0.1% SDS, 1% (v/v) protease and phosphatase 
inhibitors, pH 7.5). Homogenates were centrifuged at 17,000 xg for 30 minutes 
at 4oC. The supernatant was separated from pellet after centrifugation and was 
then used for all experiments. 
3.2.n. Protein extraction 
Frozen human brain tissues were homogenized in homogenate buffer (150 
mM NaCl, 50 mM Tris-HCl, 50 mM NaF, 2% Triton X-100, 0.1% SDS, 1% (v/v) 
protease and phosphatase inhibitors, pH 7.5). Homogenates were centrifuged 
at 17,000 xg for 30 minutes at 4oC. The supernatant was separated from pellet 
after centrifugation and was then used for all experiments. For rat brain tissue, 
half hemisphere was used for histological analyses, and the other half was 
used for brain capillary isolation and other protein extractions. Rat brain tissues 
were subjected to serial extraction methods using Triton and Guanidine HCl 
(GndHCl). Frozen brain samples were homogenized with 1% Triton buffer (25 
times tissue volume) containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X-100 (v/v), 1% (v/v) protease and phosphatase inhibitors, 
pH 7.5. The homogenates were left on ice for 15 minutes. The homogenates 
were centrifuged at 15,000 rpm for 15 minutes at 4oC. The supernatant (Triton-
soluble fraction) was separated from the pellet. 5 M GndHCl (with 50 mM Tris, 
pH 8.0) solution was added to the pellet (10 times the pellet volume). 
Homogenates were rocked for 3-4 hours at R.T. The samples were stored at -
80oC until analysis. Before analysis, the GndHCl samples were diluted at 1:10 
ratio with lysate buffer (1% NP-40 (v/v), 150 mM NaCl, 10 mM Tris, 2 mM 
EGTA, 50 mM NaF). The samples were centrifuged at 16,000 xg for 20 minutes 
at 4oC. The supernatant (GndHCl-soluble fraction) was separated from the 
pellet. BCA protein estimation was performed for Triton-soluble fractions. 
MicroBCA protein estimation was performed for diluted GndHCl-soluble 
fraction.      
3.2.o. Enzyme-linked immune absorbance assay (ELISA) 
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Levels of amylin in human brain samples were measured using sandwich 
amylin ELISA from Millipore (EZHA-52K). Levels of amylin in brain homogenate 
and CSF samples from rats were measured using amylin sandwich ELISA from 
RayBiotech (EIA-AMY). Total Aβ levels in rat CSF were measured using high 
sensitivity electrochemiluminescence ELISA (MSD 6E10, K15200G-2, Meso 
Scale Discovery). Aβ42 and Aβ40 levels in rat brains were measured using 
Aβ42 and Aβ40 ELISA (KHB3442, KHB3482, Invitrogen). ELISAs were 
performed according to the manufacturer’s protocol. Levels of measured 
proteins in tissue homogenates were normalized to the total protein input. 
3.2.p. Statistical analysis 
The number of samples or animals analyzed in each experiment, the 
statistical analysis performed, as well as the P values for all results are reported 
in the figures and figure legends. The reported ‘‘n’’ represents the number of 
animals. Gaussian distribution of the data was tested with D'Agostino-Pearson 
and Kolmogorov-Smirnov test. Parametric comparison between two groups 
was performed using two-tailed t-tests. Relationships between two variables 
were analyzed by correlation analysis. Z-scores and data from the Morris Water 
Maze were analyzed by ANOVA, followed by post-hoc tests. Analyses were 
performed using GraphPad Prism 8.0. Data are presented as means ± SEM, 
individuals, or as box and whisker plots. The difference between groups was 
considered significant when P ≤ 0.05.  
3.3. Results 
3.3.a. Brains of fAD mutation carriers contain amylin deposits in 
microvasculature and plaques.  
Amylin is known to form pancreatic amyloid in patients with type 2 diabetes 
(Fig. S3.1a) and also interacts with AD pathology in individuals with sporadic 
AD (sAD) (2-7, 99, 129). To test the potential relationship between pancreatic 
amylin, the brain and fAD, we analyzed brain tissues from human PSEN1 and 
APP mutation carriers for amylin deposition and interaction with areas of AD-
related histopathology (Aβ and tau deposits). Details on patient information are 
given in Table S3.1. Temporal cortex homogenates from fAD patients had 
higher amylin concentrations compared to those from cognitively unaffected 
(CU) individuals (Fig. 3.1a). The average amylin levels were higher in brain 
homogenates from PSEN1 mutation carriers than in APP mutation carriers and 
in CU individuals (Fig. S3.1b). Immunohistological analysis uncovered amylin 
and mixed amylin-Aβ plaques in fAD brains (Figs. 3.1b-l) (see also Methods; 
Image analysis). Amylin was detected in about 1/3rd of the total plaques within 
the grey matter of fAD brains (Figs. 3.1b, d). Brains from the CU group had 
sporadic amylin and Aβ deposits (Fig. 3.1c). Within the CU group, cerebral 
plaques showed a higher immunoreactivity signal compared to that of Aβ (Fig. 
3.1e), which was anticipated based on previous reports (5, 6, 99, 100, 129) that 
amylin accumulates in both cognitively unaffected and sAD brains.  
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In fAD brains, amylin immunoreactivity was detected in neuronal soma 
(Figs. 3.1f and 3.1g; arrowheads; 26/27 patients (Table S3.1)) and neuritic 
plaques (Figs. 3.1h-l, 16/27 patients (Table S3.1)). In some amylin-Aβ neuritic 
plaques, immunostaining showed the presence of amylin in small 
proteinaceous fragments (Figs. 3.1f and 3.1g; arrows). Confocal microscopic 
analysis of areas containing amylin-positive neurons revealed no overlapping 
between the immunoreactivity signals for amylin and phosphorylated tau (p-
tau) (Fig. S3.1c) suggesting distinct amylin and tau pathologies. Some plaques 
stained positive for amylin adjacent to Aβ deposition (Figs. 3.1h and 3.1i), and 
some had layered amylin-Aβ compositions with amylin-positive cores (Figs. 
3.1j-l). CU brains showed sparse amylin and Aβ immunoreactivity signals (Fig. 
3.1m). Confocal microscopic analysis of fAD brain slices triple-stained with 
Thioflavin-S and anti-amylin and anti-Aβ antibodies suggests that the amylin-
positive core of amylin-Aβ plaques has biochemical characteristics of amyloid 
because it is localized with Thioflavin-S signal (Fig. 3.1n) and is structurally 
similar to those detected in brain slices from patients with sAD (Fig. S3.1d). 
Amylin deposition was present in both grey matter (GM) and white matter 
(WM) regions (Figs. 3.2a-c). Sparse amylin immunoreactivity signal was 
detected also in CU brains (Fig. 3.2b). In fAD, while Aβ was predominantly 
deposited in GM areas, the area of amylin deposition is higher than that of Aβ 
in the WM (Fig. 3.2c).  
In humans, AD pathology co-occurs with vascular abnormalities (15) and 
BBB injury (192). Co-staining human fAD brain tissues for Aβ and amylin 
showed the presence of mixed amylin-Aβ immunoreactivity signals within the 
blood vessel wall and Aβ surrounding the blood vessel in GM regions (Fig. 
3.2d), compared to CU brains (Fig. 3.2e). The average amylin content in 
vascular mixed amylin-Aβ deposits was higher in brain tissues from PSEN1 
mutation carriers than in APP mutation carriers and in CU individuals (Fig. 
3.2f). Amylin formed amyloid in small arteries as inferred from serial sections 
tested for amylin deposition and Congo red staining (Figs. 3.2g-j). This result 
mirrors previous findings in sAD brains, where amylin deposition within blood 
vessels walls appeared as part of cerebral amyloid angiopathy (CAA) (5, 
6).Figures 3.2k-n show a presumed capillary positive for amylin and Thioflavin-
S, but negative for Aβ, indicating that capillary amylin deposition has 
biochemical characteristics of amyloid. In WM regions, amylin deposition was 
detected in occluded small vessels (Fig. S3.2 (arrowheads)), in perivascular 
and chronic infarct areas (Fig. S3.2 (arrows)), and in the parenchyma (Fig. 
S3.2 (double arrows)). Pancreatic tissue from a patient with type 2 diabetes 
served as positive control for amylin deposition (Fig. S3.1a). 
3.3.b. Amylin-AD interaction does not involve a genetic 
predisposition. 
A variant in the amylin gene (rs73069071) was associated with cortical Aβ 
deposition in patients with AD-related cognitive impairment and temporal lobe 
atrophy in a genome-wide interaction study (137). To test whether genetic 
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predisposition may play a role in amylin-AD interaction, we analyzed specific 
associations of the amylin gene variants with the risk for developing AD using 
data from the International Genomics of Alzheimer’s Project (IGAP) (n = 17,008 
AD cases and n = 13,154 controls). No significant associations were detected 
for the amylin gene. To assess rare genetic variants in the amylin gene 
(ENST00000240652) in AD, we analyzed exome sequencing data from a 
cohort of 331 AD cases (Table S3.2). We also analyzed the variability of the 
amylin gene in a cohort of cognitively healthy and neuropathologically normal 
individuals (n = 468) from the Healthy Exosomes (HEX) database (Table S3.2). 
Our analysis showed no genetic role of amylin in AD. 
These results suggest that amylin secreted from the pancreas may 
contribute to small-vessel-type pathology in white matter and grey matter 
regions and modulate brain amyloid composition in fAD via mechanisms that 
are not linked to a genetic predisposition. 
3.3.c. Co-expression of amyloid-forming human amylin in the 
pancreas and APPSwe/PS1DE9 in the brain accelerates neurological 
deficits in rats (ADHIP rats). 
The rat experimental models used in this study are summarized in Fig. 3.3 
schematic. To test the impact of brain amylin deposition on behavior deficits 
associated with AD pathology, we generated AD model rats that are prone to 
amylin dyshomeostasis (ADHIP rats). The model was created by crossing non-
AD rats that overexpress human amylin (3-fold) in the pancreas (HIP rats) (95) 
and develop systemic amylin dyshomeostasis on a normal chow diet (2) (8, 95, 
98, 123) with APP/PS1 rats that overexpress human APPSwe/PS1DE9 (194) 
without amylin dyshomeostasis (AD rats) (Fig. 3.3), as rat amylin does not form 
amyloid (100). HIP and wild type (WT) rats from the same litters as ADHIP and 
AD rats were used to assess the effects of amylin dyshomeostasis on behavior, 
in the absence of AD pathology (Fig. 3.3). Rats in all groups were tested for 
motor and cognitive performance at 8 (normal behavior), 12 (development of 
amylin dyshomeostasis in HIP rats) (2, 8), and 16 months of age (development 
of AD pathology in AD rats) (194). At 8 months of age, ADHIP rats and AD rats 
had comparable neurological scores for motor and cognitive performance (Fig. 
3.4a). With aging, rats in the ADHIP group had greater deficits for both motor 
(Fig. 3.4b and Figs. S3.3a-d) and cognitive (Fig. 3.4c and Figs. S3.4a-c) 
function, which worsened at a higher rate than those in AD littermates (Figs. 
3.4b-c). Motor and cognitive performance declined faster also in aged HIP rats 
than in WT littermates (Figs. 3.4d-f and Figs. S3.3e-h and S3.4d-f). Multiple 
comparison analysis between rat groups at each time point suggests that 
amylin-AD pathology interaction accelerates functional decline, beginning at 12 
months of age (Fig. 3.4a). The analysis also indicates that the amylin-AD 
pathology interaction synergistically augments the behavioral deficits with 
aging (schematic summary in Fig. 3.4g). 
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3.3.d. Accelerated behavior deficits in ADHIP rats are associated 
with brain microhemorrhages and white matter changes. 
We reported (2, 97) that high blood levels of amyloid-forming human amylin 
in HIP rats are associated with disruption of vascular endothelium associated 
with brain microhemorrhages and white matter disease (2). 
Immunohistochemistry analysis of brain slices from 16-month old ADHIP and 
AD littermates co-stained for amylin (red) and Aβ (green) (Figs. 3.5a-b) 
revealed vascular amylin deposition in both GM and WM regions, in ADHIP 
rats. Amylin also paired with Aβ in blood vessels (Fig. 3.5a). AD littermates had 
no significant amylin or Ab deposition in brain blood vessels (Figs. 3.5c-d). 
Based on these results, we anticipated two consequences from the amylin-
mediated microvascular changes: brain microhemorrhages and white matter 
injuries (schematic, Fig. 3.5e). 
Brain microhemorrhages: In brain tissues from ADHIP, AD, HIP, and WT 
rats, we analyzed: 1) the presence of brain microhemorrhages, by Prussian 
blue staining; and 2) vascular recruitment of monocytes and macrophages, by 
immunohistochemistry using antibodies against Cluster of Differentiation 68 
(CD68) and 11b (CD11b) molecules. Aged ADHIP rats had more 
microhemorrhages than AD littermates (Fig. 3.5f). Brain microhemorrhages 
were also detected in HIP rat brains (Fig. 3.5g). Histological analysis of brain 
tissues revealed greater accumulation of phagocytic microglia, a marker of 
blood-brain barrier (BBB) damage (192), in the GM and WM of aged ADHIP vs. 
AD rats and in HIP vs. WT rats (Figs. 3.5h-i).  
Brain white matter changes: Next, we investigated aged ADHIP rats and 
AD littermates by in vivo brain magnetic resonance imaging (MRI) followed by 
analyses of brain slices for evidence of axonal degeneration by staining with 
myelin basic protein antibody and luxol fast blue. In vivo structural MRI of the 
brain revealed areas of high T2 signal in the lateral hippocampus and around 
the temporal horns of the lateral ventricles (Fig. 3.6a) and expansion of the 
ventricles (Fig. 3.6b) in aged ADHIP rats, which were not present in AD 
littermates. Consistent with subcortical atrophy, ADHIP rats had lower brain 
weight (Fig. 3.6c), compared to AD littermates. The results from ADHIP vs. AD 
rats are in agreement with our published comparative analysis in HIP vs. WT 
rats (2). Histological analysis of brain tissues revealed greater levels of axonal 
degeneration in aged ADHIP vs. AD rats and in HIP vs. WT rats (Fig. 3.6d and 
Fig. S3.5).  
Brain microhemorrhages following intravenous injection of human 
amylin in AD rats: We tested whether abnormal circulating levels of amyloid-
forming human amylin affect brain microvasculature in the absence of 
confounding factors due to development of amylin dyshomeostasis (at ~ 12 
months of age, in ADHIP rats) and AD pathology (at ~ 16 months of age, in AD 
rats). We infused low amounts of oligomerized human amylin intravenously in 
young AD rats (7 months of age), for 2 months (Fig. 3.6e). At the conclusion of 
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the infusion regimen, rats injected with human amylin had increased amylin 
concentration in brain capillary lysates (Fig. 3.6f) and developed brain 
microhemorrhages (Fig. 3.6g), indicating disruption of brain microvascular 
endothelium as seen in ADHIP rats (Fig. 3.5f). 
3.3.e. APPSwe/PS1DE9 and amylin dyshomeostasis promote 
amylin-Aβ cross-seeding. 
Altered composition of secreted amylin in ADHIP vs. AD rats was 
associated with changed dynamics of the CSF Aβ concentration with aging 
(Fig. 3.7a). The ratio Aβ42/Aβ40 protein levels were higher in brain homogenates 
from ADHIP rats than in those from AD littermates (Fig. 3.7b) suggesting an 
increased propensity for plaque formation in ADHIP rats. These changes were 
associated with increased plasma amylin levels with aging (Fig. 3.7c) and brain 
accumulation of amylin (Fig. 3.7d) in ADHIP vs. AD rats, indicating amylin 
dyshomeostasis in ADHIP rats. Immunohistochemistry analysis of brain slices 
from 16-month old ADHIP and AD littermates co-stained for amylin (red) and 
Aβ (green) (Figs. 3.7e and 3.7f) revealed amylin deposition in both GM and 
WM regions in ADHIP rats (Fig. 3.7e), mirroring findings in human AD brains 
(Fig. 3.1b). The amylin WM to GM coverage ratio was elevated in ADHIP 
compared to AD brains (Fig. 3.7g) and tended to increase in 16-month old 
compared to 12-month old ADHIP rats (P = 0.06), consistent with progression 
of amylin dyshomeostasis. A similar analysis in the HIP vs. WT rats (Figs. 3.7h-
m) suggests that elevated blood levels of amyloid-forming human amylin (Fig. 
3.7h) are associated with altered CSF Aβ concentration (Fig. 3.7i), brain amylin 
accumulation (Fig. 3.7j) and amylin pathology in WM regions (Figs. 3.7k-m). 
These data indicate that amylin dyshomeostasis induced by expressing human 
amylin in the pancreas of AD model rat promotes amylin interaction with brain 
Aβ and changes in brain white matter (summarized in Fig. 3.7n). 
Based on our reported data in HIP rats (2), amylin pathology in the WM 
microvasculature in ADHIP rats (as in Figs. 3.5a and 3.7e) is an intrinsic 
constructive validity of the ADHIP model rat linked to the expression of human 
amylin in the pancreas. ADHIP and HIP rats differed, however, by the 
composition of protein deposition in GM regions. In ADHIP rats, amylin formed 
the protein core of the Aβ plaques (Fig. 3.8a and Fig. S3.6a). AD littermates 
had Ab plaques in GM regions (Fig. 3.8b and Fig. S3.6a), as reported (194). 
GM regions in HIP rat brains had sparse amylin deposition, without obvious Ab 
immunoreactivity signal (Fig. 3.8c). Brains of WT littermates had neither amylin 
nor Aβ deposition (Fig. 3.8d). Pancreatic tissues from rats in the four groups 
were used as positive controls for characteristic amylin immunoreactivity 
signals in each rat group (Figs. 3.8e-h).  
Intriguingly, sparse amylin deposition within the protein core of Aβ plaques 
was detected in brain tissues from 16-month old AD rats (Fig. 3.8b and Figs. 
S6a), although amylin from rodents is non-amyloidogenic (100). There was no 
hippocampal amylin plaques deposition in WT rats (Figs. S3.6a-b) suggesting 
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that rat amylin does not accumulate in the brain, in non-AD rats that express 
endogenous non-amyloidogenic rat amylin.   
To determine cerebrovascular effects of amylin dyshomeostasis induced 
before the development of AD pathology, we examined the pathology in AD 
rats that were infused with low amounts of human amylin, as described above 
(Fig. 3.6e). Infusion of human amylin did not significantly increase the plasma 
amylin level in AD rats (Fig. S3.6c). At the end of the infusion regimen, 
cognitive and motor performance were not significantly different between AD 
rats that were given human amylin vs. control rats (Fig. S3.6d). Brain tissue 
sections co-stained for amylin and Aβ showed amylin-Aβ plaque formation 
(Fig. S3.6e, arrow) and patchy areas of amylin-positive neurons (Fig. S3.6e, 
circles). These data suggest that human amylin from the periphery promotes 
amylin-Aβ plaque formation in the brain and neuronal amylin accumulation, 
before the development of AD pathology.  
To test the source of brain amylin deposition in AD rats, we generated 
APPSwe/PS1DE9 rats that lack the amylin gene (AD-AKO rats) by crossing 
APPSwe/PS1DE9 rats with amylin knockout (AKO) rats (AKO rats were 
generated in our previous work (2)). Deletion of amylin gene in AD rats resulted 
in no amylin deposition in the brain GM parenchyma (Fig. 3.8i), blood vessels 
(Fig. 3.8j), brain WM (Fig. 3.8k), or the pancreas (Fig. 3.8l), providing critical 
evidence that the pancreas is the source of amylin that is deposited in the brain. 
The number of mixed amylin-Aβ plaques also significantly less in AD-AKO 
group (Fig. 3.8m), suggesting that the genetic suppression of amylin decreases 
amylin-Aβ cross-seeding.  
Overall, these results (Figs. 3.7 and 3.8a-m) suggest that: 1) amylin 
dyshomeostasis disrupts the CSF-brain Ab balance; 2) there is a robust in vivo 
amylin-Aβ cross-seeding promoted by overexpression of human 
APPSwe/PS1DE9; 3) APPSwe/PS1DE9 rats with the pancreatic expression of 
human amylin mirror amylin-Aβ cross-seeding in PSEN1 and APP mutation 
carriers. 
3.3.f. Suppressed amylin expression reduces behavior deficits in 
APPSwe/PS1DE9 rats. 
The unexpected cross-seeding between rat amylin and Aβ in brains of AD 
rats suggested the hypothesis that suppression of amylin secretion affects 
neurological function in AD rats. Neurological function changes with aging in 
AD-AKO rats vs. AD littermates are shown in Figs. 3.8n-p. Overall, AD-AKO 
rats had less severe neurological deficits with aging compared to AD rats (Fig. 
3.8n), an unanticipated result indicating that amylin depletion protected against 
AD effects because rat amylin is non-amyloidogenic (100). The cognitive 
function, assessed from the novel object recognition, declined significantly 
slower in AD-AKO rats, compared to AD (Fig. 3.8o). The novel object 
recognition test, which detects short-term recognition memory impairments, 
differed between AD and AD-AKO rat groups at 16-months of age (Fig. S3.7a). 
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The motor function assessed from the forelimb use (Fig. S3.7b) and hind limb 
clasping (Fig. S3.7c) was not significantly different between AD and AD-AKO 
at 8-, 12-, and 16-months of age (Fig. 3.8p). Consistent with amylin’s function 
as a satiation hormone (55), suppression of amylin expression caused the body 
weights of AD-AKO rats to increase at a greater rate than those of AD 
littermates (Fig. 3.8q). Because of the impact of the amylin gene deletion on 
the body weight, the results from the inclined plane, rotarod, and water maze 
tests were not included in the analysis. 
3.3.g. The pharmacological lowering of amylin dyshomeostasis 
improves brain function in Alzheimer disease model rats. 
To further test the hypothesis that amylin dyshomeostasis accelerates the 
development of AD, we pharmacologically lowered amylin dyshomeostasis in 
aged ADHIP rats and assessed behavior, brain amylin-Ab depositions, cerebral 
vascular, and white matter injuries in treated and untreated rat groups. ADHIP 
rats were treated with an inhibitor of soluble epoxide hydrolase (sEH), the 
enzyme that degrades endothelial cell-formed epoxyeicosatrienoic acids 
(EETs). EETs was shown to protect against cardiac amylin deposition in a rat 
model for amylin dyshomeostasis (122). Separate cohorts of ADHIP rats were 
treated starting at different disease stages of amylin dyshomeostasis (2, 8): 12-
month old (early-stage (T-ES)) and 16-months old (late-stage (T-LS)). Age-
matched control animals in each study group received vehicle treatment (UT-
ES and UT-LS). The schematic of treatment regimen is in Fig. 3.9a. Here, we 
found that both treatments with sEH inhibitor (sEHi) slowed the neurological 
deficits in ADHIP rats (Fig. 3.9b, Figs. S3.8a-n). At the end of the treatment, 
amylin concentration in plasma and brain homogenates was significantly lower 
in rats treated at an early stage, compared to age-matched 16M old UT rats 
(Figs. 3.9c and d). ADHIP rats treated at late stage also had lower levels of 
plasma amylin (P = 0.051; Fig. 3.9c) and slightly lower levels brain amylin in 
the Guanidine HCl-soluble fractions (P = 0.21; Fig. 3.9e), at the end of 
treatment, compared to age-matched 18M UT rats. Levels of amylin in 
independent plaques and mixed-plaques with Aβ were lower in treated groups 
(Figs. 3.9f, 3.9h-i, Fig. S3.9). In addition, amylin depositions in brain capillaries 
were lower in treated groups, compared to untreated rats (Figs. 3.9g and 3.9j). 
In addition, the amylin WM-to-GM coverage ratio was lower in T-ES rats, but 
not in rats received treatment at later stage (Fig. S3.8o) 
Next, we compared markers of brain capillary and white matter injuries in 
16M-UT vs. T-ES and 18M-UT vs. T-LS ADHIP rat groups. Histological analysis 
of brain tissues showed a significant reduction in brain microhemorrhages in T-
ES group (Fig. 3.9k). T-LS group also displayed a lower number of brain 
microhemorrhages though not significant (Fig. 3.9k). Axonal myelination was 
better preserved in the treated groups (Fig. 3.9l and Fig. S3.8p). Levels of 
CD68 increased in the GM of T-ES but decreased in the WM of T-LS (Fig. 
3.9m), suggesting changes in phagocytic microglia in response to BBB injuries 
ameliorated by the treatments (Fig. 3.9k). 
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These results show that peripherally mediated amylin dyshomeostasis 
induced axonal degeneration as a result of progressive amylin deposition in 
small blood vessels through mechanisms that appear to involve plaque 
formation and microhemorrhages. Pharmacologically lowering amylin 
deposition in the brain parenchyma and brain capillaries protected against 
microhemorrhages and consequent brain white matter injury. 
3.4. Discussion 
By staining and imaging of amylin and Aβ in brain tissues from humans with 
and without fAD, AD model rats with the pancreatic expression of amyloid-
forming human amylin, and AD model rats expressing non-amyloidogenic rat 
amylin, we found that amylin accumulated in small blood vessels, paired with 
Aβ in plaques and formed independent plaques and in space-filling lesion 
within neurons. The results indicate amylin dyshomeostasis as a peripherally 
mediated process that may contribute to the modulation of brain microvascular 
and Alzheimer pathologies. Co-expressing amyloid-forming human amylin in 
pancreatic islets and APPSwe/PS1DE9 in the brain in rats synergistically 
accelerated neurological deficits. This was associated with brain amylin-Aβ 
cross-seeding along with microhemorrhages and white matter changes. Similar 
molecular processes were triggered by intravenous injection of human amylin 
in APP/PS1 rats. These findings (summarized in Fig. 3.10) are of interest 
because 1) a role of pancreatic amylin in the modulation of brain microvascular 
and Alzheimer pathologies in fAD mutation carriers was previously unknown; 
2) there is accumulating evidence (2-7, 99, 129, 193) showing brain amylin 
deposition in the sporadic form of AD; 3) amylin deposition in tissues in humans 
is associated with cell apoptosis (93) and inflammation (99, 123); and 4) blood 
amylin may be a therapeutic target for slowing the progression of sAD and 
improving the lives of fAD mutation carriers. 
In sAD, brain amylin pathology was explained by hyperamylinemia (128), 
as it coincides with hyperinsulinemia, a risk factor for sAD (200). We did not 
anticipate amylin dyshomeostasis in fAD, given the earlier onset of the disease 
with reduced age-dependence of amyloid pathology and insulin resistance. 
What triggers brain amylin accumulation in fAD mutation carriers has yet to be 
elucidated. It is intriguing that the brain amylin levels are higher in PSEN1 vs. 
APP mutation carriers. Presenilins are present in the pancreatic β-cells (201); 
whether the mutation of presenilin genes is a link between increased brain 
amylin accumulation and fAD needs further investigation.    
In human brains, amylin pathologies appeared more prevalent than Aβ 
pathologies in white matter regions. This characteristic was mirrored in human 
amylin-expressing AD rats and is consistent with our previous report indicating 
axonal degeneration and late-onset neurological deficits in non-AD rats that 
develop amylin dyshomeostasis (2, 8). Amylin crosses BBB with saturation at 
physiological levels (64), and we found evidence of BBB injury and increased 
brain amylin levels in response to high amylin in the periphery. We did find that 
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acute “human” hyperamylinemia in young AD rats induced amylin accumulation 
in the brain capillaries and brain hemorrhages, mirroring our findings in the 
amylin-expressing AD rats. The results imply that high circulating levels of 
amylin (common in patients with AD (193)) would lead to microvascular 
dysfunction and disruption. They also imply that targeting fluctuation or peaks 
of blood amylin level could reduce vascular amylin deposition, prevent amylin 
from interacting with Aβ-associated pathology, and provide benefit in patients 
with AD. The present results evoke a number of questions (How is amylin from 
blood delivered to the brain parenchyma and cleared from brain tissues? Does 
the amylin pathway change in response to AD? Is brain amylin delivery 
potentiated by peripheral insulin resistance?), which are requisite for both a 
basic understanding of amylin physiology and the rational design of amylin-
centered therapeutics. 
It was proposed that circulating amylin clears Aβ peptide from the brain 
(143) and that amylin analogs may protect the brain in human AD (193). If 
amylin decreased Aβ pathology, we would then expect that overexpressing 
human amylin in AD rats would slow disease progression, whereas the deletion 
of the amylin gene would exacerbate AD pathology and behavior deficits. Our 
results demonstrated the opposite and are consistent with data study showing 
that human amylin administration in AD mice accelerated AD pathology (133).     
Demonstrating that regulation of amylin homeostasis slows the progression 
of AD is difficult because of a lack of anti-amylin drugs, but we showed that 
suppression of amylin expression in AD rats is protective. This result has also 
brought to light a potential paradoxical relationship between increased body fat 
and effects on brain function in the setting of restricted amylin secretion. 
Together, these findings suggest that amylin may play a critical role in energy 




Figure 3.1. Brain amylin-Aβ composition in PSEN1 and APP mutation 
carriers. (a) Amylin levels in temporal cortex specimens from PSEN1 and APP 
mutation carriers (fAD; n = 18) and cognitively unaffected individuals (CU; n = 12). 
(b, c) Representative images of immunohistological analysis using anti-amylin 
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(brown) and anti-Aβ (green) antibodies on temporal cortex slices from fAD brains 
(n = 27) and CU brains (n = 5). (d, e) Relative distribution of amylin amylin, Aβ and 
amylin-Aβ calculated from immunohistological analysis of amylin and Aβ in the 
grey matter plaques (left panel) in fAD brains (d; n = 27) and CU brains (e; n = 5). 
See Methods section for image analysis. (f-l) In fAD brains (n = 27), amylin 
deposition in neurons (f, g; arrowheads), or forming homogenous plaques (h, i) 
and amylin-Aβ plaques (j-l) are shown. (m) Representative image of amylin and 
Aβ depositions in CU brains (n = 5). (n) Confocal microscopic analysis of a fAD 
brain section triple stained with Thioflavin S (ThioS, green), anti-amylin antibody 
(red), and anti-Aβ antibody (magenta). Type of PSEN1 or APP mutation is labeled 
on each image; 3 sections/brain. Scale bars, 200 µm (b, c), 50 µm (f-m), 10 µm 
(n). Data are means ± SEM; P ≤ 0.01 **, P ≤ 0.001 ***, P ≤ 0.0001 ****; two-tailed, 




Figure 3.2. Brain amylin-Aβ vascular pathology in PSEN1 and APP mutation 
carriers. (a, b) Representative images of immunohistological analysis using anti-
amylin (brown) and anti-Aβ (green) antibodies on temporal cortex slices from fAD 
brains (n = 27) and CU brains (n = 5). (c) Estimated amylin-positive vs. Aβ-positive 
areas in the white matter and grey matter of fAD brains (n = 27) and CU brains (n 
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= 5). (d, e) Representative images of co-staining with anti-amylin (brown) and anti-
Aβ (green) antibodies showing vascular amylin and Aβ deposits in a fAD brain (d) 
and a CU brain (e). (f) Estimated area percentage of amylin in mixed amylin-Aβ 
deposits in the blood vessels of individuals with PSEN1 (n = 20) or APP (n = 7) 
mutation, and CU brains (n = 5). See Methods section for image analysis. (g-j) 
Consecutive fAD brain sections stained with Congo Red (g), anti-Aβ (h), anti-
amylin (i), or a combination of anti-amylin and anti-Aβ (j) antibodies. (k-n) Confocal 
microscopic analysis of a fAD brain section triple stained with Thioflavin S (ThioS, 
green, k), anti-Aβ antibody (magenta, l), anti-amylin antibody (red, m). Type of 
PSEN1 or APP mutation is labeled on each image; 3 sections/brain. Scale bars, 
200 µm (a, b), 50 µm (d-e, g-j), 10 µm (k-n). Data are means ± SEM; P ≤ 0.05 *, 
P ≤ 0.0001 ****; two-tailed, unpaired t test with Welch’s correction.   
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Figure 3.3. Schematic summary of rat models generated for this study and 
time points of behavior and molecular analyses. Genetic manipulation of 
amylin expression was performed in rats with and without AD pathology through 
transgenic expression of human amylin in the pancreas (red color code) and by 
deletion of the amylin gene (light blue color code). The time points for behavioral 
studies were chosen based on previous reports that amylin dyshomeostasis 
develops at 12 months of age in human amylin expressing rats (HIP rats) and that 
Aβ pathology is developed in APP/PS1 rats (AD rats) at about 16 months of age. 
ADHIP rat: human amylin expressing Alzheimer disease model rat; AD rat: 
Alzheimer disease model rat; HIP rat: human amylin expressing rat; WT rat: wild-
type rat; AKO rat: amylin knock-out rat; AD-AKO: amylin knock-out Alzheimer 





Figure 3.4. Co-expression of amyloid-forming human amylin in the pancreas 
and APPSwe/PS1DE9 in the brain accelerates neurological deficits in rats 
(ADHIP rats). (a-f) Longitudinal average neurological scores of behavior tests for 
motor function (assessed from forelimb use, balance ability on the inclined plane, 
hind limb clasping, and Rotarod test) and cognitive function (assessed from the 
novel object recognition and Morris water maze tests) in ADHIP vs. AD rats (n = 
10 rats/group) (a-c); in HIP vs. WT rats (n = 10 rats/group) (d-f). Data for individual 
tests are shown in Figures S3.3. (g) Schematic summary of results from (a-f). Data 
are means ± SEM. P ≤ 0.05 *, P ≤ 0.01 **, P ≤ 0.001 ***, P ≤ 0.0001 ****; 2-way 
ANOVA with Sidak post-hoc (a-f). ADHIP rat: human amylin expressing Alzheimer 
disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin 
expressing rat; WT rat: wild-type rat. 
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Figure 3.5. Biomarkers of vascular endothelial injury in rats with pancreatic 
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hypersecretion of amylin. (a-d) Representative images of co-staining with anti-
amylin (brown) and anti-Aβ (green) antibodies in brain sections in 16M old ADHIP 
(a, b) and AD rats (c, d) (n = 5 rats/group). (e) Schematic of mechanisms tested 
in the following experiments. (f, g) Representative images and analysis of brain 
microhemorrhages stained with Prussian blue dye in 16M old ADHIP vs. AD rats 
(f) and HIP vs. WT rats (g) (n = 5 rats/group). (h, l) Representative images and 
analysis of marker for phagocytic microglia (CD68) (h) and vascular monocyte 
recruitment (CD11b) (l) in brain sections from 16M old ADHIP vs. AD rats, HIP vs. 
WT rats (n = 5 rats/group). (GM- grey matter; WM- white matter). Scale bars, 100 
μm (a, c), 50 μm (b, d, h, i), 20 μm (f, g). Data are means ± SEM; P ≤ 0.05 *; two-
tailed, unpaired t test. ADHIP rat: human amylin expressing Alzheimer disease 
model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin expressing 
rat; WT rat: wild-type rat. 
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Figure 3.6. Brain white matter changes in AD rats expressing human amylin 
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in the pancreatic islets (ADHIP rats) and microvascular injury in AD rats 
intravenously infused with human amylin. (a) Slices 3 and 5 out of 7 
consecutive slices of coronal T2-weighted MRI in brains of 16M old ADHIP and AD 
rats (n = 6 rats/group). Arrowheads indicate the lateral side of hippocampus; 
arrows indicate the temporal horns of lateral ventricles. (b) Volumes of ventricular 
hyperintensity computed from MR images; 1 image pixel area = 0.024 mm2. (c) 
Gross brain weights of 16M old ADHIP and AD rats (n = 10 rats/group). (d) 
Representative images and analysis of brain myelin basic protein (MBP) in the 
same rats as in (a) (n = 5 rats/group). (e) Intravenous infusion of human amylin in 
AD rats. (f) Levels of amylin in the brain capillary lysates from human amylin-
injected AD rats vs. AD control rats (n = 5 rats/group). (g) Representative images 
and analysis of brain microhemorrhages in human amylin-injected AD rats vs. AD 
controls (n = 3 rats/group). Scale bars, 50 μm (d, f). Data are means ± SEM; P ≤ 
0.05 *, P ≤ 0.01 **; two-tailed, unpaired t test. ADHIP rat: human amylin expressing 
Alzheimer disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human 




Figure 3.7. Changes in brain and CSF Aβ associated with amylin-Aβ cross-
seeding in the brain. (a) CSF total Aβ levels in ADHIP vs. AD rats (n = 6-7 
rats/group) at 12M and 16M of age. (b) Ratio of Aβ42-to-Aβ40 levels (Guanidine 
HCl-fractions of brain homogenates) in 16M old ADHIP vs. AD rats (n = 6-7 
rats/group). (c) Levels of amylin in the plasma of AD vs. ADHIP rats at 12M and 
16M of age (n = 10 rats/group). (d) Brain amylin levels (Triton-fractions of tissue 
homogenate) in 16M old ADHIP vs. AD rats (n = 7 rats/group). (e, f) Representative 
immunohistological images of amylin (brown) and Aβ (green) depositions in brain 
sections from 16M old ADHIP (e) and AD rats (f) (n = 5 rats/group). (g) Amylin 
WM-to-GM coverage ratio on brain slices from 12M and 16M old ADHIP and AD 
rats (n = 4-5 rats/group). (h) Levels of amylin in the plasma of HIP vs. WT rats at 
12M and 16M of age (n = 10 rats/group). (i) CSF total Aβ levels in HIP vs. WT rats 
(n = 3 rats/group) at 12M and 16M of age. (j) Brain amylin levels (Triton-fractions 
of tissue homogenate) in 16M old HIP vs. WT rats (n = 7 rats/group). (k, l) 
Representative immunohistological images of amylin (brown) and Aβ (green) 
depositions in brain sections from 16M old HIP (k) and WT rats (l) (n = 5 
rats/group). (m) Amylin WM-to-GM coverage ratio on brain slices from HIP and 
WT rats (n = 5 rats/group). (n) Summary of results from testing hypothesis from 
Figs. 3.4-3.7. Scale bars, 200 μm (e, f, k, l). Data are means ± SEM; P ≤ 0.05 *, P 
≤ 0.001 ***, P ≤ 0.0001 ****; two-tailed, unpaired t test. ADHIP rat: human amylin 
expressing Alzheimer disease model rat; AD rat: Alzheimer disease model rat; HIP 
rat: human amylin expressing rat; WT rat: wild-type rat. 
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Figure 3.8. Suppressed pancreatic expression of amylin reduced 
neurological deficits and amylin-Aβ cross-seeding in the brains of 
APPSwe/PS1DE9 rats. (a-d) Representative immunohistological images of co-
staining with anti-amylin (brown) and anti-Aβ (green) antibodies in brain sections 
from 16M old ADHIP (a), AD (b), HIP (c) and WT (d) rats (n = 5 rats/group). (e-h) 
Representative immunohistological images of staining with anti-amylin (brown) 
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antibody in pancreas sections from the same rats as in (a-d). (i-k) Representative 
images of immunostaining for amylin and Aβ in brain tissues from 16M old AD rats 
with deleted amylin genes (AD-AKO rats) (n = 5 rats/group). (l) Representative 
images of immunostaining for amylin in pancreas tissues from the same rats as in 
(i-k). (m) Counts of mixed amylin-Aβ plaques (i.e., amylin-core Aβ plaques) in AD 
and AD-AKO rat brains assessed from immunohistological images (n = 5 
rats/group) (data were normalized to total imaging area). (n-p) Longitudinal 
average neurological scores of behavior tests for cognitive function (assessed from 
novel object recognition test) and motor function (assessed from forelimb use and 
hind limb clasping tests) in AD rats vs. AD-AKO rats at 8, 12 and 16 months of age 
(n = 9 rats/group) (see also Fig. S3.7). (q) Longitudinal average body weights of 
AD rats vs. AD-AKO rats (n = 9 rats/group). Data are means ± SEM. P ≤ 0.05 *, P 
≤ 0.01 **, P ≤ 0.0001 ****; two-tailed, unpaired t test (m); 2-way ANOVA with Sidak 
post-hoc (n-p); 2-way ANOVA (q). ADHIP rat: human amylin expressing Alzheimer 
disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin 






Figure 3.9. Pharmacologically ameliorated amylin dyshomeostasis improves 
functionality of human amylin-expressing AD rats. (a) Diagram of 
pharmacological interventions to ameliorate early stage and late-stage amylin 
dyshomeostasis in ADHIP rats using a soluble epoxide hydrolase inhibitor (sEHi). 
(b) Neurological score (z-score) of behavioral tests (cognitive function and motor 
function; see also Fig. S3.8) in the sEHi early-stage treated ADHIP rats (T-ES) vs. 
age-matched untreated (UT-ES) rats (n = 5 rats/group); in the sEHi late-stage 
treated ADHIP rats (T-LS) vs. age-matched untreated (UT-LS) rats (n = 6 
rats/group). (c) Amylin levels in the plasma from 16M T-ES vs. UT-ES rats (n = 5 
rats/group) and 18M T-LS vs. UT-LS rats (n = 6 rats/group). (d, e) Amylin levels in 
the brain homogenates (Triton and Guanidine HCl-soluble fractions) from 16M T-
ES vs. UT-ES rats (n = 5 rats/group, d) and 18M T-LS vs. UT-LS rats (n = 6 
rats/group, e). (f) Representative immunohistological images for amylin and Aβ in 
the parenchymal plaques of 16M T-ES vs. UT-ES rats (n = 5 rats/group) and 18M 
T-LS vs. UT-LS rats (n = 3-6 rats/group). (g) Representative immunohistological 
images for amylin in the brain capillaries of 16M T-ES vs. UT-ES rats (n = 5 
rats/group) and 18M T-LS vs. UT-LS rats (n = 3-6 rats/group). (h-j) Analysis of total 
plaques deposition (h), number of mixed amylin-Aβ plaques (i), and amylin in the 
luminal vascular deposition (j). (k-m) Representative images of histological 
analysis of brain microhemorrhages (k), myelin basic protein (MBP) (l), and 
macrophage marker (Cluster of differentiation 68, CD68) (m) in brain sections from 
16M T-ES vs. UT-ES  rats (n = 5 rats/group) and 18M T-LS vs. UT-LS  rats (n = 3-
6 rats/group). Scale bar, 50 µm (f, g, m), 20 µm (k), 100 µm (l) (GM-grey matter; 
WM-white matter). Data are means + SEM; P < 0.05 *, P < 0.01 **, P ≤ 0.0001 ****; 
2-way ANOVA with Sidak post-hoc (b); two-tailed, unpaired Student’s t test (c-e, 
h-m). ADHIP rat: human amylin expressing Alzheimer disease model rat. 
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Figure 3.10. Schematic summary of the results and proposed mechanism. 
Circulating amylin affects brain and CSF Aβ levels via amylin-Aβ cross-seeding 
and brain amylin accumulation that induces microvascular injuries and white 
matter changes. Pharmacological lowering of blood amylin decreases amylin-Aβ 
cross-seeding and brain amylin accumulation. Amylin gene deletion in APP/PS1 
rats blocks amylin accumulation in the brain and amylin-Aβ cross-seeding, 
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providing protection against AD-related behavior changes. ADHIP rat: human 
amylin expressing Alzheimer disease model rat; AD rat: Alzheimer disease model 
rat; HIP rat: human amylin expressing rat; WT rat: wild-type rat; AD-AKO: amylin 




SUPPLEMENTAL TABLES AND FIGURES 
 
Table S3.1. Neuropathological information, age and sex of patients included 
in the study in Chapter 3.  
Top: Numbers of familial AD brains with different amylin and Aβ pathologies that 
were assessed by immunohistochemical analysis. The total number of human 
brains analyzed is 27.  
Bottom: Neuropathological information, age, and sex for individuals with cognitive 
unaffected (control), familial AD, or sporadic AD included in the present study. 
 
Familial AD brain pathology Patients/total (%) 
Mixed amylin-Aβ plaques in tissue parenchyma 17/27 (63%) 
Mixed amylin-Aβ plaques in blood vessels 22/27 (81%) 
Amylin plaques 16/27 (59%) 













n = 5 (for fAD) 
n = 3 (for sAD)  n = 27 n = 6 
Gender, female/male 
(% female) 2/1 (67%) (for sAD) 17/10 (63%) 4/6 (67%) 
Age at death (avg + 
SEM) 84.7 ± 2.3 (for sAD) 54.2 ± 1.8 89.8 ± 2 
Braak stage  N.A. V-VI V-VI 






Amylin ELISA n = 12 n = 18  
Gender, female/male 
(% female) 11/1 (92%) 12/18 (67%)  
Age at death (avg + 
SEM) 88.4 ± 2.0 54 ± 2.4  
Braak stage  0-IV V-VI  
Mutation, PSEN1/APP N.A. 11/7  
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Table S3.2. Analysis of associations of the amylin gene variants with the risk 
for developing AD.  
Top: Loss of function gene variants in amylin (islet amyloid polypeptide; IAPP) 
present in gnomAD and respective ages. Loss of function variants with a 
consequence in the canonical transcript of IAPP and without quality flags in 
gnomAD. *Age information available for 2 individuals. #CHR: Chromosome; Ref.: 
Reference; Alt.: Alternate; Trans. Cons.: Transcript consequence. AC: Allele 
count; Allele Freq.: Allele frequency.  
Bottom: Association results from the IGAP consortium for IAPP variants. #CHR: 
Chromosome; POS: position of the SNP (Build 37, Assembly Hg19); MarkerName: 
SNP rsID; Effect_allele: reference allele (coded allele); Non_Effect_allele: non 
reference allele; Beta: overall estimated effect size for the effect allele; SE: overall 
standard error for effect size estimate; P: meta-analysis P-value using regression 




























































































































Table S3.2. (continued) 
#CH






Beta SE P 
12 21526443 rs41275208 A C -0.0448 0.0362 0.2159 
12 21526472 rs12306121 G A -0.044 0.0197 0.02536 
12 21526651 rs12319824 A G -0.0425 0.0199 0.0326 
12 21526883 rs12300126 C T -0.0421 0.0203 0.03793 
12 21527044 rs73080823 T C -0.0452 0.0362 0.2124 
12 21527681 rs17680758 G T -0.0319 0.0314 0.309 
12 21527955 rs12308285 T A -0.0352 0.0193 0.06842 
12 21528337 rs12811082 T G -0.0415 0.0217 0.05627 
12 21529150 rs17680787 T G -0.0437 0.0208 0.03531 
12 21529212 rs12305367 C T -0.0507 0.0201 0.01168 
12 21529687 rs34417126 C A -0.046 0.0204 0.02398 
12 21529882 rs34996992 C G -0.0476 0.0203 0.01902 
12 21530485 rs78331403 A G -0.0405 0.0365 0.2661 
12 21531437 rs5484 T C -0.0437 0.0205 0.0333 
12 21532100 rs5486 G A -0.0454 0.0361 0.2087 
12 21532138 rs1056007 T G -0.0471 0.0209 0.02439 
12 21532191 rs5487 C T 0.1076 0.0579 0.06315 
12 21532217 rs5488 A T -0.0515 0.0201 0.01039 
12 21532459 rs3213208 G T -0.0358 0.0383 0.3504 




Figure S3.1. Brain amylin pathology in PSEN1 and APP mutation carriers, 
and in patients with sporadic AD. (a) Example of amylin deposition in the 
pancreatic tissue from a patient with type 2 diabetes (positive control for amylin 
deposition in human tissue). (b) Amylin levels in human brain homogenates from 
PSEN1 mutation carriers (n = 11) and APP mutation carriers (n = 7) vs. CU 
individuals (n = 12). (c) Representative confocal microscopy analysis of brain 
tissue from a patient with fAD (PSEN1 intron 4) double-stained with anti-amylin 
antibody (green) and anti-p-tau antibody (red). (d) Representative confocal 
microscopy analysis of brain tissue from a patient with sporadic AD double-stained 
with anti-amylin antibody (green) and anti-Aβ antibody (red). Nuclei are stained 
blue. Scale bars, 100 μm (a), 10 μm (c, d). Data are means ± SEM; P ≤ 0.05 *; P 
≤ 0.001 ***; two-tailed, unpaired t test with Welch’s correction.  
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Figure S3.2. Brain amylin pathology in the white matter of fAD patients. 
Typical characteristics of amylin-associated pathology in the white matter regions 
of fAD brains, including amylin deposition in old infarct areas (arrows), perivascular 
region (arrowheads) and diffusive plaques (double arrowheads). The 
representative image is from fAD brain with mutation in PSEN1 I202F. 
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Figure S3.3: Motor function deficits in AD and non-AD rats with pancreatic 
expression of human amylin. Measurements of forelimb use (a, e), balance 
ability on the inclined plane (b, f), hind limb clasping (c, g) and Rotarod test (d, h) 
at 8M, 12M and 16M of age in ADHIP, AD, HIP and WT rats. ADHIP rats were 
compared to AD littermates (n = 10 rats/group) (a-d). HIP rats were compared to 
WT littermates (n = 10 rats/group) (e-h). Data are means ± SEM. P ≤ 0.05 *, P ≤ 
0.01 **; two-tailed, unpaired t test (a, b, e, f); Mann-Whitney test (c, g); mixed-
model ANOVA (because of missing values from non-performing animals) with 
Sidak post-hoc (d, h). Non-performing animals on the Rotarod test (see text in 
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Methods) were excluded from the analysis. ADHIP rat: human amylin expressing 
Alzheimer disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human 
amylin expressing rat; WT rat: wild-type rat. 
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Figure S3.4. Effects of increased circulating amylin on cognitive function in 
AD and non-AD rats with pancreatic expression of human amylin. Results of 
novel object recognition test (a, d) and the percentage of time spent in the target 
quadrant in the Morris water maze test on learning trials (b, e) and probe trials (c, 
f) at 8M, 12M and 16M of age in ADHIP, AD, HIP and WT rats. ADHIP rats were 
compared to AD littermates (n = 10 rats/group) (a-c). HIP rats were compared to 
WT littermates (n = 10 rats/group) (d-f). Data are means ± SEM. P ≤ 0.05 *; two-
tailed, unpaired t test (a, c, d, f mixed-model ANOVA (because of missing values 
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from non-performing animals) with Sidak post-hoc (b, e). Non-performing animals 
on the water maze test (see text in Methods) were excluded from the analysis. 
ADHIP rat: human amylin expressing Alzheimer disease model rat; AD rat: 




Figure S3.5. Brain white matter demyelination in ADHIP, AD, HIP, and WT 
rats. Representative images and analysis of brain white matter demyelination with 
luxol fast blue in the same rats as in Figs. 3.5a-d (n = 5 rats/group). Scale bars, 50 
µm. Data are means ± SEM. P ≤ 0.01 **; Mann-Whitney test. ADHIP rat: human 
amylin expressing Alzheimer disease model rat; AD rat: Alzheimer disease model 
rat; HIP rat: human amylin expressing rat; WT rat: wild-type rat. 
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Figure S3.6. Plaques deposition in the brain of AD and non-AD rats with 
pancreatic expression of human amylin; Amylin-Aβ cross-seeding induced 
by intravenous infusion of human amylin in young AD rats. (a) Representative 
immunohistochemical images of amylin (brown)-Aβ (green) plaques in the 
hippocampus of ADHIP, AD, HIP, and WT rat brains (n = 5 rats/group). (b) 
Estimated percentage of area stained positive for amylin in the hippocampal 
plaques of ADHIP, AD, HIP and WT rat, assessed from immunohistological images 
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(n = 5 rats/group). (c) Plasma amylin levels in AD rats intravenously infused with 
human amylin and age matched AD control rats after injections (n = 5 rats/group). 
(d) Neurological scores calculated from behavior tests for cognitive function and 
motor function in AD-amylin injected rats vs. AD-controls (n = 5 rats/group). (e) 
Representative immunohistological images of amylin (brown) and Aβ (green) 
showing amylin-Aβ plaques (arrow) and amylin accumulation in neurons (circles) 
(n = 3 rats/group). Scale bars, 200 µm (a), 50 µm (e). Data are means ± SEM; P ≤ 
0.05 *; two-tailed, unpaired t test. ADHIP rat: human amylin expressing Alzheimer 
disease model rat; AD rat: Alzheimer disease model rat; HIP rat: human amylin 




Figure S3.7. Suppression of amylin gene in AD rats slows cognitive 
dysfunction. (a-c) Novel object recognition (a), forelimb use (b), and hind limb 
clasping (c) of AD rats vs. AD rats with deleted amylin genes (AD-AKO rats) at 8, 
12 and 16 months of age (n = 8-9 rats/group).Data are means ± SEM; P ≤ 0.01 **; 
two-tailed, unpaired t test. AD: Alzheimer disease model rat; AD-AKO: amylin 
knock-out Alzheimer disease model rat. 
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Figure S3.8. Pharmacologically ameliorated amylin dyshomeostasis 
improves neurological function of human amylin-expressing AD rats. (a-m) 
Hind limb clasping test (a, h), inclined plane test (b, i), forelimb use test (c, j), 
rotarod performance (d, k), novel object recognition (e, l) and performance in water 
maze test (f, g, m, n) in sEHi early-stage treated ADHIP rats (T-ES) vs. age-
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matched untreated (UT-ES ) rats (n = 5 rats/group) (a-g); in the sEHi late-stage 
treated ADHIP rats (T-LS) vs. age-matched untreated (UT-LS ) rats (n = 6 
rats/group) (h-n). (o) Amylin WM-to-GM coverage ratio on brain slices from 16M 
T-ES vs. UT-ES rats (n = 5 rats/group) and 18M T-LS vs. UT-LS rats (n = 6 
rats/group). (p) Representative histological images and analysis for white matter 
demyelination in the brains of 16M T-ES vs. UT-ES rats (n = 5 rats/group) and 18M 
T-LS vs. UT-LS rats (n = 3-6 rats/group). Scale bar, 100 µm (p). Data are means 
+ SEM; P < 0.05 *; Mann-Whitney test (a, h, p); two-tailed, unpaired Student’s t 
test (b, c, e, g, I, j, l, n, o); 2-way ANOVA with Sidak post-hoc (d, f, k, m). ADHIP 
rat: human amylin expressing Alzheimer disease model rat. 
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Figure S3.9. Pharmacologically ameliorated amylin dyshomeostasis 
decreases amylin-Aβ cross-seeding in human amylin-expressing AD rats. 
Representative immunohistological images of amylin (brown) and Aβ (green) 
showing amylin-Aβ plaques in the brains of 16M T-ES vs. UT-ES rats (n = 5 
rats/group) and 18M T-LS vs. UT-LS rats (n = 3-6 rats/group). Scale bar, 200 µm. 
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CHAPTER 4. CONCLUDING REMARKS 
4.1. Summary 
Investigations of human brain tissues and rodent models expressing human 
amylin in the pancreas suggest that amylin dyshomeostasis is a contributing 
factor to the pathology and progression of the cerebrovascular disease (CVD) 
and Alzheimer disease (AD). Amylin from the pancreas accumulates in the 
brains of AD patients with or without T2D (2-7, 99, 129). Additionally, amylin 
accumulation is abundant in the cerebral small vessels and co-localizes with 
Aβ in cerebral amyloid of AD patients with or without T2D (2, 5, 129) and of 
patients with familial AD (Chapter 3). Amylin depositions were found in the brain 
parenchyma as independent plaques or as mixed plaques with Aβ in both 
sporadic and familial forms of AD ((5, 6, 129) and Chapter 3). Interestingly, 
intracellular amylin accumulation was detected in neurons (99), pericytes (4), 
astrocytes (129), and microglia (129). And such accumulation is associated 
with changes in cellular metabolism and viability (4, 99), impeding proper 
cellular functioning. The results suggest a role of amylin dyshomeostasis in 
brain microvascular pathologies and AD. 
This chapter is focused on future research directions related to mechanisms 
of amylin-mediated pathological processes in CVD and AD. 
4.2. Gap of knowledge and future directions for laboratory studies 
(Refer to Figure 4.2 for the schematic summary of the cellular and molecular 
mechanisms proposed in this section) 
4.2.a. Studies on the mechanisms of cerebrovascular pathology 
mediated by peripheral amylin 
4.2.a.i Proposed investigations on the mechanisms of 
transporting amylin from the circulation into the brain 
1. Molecular and cellular carriers of amylin in the circulation 
Cerebral or cerebrovascular accumulation of amylin may require carrier(s) 
in the circulation. Carrier(s) could be macro-/micro-molecules or cellular 
components in the circulation. Several lines of evidence mentioned below have 
prompted us to speculate that amylin interaction with other molecules or cellular 
components in the circulation may initiate pathological changes in those 
molecules/components important for physiological functions.  
1.a. Molecular and cellular carriers of amylin in the circulation: plasma 
apolipoproteins 
One of our studies has identified several forms of apolipoprotein 
(apolipoprotein E and apolipoprotein A) that interact with, and potentially carry, 
amylin in the circulation (2). Apolipoprotein (APOE) is a plasma protein 
 102 
produced primarily by the liver and macrophages in the periphery and also by 
the brain (190). APOE serves as a ligand for low-density lipoprotein receptor 
and participates in the transport of cholesterol and other lipids among various 
cells of the body (190). There are three major isoform of human APOE—
APOE2, APOE3, and APOE4 — differ by single amino acid interchanges at two 
residues that affects their binding to apolipoprotein receptors, lipids and Aβ 
(202). The APOE4 gene strongly associates with the pathology and clinical 
outcome of late-onset familial and sporadic AD (203-206). APOE4 is also 
associated with an increased risk of cerebral amyloid angiopathy and age-
related cognitive decline in normal aging (202). APOE4 affects extensive 
pathological processes associated with AD, including impaired neuronal 
structure and function, neuronal mitochondrial dysfunction, increased Aβ 
production, altered Aβ peptide clearance and/or deposition, and impaired 
cognitive function in mice (207).  
Recent studies found APOE in amylin amyloid-containing pancreatic tissue 
from humans (169, 171). The infusion of APOE4, an isoform of APOE, 
exacerbated amylin-mediated capillary injury and brain amylin accumulation in 
human amylin expressing (HIP) rats (2). These results suggest that the 
interaction between amylin and plasma APOE is a potential mechanism 
underlying brain amylin pathology. APOE4 binds to amylin strongly and 
facilitates amylin aggregation in the pancreas of T2D patients (169), thus we 
speculate that the elevated level of plasma APOE4 could trigger toxic amylin 
aggregates formation in the blood, increasing the amount of toxic amylin 
aggregate entering the brain. Intriguingly, a recent study points out that different 
isoform of APOEs bind and inhibit toxic amylin aggregate formation, protecting 
the brain vascular pericyte (208). Among three isoform, APOE4 has the 
weakest protective effect on vascular pericyte because of its lower ability to 
inhibit toxic amylin aggregate formation (208). Because APOE4 is a strong risk 
factor for AD development, the findings that APOE4 affects amylin aggregation 
(169, 208) and amylin-mediated capillary injuries (2, 208) suggest an 
interaction between amylin and the development of AD. Additional studies are 
still needed to test the potential role of APOE alleles in promoting vascular 
amylin deposition, how APOE-amylin complex interacts with receptors, 
particularly low-density lipoprotein receptors (LDL-R) on the vascular 
endothelium, and promotes amylin accumulation and translocation to the brain, 
resulting in vascular injuries. 
1.b. Molecular and cellular carriers of amylin in the circulation: red blood 
cells 
Erythrocytes or red blood cells (RBCs) deliver oxygen to cells and tissues 
in the body and carry carbon dioxide waste to the lungs. In patients with T2D, 
the oxygen-carrying capacity of RBCs declines, exacerbating the risk for 
hypoxia-induced tissue damage and microvascular complications, including 
cerebrovascular disease (209, 210). We found aggregated amylin in RBCs 
from T2D rats and humans with diabetic complications (97). In humans, amylin 
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deposition in RBCs is associated with T2D, heart failure, cancer, and stroke 
(97). The concentration of amylin in RBC lysates from individuals with a primary 
diagnosis of T2D (without heart failure, cancer, or stroke) is higher than those 
from healthy individuals and patients with type 1 diabetes. Patients with a 
primary diagnosis of heart failure, cancer, or stroke also have elevated RBC 
amylin levels independent of T2D (97). These clinical data pose a hypothesis 
that elevation of circulating amylin is linked to cardiovascular and microvascular 
dysfunction. Further experiments in HIP rats suggested that amylin deposition 
in RBCs may cause of RBC shape change, reduced functional hemoglobin, 
increased RBC attachment to the vascular endothelium, and renal 
microvascular ischemic-hypoxic injuries even before the onset of overt 
hyperglycemia (97). The morphological changes in RBC from amylin deposition 
potentially hinder RBC function, thus affecting cellular metabolism in many 
organs; for example, the brain (2, 8, 99) and the kidney (97). The finding that 
RBC as a carrier for circulating amylin is important because it could serve as a 
molecular link between pancreatic dysfunction and diabetic-related 
microvascular complications, and as a biomarker for early detection (before the 
onset of hyperglycemia) of diabetes-related end-organ damage.  
Yet, much work is still needed to elucidate the mechanisms in which amylin 
deposits on the RBC membrane and how it affects hemoglobin binding to 
oxygen, as deformities in RBC decreases oxygen binding with hemoglobin 
(211). The accumulation of amylin on the RBC membrane and amylin-mediated 
RBC membrane disruption are consistent with previous studies on amylin 
harmful effects on the plasma membrane of other cell types including 
pancreatic β-cell (107) and neurons (99, 141). The proposed mechanisms for 
amylin-membrane interaction and membrane disruption are pore formation 
(107-110) and damage from fibril growth (104, 107), which could be challenging 
to study and to develop therapeutic strategies as the amyloid formation on the 
cellular membrane is not fully understood (212). Hence, a more feasible route 
is to test for potential receptors on RBC for amylin ligand binding (Fig. 4.2). 
Indeed, published research shows that human amylin is recognized by receptor 
CD36 on the macrophage surface, then is engulfed by macrophages to trigger 
inflammatory responses (151). Interestingly, CD36 is also present on the RBC 
membrane and is important for RBC adhesion to endothelial cells (213). It will 
be beneficial to test whether this receptor and others on the RBC bind to amylin 
and facilitate downstream signaling responding to the toxic amyloid 
accumulation, including injuries to the RBC-capillary interaction. This could 
lead to hypoxia-induced brain damage, which is currently proposed as one of 
the mechanisms that facilitate AD (214). 
1.c. Molecular and cellular carriers of amylin in the circulation: white blood 
cells 
Along with RBCs, white blood cells may be cellular carriers as amylin is also 
detected in the white blood cells lysate from patients with T2D in our study (97). 
This is a feasible hypothesis because white blood cells protect the body from 
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infectious disease and harmful substances; and toxic amylin aggregate is a 
target for macrophage endocytosis, as previously reported (151). There are 
several primary questions regarding this topic that we need to answer. First, is 
the endocytosis of amylin aggregates by white blood cells important to 
decrease amylin amyloid accumulation in the circulation? If yes, how efficient 
is this process in normal individuals compared to diabetic ones? Second, when 
does the inflammatory response triggered by the endocytosis of amylin become 
harmful to surrounding tissues? Third, do white blood cells inadvertently 
become carriers of engulfed amylin because of their ability to infiltrate to other 
organs during inflammatory responses? Therefore, future investigations on 
cellular carriers of amylin in the circulation are needed to identify therapeutic 
targets to prevent amylin accumulation in extra-pancreatic organs, including 
the brain.  
2. Identify the mechanism of amylin release at the brain 
endothelium  
Since amylin is from the periphery, the translocation of amylin from the 
blood vessels to the parenchyma may require adhesion of cellular/molecular 
carriers and protein transporters. Likely, such translocation is concentration-
dependent, because a high concentration of aggregated amylin induces 
endothelial apoptosis (2). Following the assessment of the cerebrovascular 
injury in the animal model of amylin dyshomeostasis, in vitro studies designed 
to identify specific adhesion mechanisms and protein transporters are 
important steps to decipher how amylin interacts with the blood-brain barrier 
units and its translocation mechanisms.  
In the kidney of HIP rats, vascular amylin accumulation associates with 
vascular damage, inflammatory, and hypoxia response (97). These effects are 
partly mediated by amylin-loaded RBCs (97). Amylin-loaded RBCs from HIP 
rats are more adhesive to the endothelium than RBCs from wild-type rats (97), 
and this effect seems to involve the upregulation of vascular cell adhesion 
molecule 1 on the endothelium. However, the specific mechanism of the 
increased RBC adhesion to the vascular endothelium remains elusive.  
RBC adhesion to the EC layer is regulated by the macromolecules such as 
glycocalyx on the endothelium (215). The endothelial glycocalyx is a thick 
carbohydrate-rich layer lining the luminal side of the vascular endothelium 
(216). It consists of membrane-bound and soluble molecules components. The 
membrane-bound component is mainly composed of proteoglycans and 
glycoproteins binding to the EC surface (216). The soluble molecules are 
plasma- or endothelium-derived soluble molecules, integrating on top of the 
membrane-bound component (216). Research shows that glycocalyx is 
fundamental in microcirculation (215, 216). The depletion of EC glycocalyx is 
important in enhancing blood cells attached to the luminal wall of the 
endothelium (215). Glycocalyx shedding is shown to respond to ischemia-
reperfusion injury, hyperglycemia, and inflammation (215). Interestingly, T2D is 
associated with glycocalyx perturbation and increased vascular permeability 
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(217), and treatment with oral glycocalyx precursor for 2 months partially 
restores glycosaminoglycan synthesis and vascular permeability in T2D 
patients (217). From here, we hypothesize that the aggregation of amylin on 
the membrane RBCs (97) and vascular ECs (2) deplete the glycocalyx layer on 
EC, which enhances RBCs adhesion onto the vascular ECs, therefore 
promoting amylin release into the brain vessels (Fig. 4.2). Restoring EC 
glycocalyx could alleviate amylin-mediated microvascular injury. 
Going from here, the steps are to understand whether the translocated 
amylin in the brain affects (a) the function of the neurovascular components in 
controlling blood-brain barrier function and cerebral perfusion; (b) the dynamic 
of the clearance and accumulation of amyloid proteins in the brain such as Aβ. 
4.2.a.ii  Proposed investigations on the mechanisms of amylin-
mediated blood-brain barrier injuries affecting vascular 
function 
The blood-brain barrier (BBB) is a dynamic multicellular vascular structure 
presented at all blood vessels within the central nervous system (CNS). The 
BBB separates the CNS from the systemic circulation and maintains a 
microenvironment for neurons to function properly by facilitating nutrients and 
oxygen uptake, protecting the brain from toxins and pathogens, extruding 
metabolic products and toxins (218-220). The barrier is formed by capillary 
endothelial cells, ensheathed by the basal lamina, pericytes, astrocytic 
perivascular end-feet, microglia, and a basement membrane made from 
collagen and laminin. The principal component of the barrier function is 
capillary ECs interconnected by tight-junctions (221). Growing evidence 
suggests that astrocyte secretes many factors for BBB formation, maintenance, 
function, and repair; interacts with other ECs for tighter physical barrier (222, 
223). In response to CNS injury, astrocytes undergo a defensive reaction or 
reactive astrogliosis that associates with progressive cellular hypertrophy; in 
the severe case, proliferation and scar formation (222). The deleterious 
consequences are the loss of their physiological supportive functions, BBB 
disturbance, cytokine over-release, and oxidative stress (224). Therefore, both 
endothelium and astrocyte dysfunction can lead to the breakdown of the BBB.  
The BBB disruption may initiate and/or contribute to the progression of white 
matter hyperintensities (WMH) and dementia (161, 225). In the brains of HIP 
rats (rats that express amyloidogenic human amylin in the pancreas), we found 
that amylin deposits in small arteries and capillaries, and such accumulation 
associates with decreased cerebral blood flow and WMH (2). Accumulation of 
amylin in the capillaries causes a decline in levels of endothelial tight-junction 
proteins, endothelium disruption, and astrogliosis (2). In contrast, age- and 
blood glucose-matched diabetic rats, which express non-amyloidogenic rat 
amylin, show no amylin deposition in the brains (99). Our studies show that 
circulating aggregated amylin plays a critical role in lesions, including BBB 
breakdown. From these results, we next postulate that the mechanisms 
underlying deep white matter capillary lesions and impaired cerebral blood flow 
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involve amylin-mediated (a) endothelial dysfunction and (b) astrocyte 
hypertrophy and inflammatory signaling activation, via calcium dysregulation, 
leading to BBB damage and vascular dysfunction. 
1. Endothelial cell injuries and endothelial dysfunction 
Clinical studies suggest that both T2D and AD are associated with brain 
insulin resistance (226). Brain insulin resistance and relevant vascular 
dysfunction in T2D could heighten the risk for AD (227). Vascular dysfunction 
in T2D patients is associated with impaired insulin signaling in ECs (228-230), 
but the direct molecular link between T2D and EC impaired insulin-mediated 
vasoregulation remains elusive. The vascular endothelium plays a critical role 
in regulating BBB permeability, cerebral blood flow, and nutrient delivery to 
surrounding tissues (231). In response to hormones, neurotransmitters and 
stimuli, endothelium ensures even blood flow through acute vasoregulation. 
Acute vasoregulation is achieved through the endothelial production of 
vasodilators such as nitric oxide (NO), and vasoconstrictors such as 
endothelin-1 (ET-1) (232). Insulin can contribute to vasoregulation as it induces 
NO and ET-1 release from ECs through PI3K and MAPK pathways, 
respectively (233). NO and ET-1 released from ECs regulate vascular smooth 
muscle cells activity, thus contributing to cerebral blood flow regulation (230, 
233). In normal individuals, the vasodilation and vasoconstriction effects of 
insulin are in balance. In individuals with insulin resistance, the insulin-
mediated vasodilation becomes defective, characterized by a reduction in 
basal and insulin-stimulated NO production by the endothelial nitric oxide 
synthase (eNOS), leading to augmented vasoconstriction from ET-1 action 
(230, 234, 235). This endothelial dysfunction disables normal vasomotion and 
contributes to stroke progression (236). Up to date, the cause of endothelial 
dysfunction in T2D remains unclear. From our previous study, we found that 
the high level of amylin in the blood (hyperamylinemia) promotes amylin 
deposition in the cerebral blood vessels, leading to EC injuries and is 
associated with decreased cerebral blood flow (2). In the kidney of HIP rats, 
amylin accumulation in the capillaries triggers hypoxia response which can 
affect downstream NO production (97), suggesting that high levels of circulating 
amylin can contribute to change in blood flow. From these results, we postulate 
that aggregated amylin contributes to blood flow alteration in the brain may 
involve changes in insulin-mediated vasoactive mediators’ production. We 
hypothesize that aggregated amylin impairs insulin-mediated NO production in 
cerebrovascular ECs, contributing to EC dysfunction and decrease cerebral 
blood flow regulation.  
The insulin signaling in vascular endothelium regulates eNOS activation by 
PI3K/AKT phosphorylation-dependent mechanism (233). The PI3K pathway is 
important in mediating insulin-stimulated production of NO in the endothelium 
(237) in which the tyrosine phosphorylation of insulin receptor substrate-1 (IRS-
1) is required (238). PI3K activates AKT, and AKT directly phosphorylates 
eNOS at Ser1177(239), resulting in enhanced NO production. In T2D, impaired 
 107 
insulin signaling prevents eNOS phosphorylation and NO release from ECs, 
inducing EC dysfunction. The role of amylin in endothelial insulin-mediated 
vascular tone has not been characterized. The finding that HIP rats developed 
peripheral insulin resistance (8, 95) and had amylin deposition on the brain EC 
(2) lead us to speculate that aggregated amylin may interact with the insulin 
receptor and/or impede the insulin-stimulated NO release machinery. To test 
the above hypothesis, it is important to first understand whether aggregated 
amylin impairs insulin-mediated NO production by inhibiting PI3K/AKT-
dependent eNOS activation. We propose to test the following hypotheses (Fig. 
4.2.a.ii.1): (a) aggregated amylin interacts with insulin receptor on EC, (b) 
aggregated amylin inhibits phosphorylation of IRS-1, AKT and eNOS and (c) 
inhibits the production of NO preventing EC dilation.  
Second, we will need to characterize aggregated amylin role in calcium-
dependent eNOS activation, specifically test if aggregated amylin inhibits 
eNOS activation by inhibiting CaMKII-dependent eNOS activation and 
promoting PKCβ activity (Fig. 4.2.a.ii.1). eNOS activation requires 
simultaneous phosphorylation by Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) (240) and dephosphorylation modulated by protein kinase C β 
(PKCβ) activity (241, 242). CaMKII, a multifunctional serine/threonine-protein 
kinase, is critical in transducing of increased intracellular Ca2+ by binding to 
Ca2+/calmodulin (CaM) complex (243). CaMKII is expressed in vascular EC 
(244) and participates in Ca2+-dependent eNOS activation (240). PKCβ is a 
calcium-dependent kinase responsible for eNOS negative regulation. T2D 
patients exhibit higher PKCβ expression associated with lower blood flow-
mediated dilation (241). From previous studies discussed in Chapter 1, we 
know that aggregated amylin is cytotoxic because it disrupts the cellular 
membrane and causes calcium dyshomeostasis (122, 245-247). Thus, we 
speculate that amylin-attenuated eNOS phosphorylation and 
dephosphorylation are achieved through Ca2+ dysregulation. To solve the 
question of aggregated amylin involvement in both regulation stages of eNOS 
signaling, we propose to test the following hypotheses: (a) amylin-induced Ca2+ 
dysregulation inactivates CaMKII-mediated eNOS phosphorylation, (b) amylin 
enhances PKCβ activity, thus preventing eNOS dephosphorylation, (c) 
prevention of amylin deposition on cellular membrane could restore eNOS 
function. 
The results will provide insight into vascular complications from T2D. If our 
hypothesis is true, then hyperamylinemia could promote endothelial cells 
dysfunction, specifically through impairing insulin-stimulated NO production. 
NO has important functions in oxidative stress and inflammation (248, 249), 
thus amylin-impaired NO production may contribute to vascular oxidative stress 
and inflammation. Extending from this, we can pursue to understand 
hyperamylinemia effect on vascular smooth muscle cells, which directly 
participate in vessel dilation/contraction. Because NO induces vascular smooth 
muscle relaxation by decreasing intracellular calcium (250), we speculate that 
defective NO production from ECs resulting from hyperamylinemia impairs 
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vascular smooth muscle cell relaxation.    
2. Astrocyte activation and reactive astrogliosis 
 Amylin deposition was found to localize with or nearby astrocytes in the 
brain of AD patients (2, 129). Brains of patients with AD and T2D and HIP rats 
show signs of astrocyte activation (2). Aggregated amylin causes a rapid 
increase of calcium by disrupting ionic channels activity (251) and deranging 
plasma and intracellular membrane (252) in the neuron. In glial cells, an 
increased level of intracellular calcium can activate calcineurin, which 
dephosphorylates the nuclear factor of activated T-cells (NFAT) (253). 
Activated NFAT translocates into nuclear and facilitates the expression of 
genes regulated astrocyte hypertrophy and inflammatory cytokines during 
central nervous system injury (253). Interestingly, our previous works found that 
hyperamylinemia is associated with intraneuronal amylin deposition and 
increases inflammatory cytokine interleukin 1 (IL-1β) synthesis (99, 254), which 
can lead to BBB dysfunction and increased permeability (2, 221, 255). Taken 
together, we hypothesize that aggregated amylin activates astrocyte 
hypertrophy and inflammatory signaling through calcium dysregulation. We 
anticipate that human amylin-induced rise in astrocyte intracellular calcium 
activates NFAT, marked by NFAT translocation to the nuclear and elevated IL-
1β expression. We postulate that the leaky endothelium resulted from the 
accumulation of amylin, allows amylin entry to neighbor astrocytes, therefore 
inducing calcium dyshomeostasis and triggering inflammation.  
4.2.b. Studies on the mechanisms of amylin-induced changes in 
metabolism and interaction with molecules involved in 
neurodegeneration.  
4.2.b.i Amylin alters the function of the neural cells in the 
neurovascular unit 
The neurovascular unit is a multicellular structure composed of the 
endothelium and its BBB, extracellular matrix, pericytes, and neural cells 
(neurons, astrocytes, neurons, and microglia) (161). This unit regulates BBB 
permeability, cerebral blood flow, neuronal and synaptic functions through 
changes in the blood flow (161). Reports from our lab (2, 99, 158) and others 
(3, 4) indicate the toxic effects of aggregated amylin on endothelium layer (2), 
neurons (99, 158), astrocytes (2), and pericytes (3, 4). Yet, the specific 
pathological functions of aggregated amylin in each component of the 
neurovascular unit and how those pathological functions interact with each 
other have not been fully investigated. The following are proposed research 
directions to decipher the role of aggregated human amylin in pathological 
production of APOE4 from astrocytes and neurons, and in neurotransmitter 
metabolism.  
1. Amylin alters the function of the neural cells in the neurovascular 
unit: APOE4 production from astrocytes and neurons 
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Besides the liver, the brain is the second major source of APOE (190). 
Astrocyte is the major cell type that secretes and lipidates APOE in the brain to 
support lipid transport and membrane repair process (190, 256, 257). Microglia 
and neurons also produce APOE in response to stressful conditions or injuries, 
probably as part of cellular repair and remodeling (207). Emerging evidence 
indicates that poorly lipidated APOE4 secreted by astrocytes during aging, a 
preferable pathway compared to APOE3 secretion in healthy stage, disrupts 
neuronal lipid homeostasis and neuronal membrane repair (258). Moreover, 
neuronal-derived APOE4 promotes excitotoxicity (259). It is established that 
human amylin causes neuronal insults through several mechanisms: 
mitochondrial dysfunction, calcium dysregulation, and oxidative stress (99, 
138, 145-149) (as discussed in Chapter 1). Our studies also show that human 
amylin is associated with astrogliosis (2), increased accumulation of 
parenchymal mixed plaques and vascular amyloid (Chapter 3). A recent study 
shows that human amylin destabilizes the cell membrane of astrocyte and 
causes mitochondrial stress and increases production of reactive oxygen 
species (149). Therefore, we hypothesize that human amylin promotes APOE4 
production from astrocytes and neurons in response to amylin-mediated 
cellular injuries, leading to the degradation of the neurovascular unit. We 
anticipate that the amylin-skewed APOE4 secretion disturbs neuronal 
homeostasis and accelerates the neurodegenerative process. Moreover, we 
speculate that elevated APOE4 levels in response to insults caused by amylin 
can increase the formation of APOE4-Aβ and/or APOE4-amylin complex, 
preventing proper clearance of amyloid out of the brain (Fig. 4.2).  
2. Amylin alters the function of the neural cells in the neurovascular 
unit: changes in neurotransmitter production 
Patients with mild cognitive impairment and AD have alteration in tyrosine 
and phenylalanine levels that affects cellular metabolism (260). We have 
previously identified metabolic changes that are uniquely related to the amylin-
driven pathology, not hyperglycemia, in the brain chemistry of HIP rats (158). 
HIP rat brains showed a deficiency in phenylalanine and tyrosine, which are 
precursors for catecholamine neurotransmitters (dopamine, norepinephrine, 
epinephrine). These changes possibly are due to altered glucose metabolism 
in neurons (158), which are commonly seen in neurodegenerative diseases 
(159). Both the reduction in the levels of neurotransmitter precursors and 
alteration in pentose phosphate pathway correlate with the neurological 
dysfunction in HIP rats ((2, 8) and Chapters 2 and 3). Since maintaining proper 
neurotransmitter levels are essential for synaptic transmission and neuronal 
health, we postulate that amylin-induced changes in tyrosine and 
phenylalanine levels lead to defective synaptic transmission and synaptic 
dysfunction, contributing to neurodegeneration (Fig. 4.2).  
4.2.b.ii Amylin promotes Aβ production through intraneuronal 
calcium dysfunction  
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While the pathological function of aggregated amylin on endothelial cells 
and pericytes have been investigated previously, much less is known about the 
effects of aggregated amylin on neuronal and glial metabolism and function. In 
vivo data in Chapter 3 suggest that amylin accumulation in the brain is 
associated with increased Aβ accumulation. Works from other lab show that 
amylin injection elevates Aβ production and Aβ-related pathology in AD mice 
brains, through the increased expression of γ-secretase in lipid raft (142). Since 
Aβ is produced by neurons and astrocytes, and its degradation is regulated by 
other glial cells (261), amylin accumulation in the neurons (99) and possibly, 
astrocytes/microglia, potentially influences Aβ production and degradation by 
mechanisms involved amyloid-beta precursor protein (APP) metabolism, APP 
internalization; and increased endosomal/lysosomal processing of toxic Aβ 
species (262). Plausible mechanisms that mediate these processes comprise 
of neuronal calcium regulation, as cellular calcium homeostasis is notoriously 
affected by human amylin due to the disruption of the cellular membrane (as 
discussed in Chapter 1).  
Although compelling more studies, neuronal calcium dyshomeostasis has 
been proposed to be a proximal cause of neurodegeneration in AD (263). It is 
due to changes in calcium signaling at the initial stage of the disease and the 
augmentation of Aβ formation, as well as Tau hyperphosphorylation during 
calcium dyshomeostasis (263). Amylin forms pore on the plasma membrane 
which allows extracellular Ca2+ influx (107-110, 146, 147), and can penetrate 
and cause leakage of stored intracellular Ca2+ (146). There is limited 
information about how amylin causes dysregulation in stored intracellular Ca2+ 
in neurons; however, extensive research efforts have demonstrated that amylin 
perturbs cardiomyocyte endoplasmic/sarcoplasmic reticulum (the main 
intracellular calcium storage) membrane permeation and induces Ca2+ leak 
(124, 125). Hence, amylin possibly exerts the same effects on the endoplasmic 
reticulum (ER) of other cell types, including neurons.  In neurons, a large 
fraction of Aβ42 is generated in the ER (264). ER is one of the compartments 
where presenilin (PS) 1 and PS2 reside (265). Presenilins are components of 
the γ-secretase complex that processes APP (265). It is undeniable that 
presenilins have important roles in regulating ER calcium signaling, and all 
clinical mutations of PS1 and PS2 have been shown to increase calcium load 
and disrupt calcium signaling (263). Interestingly, modulation of intracellular 
calcium both from the extracellular source and from the ER change Aβ 
production (263). Therefore, amylin-induced changes in intracellular calcium by 
causing a leak in the ER membrane may have potential effects in altering 
presenilin function and Aβ production (Fig. 4.2).  
4.2.b.iii Identify the mechanisms of amylin impairs clearance of 
amyloid (amylin and Aβ) in the vasculature  
Next, we propose that understanding how amylin inhibits amyloid clearance 
through the brain blood vessels could be beneficial for therapeutic 
development. One school of thought posits that in the late-onset AD, the 
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accumulation of Aβ may not be caused by the increased production, but by the 
inefficient clearance from the brain (266). Data from Chapter 3 (Fig. 3.1) 
suggest the brain blood vessels of humans with familial AD contain amylin 
accumulation, surrounding by Aβ deposits in the abluminal side of the blood 
vessels or in the perivascular space. Similar pathology was also observed in 
the brains of patients with sporadic AD (5). The luminal amylin deposits were 
confirmed to be amyloid-rich in both familial and sporadic forms of AD (Chapter 
3, (5)). These data indicate that the peripheral amylin accumulated in the 
cerebral blood vessels may cause blockage of the Aβ drainage system. This 
may be due to (a) amylin pathological functions in causing BBB injuries (results 
from (2) and Chapter 3), which can deplete the receptors participated in 
amyloid clearance process at the BBB; (b) amyloid formation by amylin 
impedes Aβ translocation from the brain to the vascular lumen.  
Another more complicated process of how parenchymal amylin-impaired Aβ 
clearance may involve receptors at the BBB. The clearance of Aβ is a complex 
process that engaged Aβ binding to transport proteins (e.g., APOE and APOJ) 
and receptors on the endothelial cells of the BBB and ependymal cells of the 
choroid plexus (e.g., low-density lipoprotein receptor (LDLR), low-density 
lipoprotein receptor-related protein (LRP)) (266). APOE4 is known to affect Aβ 
peptide clearance from the brain (207), specifically, APOE4 binding to Aβ 
redirects Aβ clearance from LRP1 to VLDLR (very-low-density lipoprotein 
receptor) at the BBB (267). The VLDLR internalizes Aβ-APOE4 complexes 
more slowly than LRP1, making this a less efficient route (267). Interestingly, 
studies from our lab (2) and other (208) demonstrate the ability of amylin to 
bind to apolipoproteins including APOE4, which may decrease the efficiency of 
its clearance from the brain and affect amyloid clearance. We hypothesize that 
the accumulation of amylin in the brain (in both familial and sporadic AD 
patients) can interfere with Aβ clearance at the BBB through two possible 
mechanisms: 1) amylin competes with Aβ to bind directly to LRPs, and 2) 
amylin competes with Aβ to bind to APOEs that participate in faster clearance 
route through certain APOE receptors (Fig. 4.2). And this can slow the 
clearance efficiency of amyloid from the brain, leading to the formation of 
vascular amyloid and vascular damage.  
4.3. Conclusions 
Published studies have opened a new research paradigm on amylin as a 
molecular link between the periphery, particularly pancreatic dysfunction, and 
dementia. Our data show evidence for the role of pancreatic amylin in AD and 
cerebral microvascular pathology and suggest that drugs reducing amylin 
accumulation in brain capillaries or preventing amylin from interacting with Aβ-
associated pathology could provide benefit in patients with AD. Therefore, 
targeting amylin dyshomeostasis may be an effective strategy to prevent or 
slow the advancement of Alzheimer and cerebrovascular disease. This is of 
clinical interest for several reasons. First, the administration of treatment in the 
circulation is much less complicated and is easier to control than delivering 
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treatment into the brain. Second, therapeutic interventions aiming to protect 
specific biological components affected by amylin, and intervention during the 
prediabetic stage may be more effective at preventing cellular injuries. 
Future research should take into consideration that the pathophysiology of 
amylin dyshomeostasis involves complex interactions of multiple deficiencies. 
Therefore, the multi-facets of the subject require research models that can 
represent the complexity of the disease to understand the underlying 





Figure 4.2. Proposed mechanisms for future laboratory studies. BBB: blood-
brain barrier; APOE: apolipoprotein; APP: amyloid precursor protein; LRP: low-
density lipoprotein receptor-related protein; LDL-R: low-density lipoprotein 




Figure 4.2.a.ii.1. Schematic view of proposed mechanism on aggregated 
amylin inhibits insulin-mediated NO release from endothelium. IRS-1/2: 
insulin receptor substrate 1/2; PI3K: phosphoinositide 3-kinase; Akt: protein 
kinase B; eNOS: endothelial nitric oxide synthase; PKCβ: protein kinase C beta 
type; CaMKII: Ca2+/calmodulin-dependent protein kinase II.  
 116 
References 
1. A. s. Association, 2019 Alzhiemer's disease facts and figures. Alzheimers 
Dement 15, 321-387 (2019). 
2. H. Ly et al., Brain microvascular injury and white matter disease provoked by 
diabetes-associated hyperamylinemia. Ann Neurol 82, 208-222 (2017). 
3. N. Schultz, E. Byman, T. Bank, M. Wennström, Levels of retinal IAPP are 
altered in Alzheimer's disease patients and correlate with vascular changes 
and hippocampal IAPP levels. Neurobiology of Aging 69, 94-101 (2018). 
4. N. Schultz, E. Byman, M. Fex, M. Wennström, Amylin alters human brain 
pericyte viability and NG2 expression. Journal of Cerebral Blood Flow & 
Metabolism 37, 1470-1482 (2016). 
5. K. Jackson et al., Amylin deposition in the brain: A second amyloid in 
Alzheimer disease? Annals of Neurology 74, 517-526 (2013). 
6. M. E. Oskarsson et al., In Vivo Seeding and Cross-Seeding of Localized 
Amyloidosis A Molecular Link between Type 2 Diabetes and Alzheimer 
Disease. The American Journal of Pathology 185, 834-846 (2015). 
7. J. N. Fawver et al., Islet amyloid polypeptide (IAPP): a second amyloid in 
Alzheimer's disease. Curr Alzheimer Res 11, 928-940 (2014). 
8. S. Srodulski et al., Neuroinflammation and neurologic deficits in diabetes 
linked to brain accumulation of amylin. Molecular Neurodegeneration 9, 30 
(2014). 
9. K. Maurer, S. Volk, H. Gerbaldo, Auguste D and Alzheimer's disease. Lancet 
349, 1546-1549 (1997). 
10. A. Alzheimer, Uber eine eigenartige Erkrankung der Hirnrinde. Zentralbl. 
Nervenh. Psych. 18, 177-179 (1907). 
11. A. Alzheimer, Über eigenartige Krankheitsfälle des späteren Alters. Zeitschrift 
für die gesamte Neurologie und Psychiatrie 4, 356-385 (1911). 
12. H. H. Klunemann et al., Alzheimer's second patient: Johann F. and his family. 
Ann Neurol 52, 520-523 (2002). 
13. C. A. Lane, J. Hardy, J. M. Schott, Alzheimer's disease. Eur J Neurol 25, 59-
70 (2018). 
14. D. J. Selkoe, J. Hardy, The amyloid hypothesis of Alzheimer's disease at 25 
years. EMBO Mol Med 8, 595-608 (2016). 
15. P. A. Boyle et al., Person-specific contribution of neuropathologies to 
cognitive loss in old age. Ann Neurol 83, 74-83 (2018). 
16. J. A. Schneider, Z. Arvanitakis, S. E. Leurgans, D. A. Bennett, The 
neuropathology of probable Alzheimer disease and mild cognitive 
impairment. Annals of neurology 66, 200-208 (2009). 
17. B. D. James et al., TDP-43 stage, mixed pathologies, and clinical Alzheimer's-
type dementia. Brain 139, 2983-2993 (2016). 
18. C. Iadecola, The pathobiology of vascular dementia. Neuron 80, 844-866 
(2013). 
19. P. B. Gorelick et al., Vascular contributions to cognitive impairment and 
dementia: a statement for healthcare professionals from the american heart 
association/american stroke association. Stroke 42, 2672-2713 (2011). 
 117 
20. R. N. Kalaria, Vascular basis for brain degeneration: faltering controls and 
risk factors for dementia. Nutr Rev 68 Suppl 2, S74-87 (2010). 
21. S. Debette et al., Midlife vascular risk factor exposure accelerates structural 
brain aging and cognitive decline. Neurology 77, 461-468 (2011). 
22. J. A. Schneider, Z. Arvanitakis, W. Bang, D. A. Bennett, Mixed brain 
pathologies account for most dementia cases in community-dwelling older 
persons. Neurology 69, 2197-2204 (2007). 
23. J. B. Toledo et al., Contribution of cerebrovascular disease in autopsy 
confirmed neurodegenerative disease cases in the National Alzheimer's 
Coordinating Centre. Brain 136, 2697-2706 (2013). 
24. F. A. Provenzano et al., White matter hyperintensities and cerebral 
amyloidosis: necessary and sufficient for clinical expression of Alzheimer 
disease? JAMA Neurol 70, 455-461 (2013). 
25. G. Biessels, S. Staekenborg, E. Brunner, C. Brayne, P. Scheltens, Risk of 
dementia in diabetes mellitus: a systematic review. The Lancet Neurology 5, 
64-74 (2006). 
26. A. Ott et al., Diabetes mellitus and the risk of dementia: The Rotterdam Study. 
Neurology 53, 1937-1942 (1999). 
27. R. Peila, B. L. Rodriguez, L. J. Launer, S. Honolulu-Asia Aging, Type 2 
diabetes, APOE gene, and the risk for dementia and related pathologies: The 
Honolulu-Asia Aging Study. Diabetes 51, 1256-1262 (2002). 
28. J. A. Luchsinger, M. X. Tang, Y. Stern, S. Shea, R. Mayeux, Diabetes mellitus 
and risk of Alzheimer's disease and dementia with stroke in a multiethnic 
cohort. American journal of epidemiology 154, 635-641 (2001). 
29. E. L. Abner et al., Diabetes is associated with cerebrovascular but not 
Alzheimer's disease neuropathology. Alzheimers Dement 12, 882-889 
(2016). 
30. A. M. Rawlings et al., Diabetes in midlife and cognitive change over 20 years: 
a cohort study. Ann Intern Med 161, 785-793 (2014). 
31. O. I. Okereke et al., Type 2 diabetes mellitus and cognitive decline in two 
large cohorts of community-dwelling older adults. J Am Geriatr Soc 56, 1028-
1036 (2008). 
32. S. L. C. Geijselaers, S. J. S. Sep, C. D. A. Stehouwer, G. J. Biessels, Glucose 
regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. 
Lancet Diabetes Endocrinol 3, 75-89 (2015). 
33. P. K. Crane et al., Glucose levels and risk of dementia. N Engl J Med 369, 
540-548 (2013). 
34. T. Cukierman-Yaffe et al., Relationship between baseline glycemic control 
and cognitive function in individuals with type 2 diabetes and other 
cardiovascular risk factors: the action to control cardiovascular risk in 
diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32, 221-
226 (2009). 
35. L. J. Launer et al., Effects of intensive glucose lowering on brain structure and 
function in people with type 2 diabetes (ACCORD MIND): a randomised 
open-label substudy. The Lancet. Neurology 10, 969-977 (2011). 
 118 
36. I. Feinkohl, J. F. Price, M. W. Strachan, B. M. Frier, The impact of diabetes 
on cognitive decline: potential vascular, metabolic, and psychosocial risk 
factors. Alzheimers Res Ther 7, 46 (2015). 
37. P. Westermark, A. Andersson, G. T. Westermark, Islet amyloid polypeptide, 
islet amyloid, and diabetes mellitus. Physiological reviews 91, 795-826 
(2011). 
38. A. Clark et al., Islet amyloid formed from diabetes-associated peptide may be 
pathogenic in type 2 diabetes. Lancet (London, England) 2, 231-234 (1987). 
39. C. Röcken, R. P. Linke, W. Saeger, Immunohistology of islet amyloid 
polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem 
series. Virchows Archiv. A, Pathological anatomy and histopathology 421, 
339-344 (1992). 
40. E. L. Opie, The Relation Oe Diabetes Mellitus to Lesions of the Pancreas. 
Hyaline Degeneration of the Islands Oe Langerhans. J Exp Med 5, 527-540 
(1901). 
41. A. Weichselbaum, E. Stangl, Zur Kenntnis der feineren Veränderungen des 
Pankreas bei Diabetes mellitus. Wiener Klinische Wochenschrift 14, 968-972 
(1901). 
42. N. Gellerstedt, Die elektive, insuläre (Para-) Amyloidose der 
Bauchspeicheldrüse. Zugleich en Beitrag zur Kenntnis der “senilen 
Amyloidose.” Beitr Path Anat 101, 1-13 (1938). 
43. J. H. Ahronheim, The Nature of the Hyaline Material in the Pancreatic Islands 
in Diabetes Mellitus. Am J Pathol 19, 873-882 (1943). 
44. J. C. Ehrlich, I. M. Ratner, Amyloidosis of the islets of Langerhans. A restudy 
of islet hyalin in diabetic and non-diabetic individuals. The American journal 
of pathology 38, 49-59 (1961). 
45. P. Westermark, Amyloid of human islets of Langerhans. II. Electron 
microscopic analysis of isolated amyloid. Virchows Arch A Pathol Anat Histol 
373, 161-166 (1977). 
46. P. Westermark, AMYLOID OF HUMAN ISLETS OF LANGERHANS. Acta 
Pathologica Microbiologica Scandinavica Section C Immunology 83C, 439-
446 (1975). 
47. C. L. Masters et al., Amyloid plaque core protein in Alzheimer disease and 
Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249 (1985). 
48. P. Westermark, C. Wernstedt, E. Wilander, K. Sletten, A novel peptide in the 
calcitonin gene related peptide family as an amyloid fibril protein in the 
endocrine pancreas. Biochemical and Biophysical Research 
Communications 140, 827-831 (1986). 
49. G. J. Cooper et al., Purification and characterization of a peptide from 
amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S 
A 84, 8628-8632 (1987). 
50. P. Westermark et al., Amyloid fibrils in human insulinoma and islets of 
Langerhans of the diabetic cat are derived from a neuropeptide-like protein 
also present in normal islet cells. Proc Natl Acad Sci U S A 84, 3881-3885 
(1987). 
 119 
51. G. J. Cooper et al., Amylin found in amyloid deposits in human type 2 diabetes 
mellitus may be a hormone that regulates glycogen metabolism in skeletal 
muscle. Proc Natl Acad Sci U S A 85, 7763-7766 (1988). 
52. A. Lukinius, E. Wilander, G. T. Westermark, U. Engstrom, P. Westermark, 
Co-localization of islet amyloid polypeptide and insulin in the B cell secretory 
granules of the human pancreatic islets. Diabetologia 32, 240-244 (1989). 
53. S. E. Kahn et al., Evidence of cosecretion of islet amyloid polypeptide and 
insulin by beta-cells. Diabetes 39, 634-638 (1990). 
54. S. Ramirez et al., Mitochondrial Dynamics Mediated by Mitofusin 1 Is 
Required for POMC Neuron Glucose-Sensing and Insulin Release Control. 
Cell Metab 25, 1390-1399 e1396 (2017). 
55. T. A. Lutz, Control of energy homeostasis by amylin. Cell Mol Life Sci 69, 
1947-1965 (2012). 
56. R. Akter et al., Islet Amyloid Polypeptide: Structure, Function, and 
Pathophysiology. J Diabetes Res 2016, 2798269 (2016). 
57. A. Abedini et al., Time-resolved studies define the nature of toxic IAPP 
intermediates, providing insight for anti-amyloidosis therapeutics. Elife 5,  
(2016). 
58. M. Miyazato et al., Identification and characterization of islet amyloid 
polypeptide in mammalian gastrointestinal tract. Biochem Biophys Res 
Commun 181, 293-300 (1991). 
59. P. J. Wookey et al., Amylin as a growth factor during fetal and postnatal 
development of the rat kidney. Kidney Int 53, 25-30 (1998). 
60. H. Mulder et al., Islet amyloid polypeptide (amylin) is expressed in sensory 
neurons. J Neurosci 15, 7625-7632 (1995). 
61. S. Gebre-Medhin, H. Mulder, Y. Zhang, F. Sundler, C. Betsholtz, Reduced 
nociceptive behavior in islet amyloid polypeptide (amylin) knockout mice. 
Brain Res Mol Brain Res 63, 180-183 (1998). 
62. X. Wu et al., IAPP modulates cellular autophagy, apoptosis, and extracellular 
matrix metabolism in human intervertebral disc cells. Cell Death Discov 3, 
16107 (2017). 
63. A. N. Bubak et al., Varicella Zoster Virus Infection of Primary Human Spinal 
Astrocytes Produces Intracellular Amylin, Amyloid-beta, and an 
Amyloidogenic Extracellular Environment. J Infect Dis,  (2019). 
64. W. A. Banks, A. J. Kastin, Differential permeability of the blood-brain barrier 
to two pancreatic peptides: insulin and amylin. Peptides 19, 883-889 (1998). 
65. W. A. Banks, A. J. Kastin, L. M. Maness, W. Huang, J. B. Jaspan, 
Permeability of the blood-brain barrier to amylin. Life Sciences 57, 1993-2001 
(1995). 
66. K. H. Johnson, T. D. O'Brien, K. Jordan, C. Betsholtz, P. Westermark, The 
putative hormone islet amyloid polypeptide (IAPP) induces impaired glucose 
tolerance in cats. Biochem Biophys Res Commun 167, 507-513 (1990). 
67. A. Ar'Rajab, B. Ahren, Effects of amidated rat islet amyloid polypeptide on 
glucose-stimulated insulin secretion in vivo and in vitro in rats. Eur J 
Pharmacol 192, 443-445 (1991). 
 120 
68. B. Ludvik et al., Increased levels of circulating islet amyloid polypeptide in 
patients with chronic renal failure have no effect on insulin secretion. J Clin 
Invest 94, 2045-2050 (1994). 
69. D. Bretherton-Watt et al., Very high concentrations of islet amyloid 
polypeptide are necessary to alter the insulin response to intravenous 
glucose in man. J Clin Endocrinol Metab 74, 1032-1035 (1992). 
70. B. Leighton, C. DaCosta, E. Foot, Effect of synthetic human amylin on 
glycogen synthesis in skeletal muscle in vivo. Biochem Soc Trans 18, 980 
(1990). 
71. A. Young, Inhibition of glucagon secretion. Adv Pharmacol 52, 151-171 
(2005). 
72. T. A. Lutz, Amylinergic control of food intake. Physiol Behav 89, 465-471 
(2006). 
73. P. M. Sexton, G. Paxinos, M. A. Kenney, P. J. Wookey, K. Beaumont, In vitro 
autoradiographic localization of amylin binding sites in rat brain. 
Neuroscience 62, 553-567 (1994). 
74. G. Paxinos et al., In vitro autoradiographic localization of calcitonin and 
amylin binding sites in monkey brain. J Chem Neuroanat 27, 217-236 (2004). 
75. T. A. Lutz, E. Del Prete, E. Scharrer, Reduction of food intake in rats by 
intraperitoneal injection of low doses of amylin. Physiol Behav 55, 891-895 
(1994). 
76. U. Arnelo et al., Chronic infusion of islet amyloid polypeptide causes anorexia 
in rats. Am J Physiol 271, R1654-1659 (1996). 
77. T. A. Lutz et al., Lesion of the area postrema/nucleus of the solitary tract 
(AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-
related peptide (CGRP) in rats. Peptides 19, 309-317 (1998). 
78. A. Mollet, S. Gilg, T. Riediger, T. A. Lutz, Infusion of the amylin antagonist AC 
187 into the area postrema increases food intake in rats. Physiol Behav 81, 
149-155 (2004). 
79. C. Mack et al., Pharmacological actions of the peptide hormone amylin in the 
long-term regulation of food intake, food preference, and body weight. Am J 
Physiol Regul Integr Comp Physiol 293, R1855-1863 (2007). 
80. J. D. Roth, H. Hughes, E. Kendall, A. D. Baron, C. M. Anderson, Antiobesity 
effects of the beta-cell hormone amylin in diet-induced obese rats: effects on 
food intake, body weight, composition, energy expenditure, and gene 
expression. Endocrinology 147, 5855-5864 (2006). 
81. T. Nie et al., Altered metabolic gene expression in the brain of a triprolyl-
human amylin transgenic mouse model of type 2 diabetes. Sci Rep 9, 14588 
(2019). 
82. G. Clementi et al., Amylin given by central or peripheral routes decreases 
gastric emptying and intestinal transit in the rat. Experientia 52, 677-679 
(1996). 
83. A. A. Young, B. R. Gedulin, T. J. Rink, Dose-responses for the slowing of 
gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, 
amylin, cholecystokinin, and other possible regulators of nutrient uptake. 
Metabolism 45, 1-3 (1996). 
 121 
84. J. Wickbom, M. K. Herrington, J. Permert, A. Jansson, U. Arnelo, Gastric 
emptying in response to IAPP and CCK in rats with subdiaphragmatic afferent 
vagotomy. Regul Pept 148, 21-25 (2008). 
85. E. T. Bell, Hyalinization of the islet of Langerhans in diabetes mellitus. 
Diabetes 1, 341-344 (1952). 
86. P. Westermark, Quantitative studies on amyloid in the islets of Langerhans. 
Ups J Med Sci 77, 91-94 (1972). 
87. E. T. Bell, Hyalinization of the islets of Langerhans in nondiabetic individuals. 
Am J Pathol 35, 801-805 (1959). 
88. T. A. Lutz, U. Meyer, Amylin at the interface between metabolic and 
neurodegenerative disorders. Front Neurosci 9, 216 (2015). 
89. Z. Ma et al., Enhanced in vitro production of amyloid-like fibrils from mutant 
(S20G) islet amyloid polypeptide. Amyloid 8, 242-249 (2001). 
90. S. Seino, M. Study Group of Comprehensive Analysis of Genetic Factors in 
Diabetes, S20G mutation of the amylin gene is associated with Type II 
diabetes in Japanese. Study Group of Comprehensive Analysis of Genetic 
Factors in Diabetes Mellitus. Diabetologia 44, 906-909 (2001). 
91. A. Lorenzo, B. Razzaboni, G. C. Weir, B. A. Yankner, Pancreatic islet cell 
toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756-
760 (1994). 
92. S. Zhang, J. Liu, M. Dragunow, G. J. Cooper, Fibrillogenic amylin evokes islet 
beta-cell apoptosis through linked activation of a caspase cascade and JNK1. 
The Journal of biological chemistry 278, 52810-52819 (2003). 
93. C. A. Jurgens et al., beta-cell loss and beta-cell apoptosis in human type 2 
diabetes are related to islet amyloid deposition. Am J Pathol 178, 2632-2640 
(2011). 
94. A. E. Butler et al., Beta-cell deficit and increased beta-cell apoptosis in 
humans with type 2 diabetes. Diabetes 52, 102-110 (2003). 
95. A. V. Matveyenko, P. C. Butler, Islet amyloid polypeptide (IAPP) transgenic 
rodents as models for type 2 diabetes. ILAR journal 47, 225-233 (2006). 
96. W. Gong et al., Amylin deposition in the kidney of patients with diabetic 
nephropathy. Kidney international 72, 213-218 (2007). 
97. N. Verma et al., Diabetic microcirculatory disturbances and pathologic 
erythropoiesis are provoked by deposition of amyloid-forming amylin in red 
blood cells and capillaries. Kidney International,  (2019). 
98. S. Despa et al., Hyperamylinemia contributes to cardiac dysfunction in 
obesity and diabetes: a study in humans and rats. Circulation research 110, 
598-608 (2012). 
99. N. Verma et al., Intraneuronal Amylin Deposition, Peroxidative Membrane 
Injury and Increased IL-1beta Synthesis in Brains of Alzheimer's Disease 
Patients with Type-2 Diabetes and in Diabetic HIP Rats. J Alzheimers Dis 53, 
259-272 (2016). 
100. P. Westermark, U. Engstrom, K. H. Johnson, G. T. Westermark, C. Betsholtz, 
Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid 
fibril formation. Proc Natl Acad Sci U S A 87, 5036-5040 (1990). 
 122 
101. E. T. Jaikaran, A. Clark, Islet amyloid and type 2 diabetes: from molecular 
misfolding to islet pathophysiology. Biochim Biophys Acta 1537, 179-203 
(2001). 
102. S. Janciauskiene, B. Ahren, Different sensitivity to the cytotoxic action of 
IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. 
Biochem Biophys Res Commun 251, 888-893 (1998). 
103. B. Konarkowska, J. F. Aitken, J. Kistler, S. Zhang, G. J. Cooper, The 
aggregation potential of human amylin determines its cytotoxicity towards 
islet beta-cells. FEBS J 273, 3614-3624 (2006). 
104. J. Janson, R. H. Ashley, D. Harrison, S. McIntyre, P. C. Butler, The 
mechanism of islet amyloid polypeptide toxicity is membrane disruption by 
intermediate-sized toxic amyloid particles. Diabetes 48, 491-498 (1999). 
105. L. E. Buchanan et al., Mechanism of IAPP amyloid fibril formation involves an 
intermediate with a transient beta-sheet. Proc Natl Acad Sci U S A 110, 
19285-19290 (2013). 
106. A. S. Reddy et al., Stable and metastable states of human amylin in solution. 
Biophys J 99, 2208-2216 (2010). 
107. L. Khemtemourian, J. A. Killian, J. W. Hoppener, M. F. Engel, Recent insights 
in islet amyloid polypeptide-induced membrane disruption and its role in beta-
cell death in type 2 diabetes mellitus. Exp Diabetes Res 2008, 421287 (2008). 
108. T. A. Mirzabekov, M. C. Lin, B. L. Kagan, Pore formation by the cytotoxic islet 
amyloid peptide amylin. The Journal of biological chemistry 271, 1988-1992 
(1996). 
109. M. Anguiano, R. J. Nowak, P. T. Lansbury, Jr., Protofibrillar islet amyloid 
polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that 
may be relevant to type II diabetes. Biochemistry 41, 11338-11343 (2002). 
110. R. Kayed et al., Permeabilization of lipid bilayers is a common conformation-
dependent activity of soluble amyloid oligomers in protein misfolding 
diseases. J Biol Chem 279, 46363-46366 (2004). 
111. P. Cao et al., Islet amyloid polypeptide toxicity and membrane interactions. 
Proc Natl Acad Sci U S A 110, 19279-19284 (2013). 
112. R. A. Ritzel, J. J. Meier, C. Y. Lin, J. D. Veldhuis, P. C. Butler, Human islet 
amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and 
impair insulin secretion in isolated human islets. Diabetes 56, 65-71 (2007). 
113. N. Bag, A. Ali, V. S. Chauhan, T. Wohland, A. Mishra, Membrane 
destabilization by monomeric hIAPP observed by imaging fluorescence 
correlation spectroscopy. Chem Commun (Camb) 49, 9155-9157 (2013). 
114. M. Magzoub, A. D. Miranker, Concentration-dependent transitions govern the 
subcellular localization of islet amyloid polypeptide. FASEB J 26, 1228-1238 
(2012). 
115. C. J. Huang et al., High expression rates of human islet amyloid polypeptide 
induce endoplasmic reticulum stress mediated beta-cell apoptosis, a 
characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56, 
2016-2027 (2007). 
 123 
116. S. Zraika et al., Oxidative stress is induced by islet amyloid formation and 
time-dependently mediates amyloid-induced beta cell apoptosis. 
Diabetologia 52, 626-635 (2009). 
117. S. L. Masters et al., Activation of the NLRP3 inflammasome by islet amyloid 
polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. 
Nat Immunol 11, 897-904 (2010). 
118. S. Casas et al., Impairment of the ubiquitin-proteasome pathway is a 
downstream endoplasmic reticulum stress response induced by extracellular 
human islet amyloid polypeptide and contributes to pancreatic beta-cell 
apoptosis. Diabetes 56, 2284-2294 (2007). 
119. C. J. Huang et al., Induction of endoplasmic reticulum stress-induced beta-
cell apoptosis and accumulation of polyubiquitinated proteins by human islet 
amyloid polypeptide. Am J Physiol Endocrinol Metab 293, E1656-1662 
(2007). 
120. M. Anello et al., Functional and morphological alterations of mitochondria in 
pancreatic beta cells from type 2 diabetic patients. Diabetologia 48, 282-289 
(2005). 
121. C. Montemurro et al., IAPP toxicity activates HIF1alpha/PFKFB3 signaling 
delaying beta-cell loss at the expense of beta-cell function. Nat Commun 10, 
2679 (2019). 
122. S. Despa et al., Cardioprotection by controlling hyperamylinemia in a 
"humanized" diabetic rat model. J Am Heart Assoc 3,  (2014). 
123. M. Liu et al., Hyperamylinemia Increases IL-1beta Synthesis in the Heart via 
Peroxidative Sarcolemmal Injury. Diabetes 65, 2772-2783 (2016). 
124. M. Liu et al., Amylin and diabetic cardiomyopathy - amylin-induced 
sarcolemmal Ca(2+) leak is independent of diabetic remodeling of 
myocardium. Biochim Biophys Acta Mol Basis Dis 1864, 1923-1930 (2018). 
125. B. D. Stewart et al., Computational modeling of amylin-induced calcium 
dysregulation in rat ventricular cardiomyocytes. Cell Calcium 71, 65-74 
(2018). 
126. K. Iglay et al., Prevalence and co-prevalence of comorbidities among patients 
with type 2 diabetes mellitus. Curr Med Res Opin 32, 1243-1252 (2016). 
127. J. A. A. Luchsinger, Type 2 diabetes and cognitive impairment: linking 
mechanisms. Journal of Alzheimer's disease : JAD 30 Suppl 2, 98 (2012). 
128. G. Biessels, F. Despa, Cognitive decline and dementia in diabetes mellitus: 
mechanisms and clinical implications. Nature Reviews Endocrinology 14, 1-
14 (2018). 
129. I. Martinez-Valbuena et al., Amylin as a potential link between type 2 diabetes 
and alzheimer disease. Ann Neurol 86, 539-551 (2019). 
130. E. Andreetto et al., Identification of hot regions of the Abeta-IAPP interaction 
interface as high-affinity binding sites in both cross- and self-association. 
Angewandte Chemie (International ed. in English) 49, 3081-3085 (2010). 
131. L. M. Yan, A. Velkova, M. Tatarek-Nossol, E. Andreetto, A. Kapurniotu, IAPP 
mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid 
toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's 
disease and type II diabetes. Angew Chem Int Ed Engl 46, 1246-1252 (2007). 
 124 
132. U. Sengupta, A. N. Nilson, R. Kayed, The Role of Amyloid-beta Oligomers in 
Toxicity, Propagation, and Immunotherapy. EBioMedicine 6, 42-49 (2016). 
133. I. Moreno-Gonzalez et al., Molecular interaction between type 2 diabetes and 
Alzheimer’s disease through cross-seeding of protein misfolding. Molecular 
Psychiatry 22, 1327-1334 (2017). 
134. G. J. Biessels, M. W. Strachan, F. L. Visseren, L. J. Kappelle, R. A. Whitmer, 
Dementia and cognitive decline in type 2 diabetes and prediabetic stages: 
towards targeted interventions. Lancet Diabetes Endocrinol 2, 246-255 
(2014). 
135. H. Ly, F. Despa, Diabetes-related Amylin Dyshomeostasis: a Contributing 
Factor to Cerebrovascular Pathology and Dementia. J Lipid Atheroscler 8,  
(2019). 
136. D. G. Drubin, M. W. Kirschner, Tau protein function in living cells. J Cell Biol 
103, 2739-2746 (1986). 
137. T. Roostaei et al., Genome-wide interaction study of brain beta-amyloid 
burden and cognitive impairment in Alzheimer’s disease. Molecular 
Psychiatry 22, 287-295 (2016). 
138. J. H. Jhamandas, D. MacTavish, Antagonist of the amylin receptor blocks 
beta-amyloid toxicity in rat cholinergic basal forebrain neurons. J Neurosci 
24, 5579-5584 (2004). 
139. J. H. Jhamandas et al., Actions of beta-amyloid protein on human neurons 
are expressed through the amylin receptor. Am J Pathol 178, 140-149 (2011). 
140. R. Kimura, D. MacTavish, J. Yang, D. Westaway, J. H. Jhamandas, Beta 
amyloid-induced depression of hippocampal long-term potentiation is 
mediated through the amylin receptor. J Neurosci 32, 17401-17406 (2012). 
141. N. Zhang et al., Multiple target of hAmylin on rat primary hippocampal 
neurons. Neuropharmacology 113, 241-251 (2017). 
142. Y. M. Mousa, I. M. Abdallah, M. Hwang, D. R. Martin, A. Kaddoumi, Amylin 
and pramlintide modulate gamma-secretase level and APP processing in lipid 
rafts. Sci Rep 10, 3751 (2020). 
143. H. Zhu et al., Intraperitoneal injection of the pancreatic peptide amylin 
potently reduces behavioral impairment and brain amyloid pathology in 
murine models of Alzheimer's disease. Mol Psychiatry 20, 252-262 (2015). 
144. B. L. Adler et al., Neuroprotective effects of the amylin analogue pramlintide 
on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging 35, 793-
801 (2014). 
145. P. M. Mark, G. Yadong, Different amyloidogenic peptides share a similar 
mechanism of neurotoxicity involving reactive oxygen species and calcium. 
Brain Research 676, 219-224 (1995). 
146. A. Demuro et al., Calcium dysregulation and membrane disruption as a 
ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 
280, 17294-17300 (2005). 
147. A. Demuro, I. Parker, G. E. Stutzmann, Calcium signaling and amyloid toxicity 
in Alzheimer disease. J Biol Chem 285, 12463-12468 (2010). 
148. Y. A. Lim et al., Abeta and human amylin share a common toxicity pathway 
via mitochondrial dysfunction. Proteomics 10, 1621-1633 (2010). 
 125 
149. N. Zhang et al., Influence of human amylin on the membrane stability of rat 
primary hippocampal neurons. Aging (Albany NY) 12, 8923-8938 (2020). 
150. H. M. Tucker, R. E. Rydel, S. Wright, S. Estus, Human amylin induces 
"apoptotic" pattern of gene expression concomitant with cortical neuronal 
apoptosis. J Neurochem 71, 506-516 (1998). 
151. F. J. Sheedy et al., CD36 coordinates NLRP3 inflammasome activation by 
facilitating intracellular nucleation of soluble ligands into particulate ligands in 
sterile inflammation. Nature immunology 14, 812-820 (2013). 
152. J. L. Guenet, The mouse genome. Genome Res 15, 1729-1740 (2005). 
153. A. J. King, The use of animal models in diabetes research. Br J Pharmacol 
166, 877-894 (2012). 
154. Neha, R. K. Sodhi, A. S. Jaggi, N. Singh, Animal models of dementia and 
cognitive dysfunction. Life Sci 109, 73-86 (2014). 
155. G. Biessels, W. Gispen, The impact of diabetes on cognition: What can be 
learned from rodent models? Neurobiology of Aging 26, 36-41 (2005). 
156. B. Wang, P. C. Chandrasekera, J. J. Pippin, Leptin- and leptin receptor-
deficient rodent models: relevance for human type 2 diabetes. Curr Diabetes 
Rev 10, 131-145 (2014). 
157. S. A. Farr, W. A. Banks, J. E. Morley, Effects of leptin on memory processing. 
Peptides 27, 1420-1425 (2006). 
158. A. Ilaiwy et al., Human amylin proteotoxicity impairs protein biosynthesis, and 
alters major cellular signaling pathways in the heart, brain and liver of 
humanized diabetic rat model in vivo. Metabolomics 12,  (2016). 
159. S. Camandola, M. P. Mattson, Brain metabolism in health, aging, and 
neurodegeneration. EMBO J 36, 1474-1492 (2017). 
160. A. Quaegebeur, C. Lange, P. Carmeliet, The neurovascular link in health and 
disease: molecular mechanisms and therapeutic implications. Neuron 71, 
406-424 (2011). 
161. B. V. Zlokovic, The blood-brain barrier in health and chronic 
neurodegenerative disorders. Neuron 57, 178-201 (2008). 
162. S. M. Greenberg et al., Cerebral microbleeds: a guide to detection and 
interpretation. Lancet Neurol 8, 165-174 (2009). 
163. A. Viswanathan, W. A. Rocca, C. Tzourio, Vascular risk factors and dementia: 
how to move forward? Neurology 72, 368-374 (2009). 
164. K. Beaumont, M. A. Kenney, A. A. Young, T. J. Rink, High affinity amylin 
binding sites in rat brain. Molecular Pharmacology 44, 493-497 (1993). 
165. C. S. Potes, T. A. Lutz, T. Riediger, Identification of central projections from 
amylin-activated neurons to the lateral hypothalamus. Brain Res 1334, 31-44 
(2010). 
166. B. A. Baldo, A. E. Kelley, Amylin infusion into rat nucleus accumbens potently 
depresses motor activity and ingestive behavior. Am J Physiol Regul Integr 
Comp Physiol 281, R1232-1242 (2001). 
167. G. W. Rebeck, J. S. Reiter, D. K. Strickland, B. T. Hyman, Apolipoprotein E 
in sporadic Alzheimer's disease: allelic variation and receptor interactions. 
Neuron 11, 575-580 (1993). 
 126 
168. D. E. Schmechel et al., Increased amyloid beta-peptide deposition in cerebral 
cortex as a consequence of apolipoprotein E genotype in late-onset 
Alzheimer disease. Proc Natl Acad Sci U S A 90, 9649-9653 (1993). 
169. P. Lei et al., Prevention and promotion effects of apolipoprotein E4 on amylin 
aggregation. Biochem Biophys Res Commun 368, 414-418 (2008). 
170. S. B. Chargé, M. M. Esiri, C. A. Bethune, B. C. Hansen, A. Clark, 
Apolipoprotein E is associated with islet amyloid and other amyloidoses: 
implications for Alzheimer's disease. The Journal of pathology 179, 443-447 
(1996). 
171. J. Guan et al., Histopathological correlations of islet amyloidosis with 
apolipoprotein E polymorphisms in type 2 diabetic Chinese patients. 
Pancreas 42, 1129-1137 (2013). 
172. M. Couce et al., Treatment with growth hormone and dexamethasone in mice 
transgenic for human islet amyloid polypeptide causes islet amyloidosis and 
beta-cell dysfunction. Diabetes 45, 1094-1101 (1996). 
173. M. J. Luitse, G. J. Biessels, G. E. Rutten, L. J. Kappelle, Diabetes, 
hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 11, 261-271 
(2012). 
174. F. Ismail-Beigi et al., Effect of intensive treatment of hyperglycaemia on 
microvascular outcomes in type 2 diabetes: an analysis of the ACCORD 
randomised trial. Lancet 376, 419-430 (2010). 
175. T. Ohara et al., Glucose tolerance status and risk of dementia in the 
community: the Hisayama study. Neurology 77, 1126-1134 (2011). 
176. P. T. Nelson et al., Human cerebral neuropathology of Type 2 diabetes 
mellitus. Biochim Biophys Acta 1792, 454-469 (2009). 
177. S. S. Mirra et al., The Consortium to Establish a Registry for Alzheimer's 
Disease (CERAD). Part II. Standardization of the neuropathologic 
assessment of Alzheimer's disease. Neurology 41, 479-486 (1991). 
178. H. Braak, E. Braak, Neuropathological stageing of Alzheimer-related 
changes. Acta Neuropathol 82, 239-259 (1991). 
179. P. T. Nelson et al., Clinicopathologic correlations in a large Alzheimer disease 
center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" 
when staging disease severity. J Neuropathol Exp Neurol 66, 1136-1146 
(2007). 
180. F. A. Schmitt et al., University of Kentucky Sanders-Brown healthy brain 
aging volunteers: donor characteristics, procedures and neuropathology. 
Curr Alzheimer Res 9, 724-733 (2012). 
181. P. T. Nelson et al., APOE-epsilon2 and APOE-epsilon4 correlate with 
increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp 
Neurol 72, 708-715 (2013). 
182. R. Hu et al., Cross-sequence interactions between human and rat islet 
amyloid polypeptides. Langmuir 30, 5193-5201 (2014). 
183. J. D. Sander, J. K. Joung, CRISPR-Cas systems for editing, regulating and 
targeting genomes. Nat Biotechnol 32, 347-355 (2014). 
 127 
184. C. V. Vorhees, M. T. Williams, Morris water maze: procedures for assessing 
spatial and related forms of learning and memory. Nat Protoc 1, 848-858 
(2006). 
185. S. Okubo, J. Strahle, R. F. Keep, Y. Hua, G. Xi, Subarachnoid hemorrhage-
induced hydrocephalus in rats. Stroke 44, 547-550 (2013). 
186. Y. S. Shim et al., Pathological correlates of white matter hyperintensities on 
magnetic resonance imaging. Dement Geriatr Cogn Disord 39, 92-104 
(2015). 
187. L. Pantoni, Cerebral small vessel disease: from pathogenesis and clinical 
characteristics to therapeutic challenges. Lancet Neurol 9, 689-701 (2010). 
188. A. H. Hainsworth, H. S. Markus, Do in vivo experimental models reflect 
human cerebral small vessel disease? A systematic review. J Cereb Blood 
Flow Metab 28, 1877-1891 (2008). 
189. E. G. Sozmen, J. D. Hinman, S. T. Carmichael, Models that matter: white 
matter stroke models. Neurotherapeutics 9, 349-358 (2012). 
190. R. W. Mahley, Apolipoprotein E: cholesterol transport protein with expanding 
role in cell biology. Science 240, 622-630 (1988). 
191. S. Lee et al., White matter hyperintensities are a core feature of Alzheimer's 
disease: Evidence from the dominantly inherited Alzheimer network. Ann 
Neurol 79, 929-939 (2016). 
192. A. H. Hainsworth et al., Neuropathology of White Matter Lesions, Blood-Brain 
Barrier Dysfunction, and Dementia. Stroke 48, 2799-2804 (2017). 
193. H. Zhu et al., Association of Plasma Amylin Concentration With Alzheimer 
Disease and Brain Structure in Older Adults. JAMA Netw Open 2, e199826 
(2019). 
194. R. M. Cohen et al., A Transgenic Alzheimer Rat with Plaques, Tau Pathology, 
Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss. The 
Journal of Neuroscience 33, 6245-6256 (2013). 
195. R. Guerreiro et al., A comprehensive assessment of benign genetic variability 
for neurodegenerative disorders. bioRxiv, 270686 (2018). 
196. R. Nirogi et al., A simple and rapid method to collect the cerebrospinal fluid 
of rats and its application for the assessment of drug penetration into the 
central nervous system. J Neurosci Methods 178, 116-119 (2009). 
197. S. J. Guyenet et al., A simple composite phenotype scoring system for 
evaluating mouse models of cerebellar ataxia. J Vis Exp,  (2010). 
198. M. K. Song, F. C. Lin, S. E. Ward, J. P. Fine, Composite variables: when and 
how. Nurs Res 62, 45-49 (2013). 
199. A. C. Boulay, B. Saubamea, X. Decleves, M. Cohen-Salmon, Purification of 
Mouse Brain Vessels. J Vis Exp, e53208 (2015). 
200. M. Stanley, S. L. Macauley, D. M. Holtzman, Changes in insulin and insulin 
signaling in Alzheimer's disease: cause or consequence? J Exp Med 213, 
1375-1385 (2016). 
201. V. Dror et al., Glucose and endoplasmic reticulum calcium channels regulate 
HIF-1beta via presenilin in pancreatic beta-cells. J Biol Chem 283, 9909-9916 
(2008). 
 128 
202. C. C. Liu, C. C. Liu, T. Kanekiyo, H. Xu, G. Bu, Apolipoprotein E and 
Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9, 106-
118 (2013). 
203. E. H. Corder et al., Gene dose of apolipoprotein E type 4 allele and the risk 
of Alzheimer's disease in late onset families. Science 261, 921-923 (1993). 
204. A. M. Saunders et al., Association of apolipoprotein E allele epsilon 4 with 
late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-
1472 (1993). 
205. W. J. Strittmatter et al., Apolipoprotein E: high-avidity binding to beta-amyloid 
and increased frequency of type 4 allele in late-onset familial Alzheimer 
disease. Proc Natl Acad Sci U S A 90, 1977-1981 (1993). 
206. L. A. Farrer et al., Effects of age, sex, and ethnicity on the association 
between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. 
APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-
1356 (1997). 
207. R. W. Mahley, Y. Huang, Apolipoprotein e sets the stage: response to injury 
triggers neuropathology. Neuron 76, 871-885 (2012). 
208. A. L. Gharibyan et al., Apolipoprotein E Interferes with IAPP Aggregation and 
Protects Pericytes from IAPP-Induced Toxicity. Biomolecules 10,  (2020). 
209. M. C. Thomas, Anemia in diabetes: marker or mediator of microvascular 
disease? Nat Clin Pract Nephrol 3, 20-30 (2007). 
210. M. C. Thomas, R. J. MacIsaac, C. Tsalamandris, D. Power, G. Jerums, 
Unrecognized anemia in patients with diabetes: a cross-sectional survey. 
Diabetes Care 26, 1164-1169 (2003). 
211. M. Diez-Silva, M. Dao, J. Han, C. T. Lim, S. Suresh, Shape and 
Biomechanical Characteristics of Human Red Blood Cells in Health and 
Disease. MRS Bull 35, 382-388 (2010). 
212. G. J. Biessels, I. J. Deary, C. M. Ryan, Cognition and diabetes: a lifespan 
perspective. Lancet Neurol 7, 184-190 (2008). 
213. M. J. Telen, Red blood cell surface adhesion molecules: their possible roles 
in normal human physiology and disease. Semin Hematol 37, 130-142 
(2000). 
214. R. Lall, R. Mohammed, U. Ojha, What are the links between hypoxia and 
Alzheimer's disease? Neuropsychiatr Dis Treat 15, 1343-1354 (2019). 
215. U. Schott, C. Solomon, D. Fries, P. Bentzer, The endothelial glycocalyx and 
its disruption, protection and regeneration: a narrative review. Scand J 
Trauma Resusc Emerg Med 24, 48 (2016). 
216. S. Reitsma, D. W. Slaaf, H. Vink, M. A. van Zandvoort, M. G. oude Egbrink, 
The endothelial glycocalyx: composition, functions, and visualization. 
Pflugers Arch 454, 345-359 (2007). 
217. L. N. Broekhuizen et al., Effect of sulodexide on endothelial glycocalyx and 
vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 
53, 2646-2655 (2010). 
218. D. J. Begley, M. W. Brightman, Structural and functional aspects of the blood-
brain barrier. Prog Drug Res 61, 39-78 (2003). 
 129 
219. L. L. Rubin, J. M. Staddon, The cell biology of the blood-brain barrier. Annu 
Rev Neurosci 22, 11-28 (1999). 
220. A. G. de Boer, I. C. van der Sandt, P. J. Gaillard, The role of drug transporters 
at the blood-brain barrier. Annu Rev Pharmacol Toxicol 43, 629-656 (2003). 
221. B. Obermeier, R. Daneman, R. M. Ransohoff, Development, maintenance 
and disruption of the blood-brain barrier. Nature Medicine 19, 1584-1596 
(2013). 
222. M. Pekny, M. Pekna, Astrocyte reactivity and reactive astrogliosis: costs and 
benefits. Physiological reviews 94, 1077-1098 (2014). 
223. J. N. Abbott, L. Rönnbäck, E. Hansson, Astrocyte–endothelial interactions at 
the blood–brain barrier. Nature Reviews Neuroscience 7, 41-53 (2006). 
224. C. Scuderi, C. Stecca, A. Iacomino, L. Steardo, Role of astrocytes in major 
neurological disorders: the evidence and implications. IUBMB life 65, 957-
961 (2013). 
225. J. M. Wardlaw, P. A. G. Sandercock, M. S. Dennis, J. Starr, Is breakdown of 
the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and 
dementia? Stroke,  (2003). 
226. S. E. Arnold et al., Brain insulin resistance in type 2 diabetes and Alzheimer 
disease: concepts and conundrums. Nat Rev Neurol 14, 168-181 (2018). 
227. K. Govindpani et al., Vascular Dysfunction in Alzheimer's Disease: A Prelude 
to the Pathological Process or a Consequence of It? J Clin Med 8,  (2019). 
228. C. Rask-Madsen, R. C. Kahn, Tissue–Specific Insulin Signaling, Metabolic 
Syndrome, and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and 
Vascular Biology 32, 2052-2059 (2012). 
229. H. O. Steinberg et al., Obesity/insulin resistance is associated with 
endothelial dysfunction. Implications for the syndrome of insulin resistance. J 
Clin Invest 97, 2601-2610 (1996). 
230. R. Muniyappa, J. R. Sowers, Role of insulin resistance in endothelial 
dysfunction. Rev Endocr Metab Disord 14, 5-12 (2013). 
231. E. Cersosimo, R. A. DeFronzo, Insulin resistance and endothelial 
dysfunction: the road map to cardiovascular diseases. Diabetes/metabolism 
research and reviews 22, 423-436 (2006). 
232. W. A. Hsueh, M. J. Quinones, Role of endothelial dysfunction in insulin 
resistance. The American journal of cardiology 92, 10J-17J (2003). 
233. M. A. Potenza, F. Addabbo, M. Montagnani, Vascular actions of insulin with 
implications for endothelial dysfunction. American journal of physiology. 
Endocrinology and metabolism 297, 77 (2009). 
234. E. B. Okon et al., Compromised arterial function in human type 2 diabetic 
patients. Diabetes 54, 2415-2423 (2005). 
235. M. A. Potenza et al., Insulin resistance in spontaneously hypertensive rats is 
associated with endothelial dysfunction characterized by imbalance between 
NO and ET-1 production. American journal of physiology. Heart and 
circulatory physiology 289, 22 (2005). 
236. F. Cosentino et al., Endothelial dysfunction and stroke. Journal of 
cardiovascular pharmacology 38 Suppl 2, 8 (2001). 
 130 
237. G. Zeng et al., Roles for insulin receptor, PI3-kinase, and Akt in insulin-
signaling pathways related to production of nitric oxide in human vascular 
endothelial cells. Circulation 101, 1539-1545 (2000). 
238. M. Montagnani, L. V. Ravichandran, H. Chen, D. L. Esposito, M. J. Quon, 
Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are 
required for insulin-stimulated production of nitric oxide in endothelial cells. 
Molecular endocrinology (Baltimore, Md.) 16, 1931-1942 (2002). 
239. B. J. Michell et al., The Akt kinase signals directly to endothelial nitric oxide 
synthase. Curr Biol 9, 845-848 (1999). 
240. D. M. Greif, D. B. Sacks, T. Michel, Calmodulin phosphorylation and 
modulation of endothelial nitric oxide synthase catalysis. Proceedings of the 
National Academy of Sciences of the United States of America 101, 1165-
1170 (2004). 
241. C. E. Tabit et al., Protein kinase C-β contributes to impaired endothelial 
insulin signaling in humans with diabetes mellitus. Circulation 127, 86-95 
(2013). 
242. M. Matsubara, N. Hayashi, T. Jing, K. Titani, Regulation of endothelial nitric 
oxide synthase by protein kinase C. J Biochem 133, 773-781 (2003). 
243. A. P. Braun, H. Schulman, The multifunctional calcium/calmodulin-dependent 
protein kinase: from form to function. Annu Rev Physiol 57, 417-445 (1995). 
244. M. A. Deli et al., Calcium/calmodulin-stimulated protein kinase II is present in 
primary cultures of cerebral endothelial cells. J Neurochem 60, 1960-1963 
(1993). 
245. S. Doré, S. Kar, R. Quirion, Insulin-like growth factor I protects and rescues 
hippocampal neurons against beta-amyloid- and human amylin-induced 
toxicity. Proceedings of the National Academy of Sciences of the United 
States of America 94, 4772-4777 (1997). 
246. A. Demuro et al., Calcium Dysregulation and Membrane Disruption as a 
Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers. Journal of 
Biological Chemistry 280, 17294-17300 (2005). 
247. S. Casas, A. Novials, F. Reimann, R. Gomis, F. M. Gribble, Calcium elevation 
in mouse pancreatic beta cells evoked by extracellular human islet amyloid 
polypeptide involves activation of the mechanosensitive ion channel TRPV4. 
Diabetologia 51, 2252-2262 (2008). 
248. P. Crosswhite, Z. Sun, Nitric oxide, oxidative stress and inflammation in 
pulmonary arterial hypertension. J Hypertens 28, 201-212 (2010). 
249. U. Forstermann, Nitric oxide and oxidative stress in vascular disease. 
Pflugers Archiv : European journal of physiology 459, 923-939 (2010). 
250. R. A. Cohen et al., Mechanism of nitric oxide-induced vasodilatation: refilling 
of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition 
of store-operated Ca2+ influx. Circ Res 84, 210-219 (1999). 
251. J. H. Jhamandas, K. H. Harris, C. Cho, W. Fu, D. MacTavish, Human Amylin 
Actions on Rat Cholinergic Basal Forebrain Neurons: Antagonism of Beta-
Amyloid Effects. Journal of Neurophysiology 89, 2923-2930 (2003). 
 131 
252. A. Demuro et al., Calcium dysregulation and membrane disruption as a 
ubiquitous neurotoxic mechanism of soluble amyloid oligomers. The Journal 
of biological chemistry 280, 17294-17300 (2005). 
253. J. L. Furman, C. M. Norris, Calcineurin and glial signaling: neuroinflammation 
and beyond. Journal of neuroinflammation 11, 158 (2014). 
254. S. Srodulski et al., Neuroinflammation and neurologic deficits in diabetes 
linked to brain accumulation of amylin. Molecular neurodegeneration 9, 30 
(2014). 
255. J. D. Huber et al., Inflammatory pain alters blood-brain barrier permeability 
and tight junctional protein expression. Am J Physiol Heart Circ Physiol 280, 
H1241-1248 (2001). 
256. R. E. Pitas, J. K. Boyles, S. H. Lee, D. Hui, K. H. Weisgraber, Lipoproteins 
and their receptors in the central nervous system. Characterization of the 
lipoproteins in cerebrospinal fluid and identification of apolipoprotein 
B,E(LDL) receptors in the brain. J Biol Chem 262, 14352-14360 (1987). 
257. S. Grehan, E. Tse, J. M. Taylor, Two distal downstream enhancers direct 
expression of the human apolipoprotein E gene to astrocytes in the brain. J 
Neurosci 21, 812-822 (2001). 
258. C. G. Fernandez, M. E. Hamby, M. L. McReynolds, W. J. Ray, The Role of 
APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia 
in Aging and Alzheimer's Disease. Front Aging Neurosci 11, 14 (2019). 
259. M. Buttini et al., Cellular source of apolipoprotein E4 determines neuronal 
susceptibility to excitotoxic injury in transgenic mice. Am J Pathol 177, 563-
569 (2010). 
260. J. W. Griffin, P. C. Bradshaw, Amino Acid Catabolism in Alzheimer's Disease 
Brain: Friend or Foe? Oxid Med Cell Longev 2017, 5472792 (2017). 
261. B. De Strooper, E. Karran, The Cellular Phase of Alzheimer's Disease. Cell 
164, 603-615 (2016). 
262. F. M. LaFerla, K. N. Green, S. Oddo, Intracellular amyloid-beta in Alzheimer's 
disease. Nat Rev Neurosci 8, 499-509 (2007). 
263. F. M. LaFerla, Calcium dyshomeostasis and intracellular signalling in 
Alzheimer's disease. Nat Rev Neurosci 3, 862-872 (2002). 
264. D. M. Skovronsky, R. W. Doms, V. M. Lee, Detection of a novel intraneuronal 
pool of insoluble amyloid beta protein that accumulates with time in culture. J 
Cell Biol 141, 1031-1039 (1998). 
265. W. G. Annaert et al., Presenilin 1 controls gamma-secretase processing of 
amyloid precursor protein in pre-golgi compartments of hippocampal 
neurons. J Cell Biol 147, 277-294 (1999). 
266. A. P. Sagare, R. D. Bell, B. V. Zlokovic, Neurovascular defects and faulty 
amyloid-beta vascular clearance in Alzheimer's disease. J Alzheimers Dis 33 
Suppl 1, S87-100 (2013). 
267. R. Deane et al., apoE isoform-specific disruption of amyloid beta peptide 





Han (Genny) Gia Ly 
Place of birth 
Ho Chi Minh city, Vietnam 
Education 
Alice Lloyd College, Pippa Passes, KY, USA  2011-2014 
Bachelor of Science in Biology 
Minor in Chemistry 
Graduated Magna Cum Laude 
Professional positions 
Graduate Research Assistant 2014-Present 
University of Kentucky, Lexington, KY 
Chemistry Teaching Assistant 2012-2014 
Alice Lloyd College, Pippa Passes, KY 
Undergraduate Researcher 2012-2014 
Alice Lloyd College, Pippa Passes, KY 
Biology Teaching Assistant 2012-2014 
Alice Lloyd College, Pippa Passes, KY 
Clinical Microbiology Laboratory Intern 2012  
Logan Memorial Hospital, Russellville, KY  
Scholastic and professional honors 
Department Travel Award, $1,000 2019 
Presenter at the Alzheimer's Association International Conference 2019  
Reviewer for scientific journal (Expert Review in Proteomics) 2018 
Served in judge panel of Fayette County Public Schools  
District Science Fair 2018 
Outstanding Poster Award, Markesbery Symposium on Aging  
and Dementia 2018 
Recipient of American Heart Association Pre-doctoral  
Fellowship, $53,688 2018 
Presenter at the Alzheimer's Association International Conference 2018  
Presenter at the International Conference of Molecular  
Neurodegeneration 2018  
Invited speaker at the CCTS Kentucky Neuroscience Institute 2017  
UK College of Medicine Student Travel Award, $800 2017 
Outstanding Poster Award, Markesbery Symposium on  
Aging and Dementia 2016 
Member, Alzheimer’s Association and American  
 133 
Heart Association 2015 –Present    
3rd Place Oral Presentation in Undergraduate Research  
Competition, the Kentucky Academy of Science 2013  
The Alice Lloyd Scholastic Society Award, Alice Lloyd College 2013  
Joseph and Irma Derderian Stepp Endowed-Scholarship and Award,  
Alice Lloyd College 2013 
Appalachian Leader Scholarship, Alice Lloyd College 2012  
Freshman Chemistry Award, Alice Lloyd College 2012 
Publications 
1. Ly H., et al. Circulating Amylin, A Possible Therapeutic Target for Alzheimer’s 
Disease. 2020. In review. 
2. Ly H., et al. Amylin Dyshomeostasis Disrupts White Matter Structural Integrity 
and Modulates Amyloid Composition and Pathology Distribution in Brains of 
Patients with AD and AD Rats. Alzheimer’s and Dementia. 2019.  
3. Ly H., et al. Genetic Manipulation of Amylin Dramatically Accelerates Aging 
and Behavioral Changes in AD Rats. Alzheimer’s and Dementia. 2019.  
4. Verma N.*, Liu M.*, Ly H., et al. Diabetic Microcirculatory Disturbances and 
Pathologic Erythropoiesis Provoked by Deposition of Amyloid-Forming Amylin 
in Red Blood Cells and Capillaries. Kidney International. 2019. (*: co-authors). 
5. Ly H. and Despa F. Diabetes-related Amylin Dyshomeostasis–a Contributing 
Factor to Cerebrovascular Pathology and Dementia. Journal of Lipid and 
Atherosclerosis. 2019.  
6. De Rossi P., Andrew RJ., Musial TF., Buggia-Prevot V., Xu G., Ponnusamy 
M., Ly H., et al. Aberrant Accrual of BIN1 near Alzheimer’s Disease Amyloid 
Deposits in Transgenic Models. Brain Pathology. 2018. 
7. Ly H., et al. Amylin Dyshomeostasis – a Non-Alzheimer’s Disease Process 
Contributing to an Alzheimer’s Disease Phenotype. Alzheimer’s and 
Dementia. 14(7): P696-697. 2018. 
8. Kotiya D., Ly H., et al. CSF Amylin: Effect Modifier of the Aβ-AD Relationship. 
Alzheimer’s and Dementia. 2018. 
9. Ly H., et al. Brain Microvascular Injury and White Matter Disease Provoked by 
Diabetes-associated Hyperamylinemia. Annals of Neurology. 2017. 
10. Ly H., et al. Diabetes-Associated Amylin Dyshomeostasis Provokes Brain 
White Matter Disease and Behavior Changes: An Animal Model. Alzheimer’s 
and Dementia. 2017. 
11. Verma N., Ly H., et al. Intraneuronal Amylin Deposition, Peroxidative 
Membrane Injury and Increased Il-1β Synthesis in Brains of Alzheimer's 
Disease Patients with Type 2 Diabetes and in Diabetic HIP Rats. Journal of 
Alzheimer’s Disease. 2016. 
12. Ly H. and Despa F. Hyperamylinemia as a Risk Factor for Accelerated 
Cognitive Decline in Diabetes. Expert Review in Proteomics. 2015. 
Presentations 
1. Ly H., et al. Amylin Pathology in Alzheimer Disease. Pharmacology and 
Nutritional Sciences Department Seminar, Lexington, KY, March 2018. 
 134 
2. Ly H., et al.  Diabetes-associated Amylin Dyshomeostasis Provokes Brain 
White Matter Disease and Behavior Changes–an Animal Model. UKY 
Department of Neurology-Trainee Research Day, Lexington, KY, December 
2017.  
3. Ly H., et al. Brain Microvascular Injury and White Matter Disease Provoked 
by Diabetes-associated Hyperamylinemia. CCTS Kentucky Neuroscience 
Institute, Lexington, KY, September 2017.  
4. Ly H., et al. Brain Microvascular Injury and White Matter Disease Provoked 
by High Blood Levels of the Pancreatic Hormone Amylin. Pharmacology and 
Nutritional Sciences Department Seminar, Lexington, KY, April 2017. 
5. Ly, H. et al. The Effect of Nutrition Levels on Fern Gametophyte Success. 
99th Annual Kentucky Academic of Science Meeting, Morehead, KY, 
November 2013. 
Posters 
1. Ly H., Verma N., Lashley T., et al. Amylin Dyshomeostasis Disrupts White 
Matter Structural Integrity and Modulates Amyloid Composition and 
Pathology Distribution in Brains of Patients with AD and AD Rats. Markesbery 
Symposium on Aging and Dementia, Lexington, KY, November 2019.  
2. Ly H., Verma N., Lashley T., et al. Amylin Dyshomeostasis Disrupts White 
Matter Structural Integrity and Modulates Amyloid Composition and 
Pathology Distribution in Brains of Patients with AD and AD Rats. CCTS 
Kentucky Neuroscience Institute, Lexington, KY, October 2019.  
3. Ly H., Verma N., Wu F., et al. Brain Microvascular Injury and White Matter 
Disease Provoked by Diabetes-associated Hyperamylinemia. 22nd 
Cardiovascular Research Day, Lexington, KY, September 2019. 
4. Ly H., Verma N., Lashley T., et al. Amylin Dyshomeostasis Disrupts White 
Matter Structural Integrity and Modulates Amyloid Composition and 
Pathology Distribution in Brains of Patients with AD and AD Rats. Alzheimer’s 
Association International Conference, Los Angeles, CA, July 2019.  
5. Ly H., Kotiya D., Despa F. Genetic Manipulation of Amylin Dramatically 
Accelerates Aging and Behavioral Changes in AD Rats. Alzheimer’s 
Association International Conference, Los Angeles, CA, July 2019.  
6. Ly H., Verma N., Wu F., et al. Amylin Dyshomeostasis – a Non-Alzheimer’s 
Disease Process Contributing to an Alzheimer’s Disease Phenotype. 
Markesbery Symposium on Aging and Dementia, Lexington, KY, October 
2018.  
7. Kotiya D., Ly H.., Chen L., Despa F. CSF Amylin: Effect Modifier of the Aβ-
AD Relationship. Markesbery Symposium on Aging and Dementia, 
Lexington, KY, October 2018.  
8. Ly H., Verma N., Wu F., et al. Amylin Dyshomeostasis – a Non-Alzheimer’s 
Disease Process Contributing to an Alzheimer’s Disease Phenotype. CCTS 
Kentucky Neuroscience Institute, Lexington, KY, September 2018.  
9. Kotiya D., Ly H.., Chen L, Despa F. CSF Amylin: Effect Modifier of the Aβ-
AD Relationship. CCTS Kentucky Neuroscience Institute, Lexington, KY, 
September 2018. 
 135 
10. Ly H., Verma N., Wu F., et al. Amylin Dyshomeostasis – a Non-Alzheimer’s 
Disease Process Contributing to an Alzheimer’s Disease Phenotype. 
Alzheimer’s Association International Conference, Chicago, IL, July 2018.  
11. Ly H., Verma N., Wu F., et al. Amylin Pathology in Familial Alzheimer’s 
Disease – Reducing Systemic Amylin Dyshomeostasis Ameliorates Behavior 
Changes in Alzheimer’s Disease Rats. International Conference in Molecular 
Neurodegeneration, Stockholm, Sweden, June 2018.  
12. Ly H., Verma N., Wu F., et al. Diabetes-associated Amylin Dyshomeostasis 
Provokes Brain White Matter Disease and Behavior Changes–an Animal 
Model. UKY Department of Neurology-Trainee Research Day, Lexington, 
KY, December 2017.  
13. Ly H., Verma N., Wu F., et al. Programming Amylin Secretion to Slow 
Alzheimer's Disease. CCTS Kentucky Neuroscience Institute, Lexington, KY, 
September 2017.  
14. Ly H., Verma N., Wu F., et al. 2017. Diabetes-associated Amylin 
Dyshomeostasis Provokes Brain White Matter Disease and Behavior 
Changes – an Animal Model. Imaging Consortium. Alzheimer’s Association 
International Conference, London, England, February 2017. 
15. Ly H., Verma N., Wu F., et al. 2017. Diabetes-associated Amylin 
Dyshomeostasis Provokes Brain White Matter Disease and Behavior 
Changes – an Animal Model. Main conference. Alzheimer’s Association 
International Conference, London, England, February 2017. 
16. Liu M., Verma N., Ly H., et al. Progression to Diabetes and Myocardial 
Capillary Injury are Associated with Marked Deposition of Pancreatic Amylin 
in Erythrocytes. Barnstable Brown Obesity and Diabetes Research Day, 
Lexington, KY, May 2017.   
17. Ly H., Sharma S., Liu M., et al. 2016. Aβ-Amylin Interaction in Brains of 
Patients with Early-Onset Familial Alzheimer's Disease. Markesbery 
Symposium on Aging and Dementia, Lexington, KY, November 2016.  
18. Verma N., Ly H., Liu M., et al. 2016. Intraneuronal Amylin Deposition, 
Peroxidative Membrane Injury and Increased IL-1β Synthesis in Brains of 
Alzheimer's disease Patients with Type 2 Diabetes and in Diabetic HIP Rats. 
Alzheimer’s Association International Conference, Toronto, Canada, July 
2016.  
19. Ly H., Verma N., Wu F., et al. Gait Abnormalities, Impaired Balance and Brain 
White Matter Hyperintensities in a Rat Model of Late-Onset Type 2 Diabetes. 
CCTS Kentucky Neuroscience Institute, Lexington, KY, October 2016.  
20. Liu M., Verma N., Ly H., et al. 2015. Hyperamylinemia Impairs Lipid 
Peroxidation Signaling and Activates IL-1β in Heart and Brain. 18th Annual 
Gill Heart Institute Cardiovascular Research Day, Lexington, KY, November 
2015.  
21. Ly H., Verma N., Liu M., et al. 2015. Amylin Proteotoxicity Links Type 2 
Diabetes to Oxidative Stress an Inflammation in the Brain. 5th Annual 
Markesbery Symposium on Aging and Dementia, Lexington, KY, October 
2015. 
 
